EP3596207B1 - Neuartige cas13b-orthologe-crispr-enzyme und systeme - Google Patents
Neuartige cas13b-orthologe-crispr-enzyme und systeme Download PDFInfo
- Publication number
- EP3596207B1 EP3596207B1 EP18715416.6A EP18715416A EP3596207B1 EP 3596207 B1 EP3596207 B1 EP 3596207B1 EP 18715416 A EP18715416 A EP 18715416A EP 3596207 B1 EP3596207 B1 EP 3596207B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- rna
- protein
- sequence
- effector protein
- cas13b
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108091033409 CRISPR Proteins 0.000 title claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 638
- 102000004169 proteins and genes Human genes 0.000 claims description 561
- 239000012636 effector Substances 0.000 claims description 336
- 210000004027 cell Anatomy 0.000 claims description 284
- 238000000034 method Methods 0.000 claims description 180
- 230000014509 gene expression Effects 0.000 claims description 124
- 239000013598 vector Substances 0.000 claims description 112
- 150000007523 nucleic acids Chemical class 0.000 claims description 105
- 102000039446 nucleic acids Human genes 0.000 claims description 100
- 108020004707 nucleic acids Proteins 0.000 claims description 100
- 239000000203 mixture Substances 0.000 claims description 93
- 241001137836 Bacteroidetes bacterium GWA2_31_9 Species 0.000 claims description 89
- 230000035772 mutation Effects 0.000 claims description 64
- 108020004999 messenger RNA Proteins 0.000 claims description 59
- 125000003729 nucleotide group Chemical group 0.000 claims description 57
- 239000002773 nucleotide Substances 0.000 claims description 55
- 108020004414 DNA Proteins 0.000 claims description 48
- 102000040430 polynucleotide Human genes 0.000 claims description 42
- 108091033319 polynucleotide Proteins 0.000 claims description 42
- 239000002157 polynucleotide Substances 0.000 claims description 42
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 41
- 238000000338 in vitro Methods 0.000 claims description 38
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 34
- 230000001105 regulatory effect Effects 0.000 claims description 33
- 230000014616 translation Effects 0.000 claims description 31
- 108020004705 Codon Proteins 0.000 claims description 28
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 26
- 238000013519 translation Methods 0.000 claims description 25
- 230000004807 localization Effects 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 21
- 230000004952 protein activity Effects 0.000 claims description 17
- 241000282414 Homo sapiens Species 0.000 claims description 16
- 239000013603 viral vector Substances 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 11
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- 238000010354 CRISPR gene editing Methods 0.000 claims description 9
- 230000004913 activation Effects 0.000 claims description 9
- 244000052769 pathogen Species 0.000 claims description 8
- 230000001717 pathogenic effect Effects 0.000 claims description 8
- 230000009870 specific binding Effects 0.000 claims description 8
- 230000032258 transport Effects 0.000 claims description 6
- 230000007306 turnover Effects 0.000 claims description 5
- 108020000999 Viral RNA Proteins 0.000 claims description 3
- 210000001808 exosome Anatomy 0.000 claims description 3
- 230000002068 genetic effect Effects 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 230000001177 retroviral effect Effects 0.000 claims description 3
- 208000009889 Herpes Simplex Diseases 0.000 claims description 2
- 230000001973 epigenetic effect Effects 0.000 claims description 2
- 210000004602 germ cell Anatomy 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 101100123845 Aphanizomenon flos-aquae (strain 2012/KM1/D3) hepT gene Proteins 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 515
- 230000009368 gene silencing by RNA Effects 0.000 description 370
- 108091030071 RNAI Proteins 0.000 description 364
- 230000008685 targeting Effects 0.000 description 218
- 241000196324 Embryophyta Species 0.000 description 165
- 108091079001 CRISPR RNA Proteins 0.000 description 85
- 230000000694 effects Effects 0.000 description 80
- 235000001014 amino acid Nutrition 0.000 description 70
- 108020005004 Guide RNA Proteins 0.000 description 62
- 229940024606 amino acid Drugs 0.000 description 62
- 150000001413 amino acids Chemical class 0.000 description 60
- 230000027455 binding Effects 0.000 description 52
- 230000004048 modification Effects 0.000 description 51
- 238000012986 modification Methods 0.000 description 51
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 44
- 230000001939 inductive effect Effects 0.000 description 37
- 230000006870 function Effects 0.000 description 34
- 239000000047 product Substances 0.000 description 34
- 230000026279 RNA modification Effects 0.000 description 27
- 239000003446 ligand Substances 0.000 description 25
- 238000010357 RNA editing Methods 0.000 description 24
- 239000005089 Luciferase Substances 0.000 description 22
- 230000004927 fusion Effects 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 22
- 238000003776 cleavage reaction Methods 0.000 description 21
- 238000003197 gene knockdown Methods 0.000 description 21
- 238000001727 in vivo Methods 0.000 description 21
- 230000007017 scission Effects 0.000 description 21
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 20
- 108060001084 Luciferase Proteins 0.000 description 20
- 125000006850 spacer group Chemical group 0.000 description 19
- 230000009261 transgenic effect Effects 0.000 description 19
- 230000015556 catabolic process Effects 0.000 description 18
- 238000006731 degradation reaction Methods 0.000 description 18
- 230000002538 fungal effect Effects 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 18
- 239000004055 small Interfering RNA Substances 0.000 description 18
- 101710163270 Nuclease Proteins 0.000 description 17
- 125000000539 amino acid group Chemical group 0.000 description 17
- 230000003993 interaction Effects 0.000 description 17
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 16
- 210000003763 chloroplast Anatomy 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 230000000087 stabilizing effect Effects 0.000 description 16
- 238000006467 substitution reaction Methods 0.000 description 16
- 210000004899 c-terminal region Anatomy 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 15
- 230000008569 process Effects 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 208000009869 Neu-Laxova syndrome Diseases 0.000 description 14
- 238000013461 design Methods 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 14
- 210000004962 mammalian cell Anatomy 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 238000011002 quantification Methods 0.000 description 14
- 108700011259 MicroRNAs Proteins 0.000 description 13
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 13
- 125000003275 alpha amino acid group Chemical group 0.000 description 13
- 230000003197 catalytic effect Effects 0.000 description 13
- 230000000875 corresponding effect Effects 0.000 description 13
- 230000006698 induction Effects 0.000 description 13
- 230000002452 interceptive effect Effects 0.000 description 13
- 239000002679 microRNA Substances 0.000 description 13
- 238000013518 transcription Methods 0.000 description 13
- 230000035897 transcription Effects 0.000 description 13
- 210000005253 yeast cell Anatomy 0.000 description 13
- 241000195493 Cryptophyta Species 0.000 description 12
- 102000053602 DNA Human genes 0.000 description 12
- 102100038191 Double-stranded RNA-specific editase 1 Human genes 0.000 description 12
- 101000742223 Homo sapiens Double-stranded RNA-specific editase 1 Proteins 0.000 description 12
- 108091028113 Trans-activating crRNA Proteins 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 108091027967 Small hairpin RNA Proteins 0.000 description 11
- 241000700605 Viruses Species 0.000 description 11
- 230000001580 bacterial effect Effects 0.000 description 11
- 238000012545 processing Methods 0.000 description 11
- 108020004422 Riboswitch Proteins 0.000 description 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 10
- 210000001938 protoplast Anatomy 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 230000010076 replication Effects 0.000 description 10
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 9
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 208000020584 Polyploidy Diseases 0.000 description 9
- 230000004570 RNA-binding Effects 0.000 description 9
- 108020004566 Transfer RNA Proteins 0.000 description 9
- 210000000805 cytoplasm Anatomy 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 210000004940 nucleus Anatomy 0.000 description 9
- 230000009437 off-target effect Effects 0.000 description 9
- 210000001236 prokaryotic cell Anatomy 0.000 description 9
- 230000004850 protein–protein interaction Effects 0.000 description 9
- 230000007115 recruitment Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 101710159080 Aconitate hydratase A Proteins 0.000 description 8
- 101710159078 Aconitate hydratase B Proteins 0.000 description 8
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 8
- -1 M12 Chemical compound 0.000 description 8
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 8
- 230000007022 RNA scission Effects 0.000 description 8
- 101710105008 RNA-binding protein Proteins 0.000 description 8
- 108020004459 Small interfering RNA Proteins 0.000 description 8
- 238000001994 activation Methods 0.000 description 8
- 229960005305 adenosine Drugs 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000010362 genome editing Methods 0.000 description 8
- 125000005647 linker group Chemical group 0.000 description 8
- 210000003705 ribosome Anatomy 0.000 description 8
- 108091007460 Long intergenic noncoding RNA Proteins 0.000 description 7
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 238000004422 calculation algorithm Methods 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 210000004708 ribosome subunit Anatomy 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 150000003384 small molecules Chemical class 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 230000009466 transformation Effects 0.000 description 7
- 241001515965 unidentified phage Species 0.000 description 7
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 6
- YHOXIEXEPIIKMD-UHFFFAOYSA-N 9a-[(4-chlorophenyl)methyl]-7-hydroxy-4-[4-(2-piperidin-1-ylethoxy)phenyl]-2,9-dihydro-1h-fluoren-3-one Chemical compound C1C2=CC(O)=CC=C2C2=C(C=3C=CC(OCCN4CCCCC4)=CC=3)C(=O)CCC21CC1=CC=C(Cl)C=C1 YHOXIEXEPIIKMD-UHFFFAOYSA-N 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 6
- 101710132601 Capsid protein Proteins 0.000 description 6
- 108090000994 Catalytic RNA Proteins 0.000 description 6
- 102000053642 Catalytic RNA Human genes 0.000 description 6
- 101710094648 Coat protein Proteins 0.000 description 6
- 241000206602 Eukaryota Species 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 6
- 101000860104 Leptotrichia wadei (strain F0279) CRISPR-associated endoribonuclease Cas13a Proteins 0.000 description 6
- 101710125418 Major capsid protein Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 108010066154 Nuclear Export Signals Proteins 0.000 description 6
- 101710141454 Nucleoprotein Proteins 0.000 description 6
- 108700026244 Open Reading Frames Proteins 0.000 description 6
- 101710083689 Probable capsid protein Proteins 0.000 description 6
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 6
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 6
- 108700019146 Transgenes Proteins 0.000 description 6
- 240000008042 Zea mays Species 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 238000005457 optimization Methods 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 230000008488 polyadenylation Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 108020004418 ribosomal RNA Proteins 0.000 description 6
- 108091092562 ribozyme Proteins 0.000 description 6
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108091023037 Aptamer Proteins 0.000 description 5
- 108700010070 Codon Usage Proteins 0.000 description 5
- 102100031562 Excitatory amino acid transporter 2 Human genes 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- 101000866287 Homo sapiens Excitatory amino acid transporter 2 Proteins 0.000 description 5
- 241000208822 Lactuca Species 0.000 description 5
- 102000015097 RNA Splicing Factors Human genes 0.000 description 5
- 108010039259 RNA Splicing Factors Proteins 0.000 description 5
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 5
- 244000062793 Sorghum vulgare Species 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 230000004075 alteration Effects 0.000 description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 230000000368 destabilizing effect Effects 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 210000005260 human cell Anatomy 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 210000003463 organelle Anatomy 0.000 description 5
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 5
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 5
- 229960002930 sirolimus Drugs 0.000 description 5
- 108020005345 3' Untranslated Regions Proteins 0.000 description 4
- 241000589158 Agrobacterium Species 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 4
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 4
- 235000002566 Capsicum Nutrition 0.000 description 4
- 241000701489 Cauliflower mosaic virus Species 0.000 description 4
- 230000007018 DNA scission Effects 0.000 description 4
- 241000134884 Ericales Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000220223 Fragaria Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 201000004408 Hypobetalipoproteinemia Diseases 0.000 description 4
- 241000227653 Lycopersicon Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241000208125 Nicotiana Species 0.000 description 4
- 241000235645 Pichia kudriavzevii Species 0.000 description 4
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 4
- 241000018646 Pinus brutia Species 0.000 description 4
- 235000011613 Pinus brutia Nutrition 0.000 description 4
- 230000014632 RNA localization Effects 0.000 description 4
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 4
- 102000006382 Ribonucleases Human genes 0.000 description 4
- 108010083644 Ribonucleases Proteins 0.000 description 4
- 241000714474 Rous sarcoma virus Species 0.000 description 4
- 241000219315 Spinacia Species 0.000 description 4
- 241000209140 Triticum Species 0.000 description 4
- 235000021307 Triticum Nutrition 0.000 description 4
- 244000078534 Vaccinium myrtillus Species 0.000 description 4
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 4
- NMFHJNAPXOMSRX-PUPDPRJKSA-N [(1r)-3-(3,4-dimethoxyphenyl)-1-[3-(2-morpholin-4-ylethoxy)phenyl]propyl] (2s)-1-[(2s)-2-(3,4,5-trimethoxyphenyl)butanoyl]piperidine-2-carboxylate Chemical compound C([C@@H](OC(=O)[C@@H]1CCCCN1C(=O)[C@@H](CC)C=1C=C(OC)C(OC)=C(OC)C=1)C=1C=C(OCCN2CCOCC2)C=CC=1)CC1=CC=C(OC)C(OC)=C1 NMFHJNAPXOMSRX-PUPDPRJKSA-N 0.000 description 4
- 230000001594 aberrant effect Effects 0.000 description 4
- 208000004622 abetalipoproteinemia Diseases 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 108010031100 chloroplast transit peptides Proteins 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000006471 dimerization reaction Methods 0.000 description 4
- 241001493065 dsRNA viruses Species 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 201000000544 familial hypobetalipoproteinemia 1 Diseases 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 210000003783 haploid cell Anatomy 0.000 description 4
- 230000017730 intein-mediated protein splicing Effects 0.000 description 4
- 235000009973 maize Nutrition 0.000 description 4
- 210000003470 mitochondria Anatomy 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 210000002706 plastid Anatomy 0.000 description 4
- 210000001850 polyploid cell Anatomy 0.000 description 4
- 230000000754 repressing effect Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 230000010474 transient expression Effects 0.000 description 4
- 230000005945 translocation Effects 0.000 description 4
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 4
- 108020003589 5' Untranslated Regions Proteins 0.000 description 3
- 241000756998 Alismatales Species 0.000 description 3
- 244000105624 Arachis hypogaea Species 0.000 description 3
- 241000235349 Ascomycota Species 0.000 description 3
- 235000005340 Asparagus officinalis Nutrition 0.000 description 3
- 244000075850 Avena orientalis Species 0.000 description 3
- 241000219198 Brassica Species 0.000 description 3
- 240000002791 Brassica napus Species 0.000 description 3
- 240000007124 Brassica oleracea Species 0.000 description 3
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 3
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 3
- 241000499511 Cabbage leaf curl virus Species 0.000 description 3
- 241000195585 Chlamydomonas Species 0.000 description 3
- 241000207199 Citrus Species 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 241000723377 Coffea Species 0.000 description 3
- 241000218631 Coniferophyta Species 0.000 description 3
- 241000724252 Cucumber mosaic virus Species 0.000 description 3
- 230000004543 DNA replication Effects 0.000 description 3
- 235000002767 Daucus carota Nutrition 0.000 description 3
- 244000000626 Daucus carota Species 0.000 description 3
- 108090000204 Dipeptidase 1 Proteins 0.000 description 3
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 3
- 241000219427 Fagales Species 0.000 description 3
- 235000016623 Fragaria vesca Nutrition 0.000 description 3
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 101000611202 Homo sapiens Peptidyl-prolyl cis-trans isomerase B Proteins 0.000 description 3
- 241000209219 Hordeum Species 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 3
- 235000003228 Lactuca sativa Nutrition 0.000 description 3
- 241000209510 Liliopsida Species 0.000 description 3
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 3
- 235000011430 Malus pumila Nutrition 0.000 description 3
- 244000070406 Malus silvestris Species 0.000 description 3
- 235000015103 Malus silvestris Nutrition 0.000 description 3
- 240000003183 Manihot esculenta Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000234295 Musa Species 0.000 description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 3
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 3
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 102100040283 Peptidyl-prolyl cis-trans isomerase B Human genes 0.000 description 3
- 101710111747 Peptidyl-prolyl cis-trans isomerase FKBP12 Proteins 0.000 description 3
- 108010043958 Peptoids Proteins 0.000 description 3
- 241000425347 Phyla <beetle> Species 0.000 description 3
- 241000218657 Picea Species 0.000 description 3
- 241001536628 Poales Species 0.000 description 3
- 241000709992 Potato virus X Species 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 240000001987 Pyrus communis Species 0.000 description 3
- 235000014443 Pyrus communis Nutrition 0.000 description 3
- 238000003559 RNA-seq method Methods 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 102000004389 Ribonucleoproteins Human genes 0.000 description 3
- 108010081734 Ribonucleoproteins Proteins 0.000 description 3
- 241000220221 Rosales Species 0.000 description 3
- 108020005543 Satellite RNA Proteins 0.000 description 3
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 3
- 235000009337 Spinacia oleracea Nutrition 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 241000723873 Tobacco mosaic virus Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 102000006635 beta-lactamase Human genes 0.000 description 3
- 239000002551 biofuel Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000020971 citrus fruits Nutrition 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000009918 complex formation Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000021953 cytokinesis Effects 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 210000001840 diploid cell Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 102000015694 estrogen receptors Human genes 0.000 description 3
- 108010038795 estrogen receptors Proteins 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 108091006047 fluorescent proteins Proteins 0.000 description 3
- 102000034287 fluorescent proteins Human genes 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000012239 gene modification Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000021121 meiosis Effects 0.000 description 3
- 108091027963 non-coding RNA Proteins 0.000 description 3
- 102000042567 non-coding RNA Human genes 0.000 description 3
- 230000030648 nucleus localization Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000002246 oncogenic effect Effects 0.000 description 3
- 229960003104 ornithine Drugs 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 229920002477 rna polymer Polymers 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000037426 transcriptional repression Effects 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 229960001082 trimethoprim Drugs 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- VUFNLQXQSDUXKB-DOFZRALJSA-N 2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]ethyl (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OCCOC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 VUFNLQXQSDUXKB-DOFZRALJSA-N 0.000 description 2
- 108020005176 AU Rich Elements Proteins 0.000 description 2
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241000234282 Allium Species 0.000 description 2
- 244000144730 Amygdalus persica Species 0.000 description 2
- 101150102415 Apob gene Proteins 0.000 description 2
- 102000018616 Apolipoproteins B Human genes 0.000 description 2
- 108010027006 Apolipoproteins B Proteins 0.000 description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 description 2
- 244000003416 Asparagus officinalis Species 0.000 description 2
- 241000208837 Asterales Species 0.000 description 2
- 235000007319 Avena orientalis Nutrition 0.000 description 2
- 241000206761 Bacillariophyta Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000221198 Basidiomycota Species 0.000 description 2
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 235000011331 Brassica Nutrition 0.000 description 2
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 2
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 2
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 2
- 241000724256 Brome mosaic virus Species 0.000 description 2
- 240000008574 Capsicum frutescens Species 0.000 description 2
- 241000219504 Caryophyllales Species 0.000 description 2
- 241000195628 Chlorophyta Species 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 241001672694 Citrus reticulata Species 0.000 description 2
- 240000000560 Citrus x paradisi Species 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 241000219112 Cucumis Species 0.000 description 2
- 235000009854 Cucurbita moschata Nutrition 0.000 description 2
- 240000001980 Cucurbita pepo Species 0.000 description 2
- 241000192700 Cyanobacteria Species 0.000 description 2
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 102100024108 Dystrophin Human genes 0.000 description 2
- 108010069091 Dystrophin Proteins 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000299507 Gossypium hirsutum Species 0.000 description 2
- 244000020551 Helianthus annuus Species 0.000 description 2
- 235000003222 Helianthus annuus Nutrition 0.000 description 2
- 108010014594 Heterogeneous Nuclear Ribonucleoprotein A1 Proteins 0.000 description 2
- 102000017013 Heterogeneous Nuclear Ribonucleoprotein A1 Human genes 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 102000016252 Huntingtin Human genes 0.000 description 2
- 108050004784 Huntingtin Proteins 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 240000007049 Juglans regia Species 0.000 description 2
- 235000009496 Juglans regia Nutrition 0.000 description 2
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 2
- 241000207832 Lamiales Species 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 241000218922 Magnoliophyta Species 0.000 description 2
- 241000219171 Malpighiales Species 0.000 description 2
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 2
- 240000004658 Medicago sativa Species 0.000 description 2
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 2
- 102000007474 Multiprotein Complexes Human genes 0.000 description 2
- 108010085220 Multiprotein Complexes Proteins 0.000 description 2
- 101100219625 Mus musculus Casd1 gene Proteins 0.000 description 2
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 description 2
- 102100022437 Myotonin-protein kinase Human genes 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 101100462611 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) prr-1 gene Proteins 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 102000043141 Nuclear RNA Human genes 0.000 description 2
- 108020003217 Nuclear RNA Proteins 0.000 description 2
- 102000002488 Nucleoplasmin Human genes 0.000 description 2
- 201000009110 Oculopharyngeal muscular dystrophy Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000123637 Pandanales Species 0.000 description 2
- 239000006002 Pepper Substances 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- 241000199919 Phaeophyceae Species 0.000 description 2
- 235000016761 Piper aduncum Nutrition 0.000 description 2
- 240000003889 Piper guineense Species 0.000 description 2
- 235000017804 Piper guineense Nutrition 0.000 description 2
- 235000008184 Piper nigrum Nutrition 0.000 description 2
- 241000219843 Pisum Species 0.000 description 2
- 241000723784 Plum pox virus Species 0.000 description 2
- 101710124239 Poly(A) polymerase Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000723762 Potato virus Y Species 0.000 description 2
- 241000611831 Prevotella sp. Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- 241000709748 Pseudomonas phage PRR1 Species 0.000 description 2
- 102000014450 RNA Polymerase III Human genes 0.000 description 2
- 108010078067 RNA Polymerase III Proteins 0.000 description 2
- 108091008103 RNA aptamers Proteins 0.000 description 2
- 241000220259 Raphanus Species 0.000 description 2
- 241000206572 Rhodophyta Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 235000017848 Rubus fruticosus Nutrition 0.000 description 2
- 240000007651 Rubus glaucus Species 0.000 description 2
- 235000011034 Rubus glaucus Nutrition 0.000 description 2
- 235000009122 Rubus idaeus Nutrition 0.000 description 2
- 244000253911 Saccharomyces fragilis Species 0.000 description 2
- 235000018368 Saccharomyces fragilis Nutrition 0.000 description 2
- 241001515849 Satellite Viruses Species 0.000 description 2
- 241000209056 Secale Species 0.000 description 2
- 241000207763 Solanum Species 0.000 description 2
- 235000002597 Solanum melongena Nutrition 0.000 description 2
- 244000061458 Solanum melongena Species 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 235000021536 Sugar beet Nutrition 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 241000016010 Tomato spotted wilt orthotospovirus Species 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 241000219793 Trifolium Species 0.000 description 2
- 108010065850 Tristetraprolin Proteins 0.000 description 2
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 102000035181 adaptor proteins Human genes 0.000 description 2
- 108091005764 adaptor proteins Proteins 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 229960004099 azithromycin Drugs 0.000 description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 235000021029 blackberry Nutrition 0.000 description 2
- 235000021014 blueberries Nutrition 0.000 description 2
- 239000001390 capsicum minimum Substances 0.000 description 2
- 101150055766 cat gene Proteins 0.000 description 2
- 230000025084 cell cycle arrest Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 235000016213 coffee Nutrition 0.000 description 2
- 235000013353 coffee beverage Nutrition 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000004879 dioscorea Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000005059 dormancy Effects 0.000 description 2
- 230000005782 double-strand break Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 241001233957 eudicotyledons Species 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 239000004009 herbicide Substances 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 238000011503 in vivo imaging Methods 0.000 description 2
- 230000010661 induction of programmed cell death Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229940031154 kluyveromyces marxianus Drugs 0.000 description 2
- 102100031622 mRNA decay activator protein ZFP36 Human genes 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 235000019713 millet Nutrition 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000030147 nuclear export Effects 0.000 description 2
- 108060005597 nucleoplasmin Proteins 0.000 description 2
- 235000014571 nuts Nutrition 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 108010079892 phosphoglycerol kinase Proteins 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 230000016434 protein splicing Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 102220194040 rs1057516488 Human genes 0.000 description 2
- 102220231381 rs1064797077 Human genes 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000003584 silencer Effects 0.000 description 2
- 108091069025 single-strand RNA Proteins 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 210000001324 spliceosome Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 108091035539 telomere Proteins 0.000 description 2
- 102000055501 telomere Human genes 0.000 description 2
- 210000003411 telomere Anatomy 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000011426 transformation method Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 235000020234 walnut Nutrition 0.000 description 2
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- BLCJBICVQSYOIF-UHFFFAOYSA-N 2,2-diaminobutanoic acid Chemical compound CCC(N)(N)C(O)=O BLCJBICVQSYOIF-UHFFFAOYSA-N 0.000 description 1
- KCYOZNARADAZIZ-CWBQGUJCSA-N 2-[(2e,4e,6e,8e,10e,12e,14e)-15-(4,4,7a-trimethyl-2,5,6,7-tetrahydro-1-benzofuran-2-yl)-6,11-dimethylhexadeca-2,4,6,8,10,12,14-heptaen-2-yl]-4,4,7a-trimethyl-2,5,6,7-tetrahydro-1-benzofuran-6-ol Chemical compound O1C2(C)CC(O)CC(C)(C)C2=CC1C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C1C=C2C(C)(C)CCCC2(C)O1 KCYOZNARADAZIZ-CWBQGUJCSA-N 0.000 description 1
- WTOFYLAWDLQMBZ-UHFFFAOYSA-N 2-azaniumyl-3-thiophen-2-ylpropanoate Chemical compound OC(=O)C(N)CC1=CC=CS1 WTOFYLAWDLQMBZ-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- 101150052384 50 gene Proteins 0.000 description 1
- 239000013607 AAV vector Substances 0.000 description 1
- 102000017919 ADRB2 Human genes 0.000 description 1
- 240000004507 Abelmoschus esculentus Species 0.000 description 1
- 241000218642 Abies Species 0.000 description 1
- 244000283070 Abies balsamea Species 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- 241001133760 Acoelorraphe Species 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- 244000298697 Actinidia deliciosa Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 235000013211 Adiantum capillus veneris Nutrition 0.000 description 1
- 241001148501 Adiantum pedatum Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 1
- 235000005254 Allium ampeloprasum Nutrition 0.000 description 1
- 240000006108 Allium ampeloprasum Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 241000605623 Alseodaphne Species 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 241000611184 Amphora Species 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 235000003840 Amygdalus nana Nutrition 0.000 description 1
- 241000192542 Anabaena Species 0.000 description 1
- 241000693997 Anacardium Species 0.000 description 1
- 235000001271 Anacardium Nutrition 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 241000744007 Andropogon Species 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 102100033715 Apolipoprotein A-I Human genes 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- 241000219195 Arabidopsis thaliana Species 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 241000186692 Araucariales Species 0.000 description 1
- 241000123640 Arecales Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241001106067 Atropa Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241001622882 Austrobaileyales Species 0.000 description 1
- 235000005781 Avena Nutrition 0.000 description 1
- 235000007558 Avena sp Nutrition 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 241000724306 Barley stripe mosaic virus Species 0.000 description 1
- 241000577998 Bean yellow dwarf virus Species 0.000 description 1
- 241000018415 Beilschmiedia Species 0.000 description 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000190863 Bergeyella zoohelcum Species 0.000 description 1
- 241000722354 Bergeyella zoohelcum ATCC 43767 Species 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 241000760366 Blastocladiomycota Species 0.000 description 1
- 241001536324 Botryococcus Species 0.000 description 1
- 241000339490 Brachyachne Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 235000011293 Brassica napus Nutrition 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 235000004221 Brassica oleracea var gemmifera Nutrition 0.000 description 1
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 description 1
- 244000304217 Brassica oleracea var. gongylodes Species 0.000 description 1
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 description 1
- 235000000540 Brassica rapa subsp rapa Nutrition 0.000 description 1
- 241001301148 Brassica rapa subsp. oleifera Species 0.000 description 1
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 241000218980 Brassicales Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- 101710172824 CRISPR-associated endonuclease Cas9 Proteins 0.000 description 1
- 238000010453 CRISPR/Cas method Methods 0.000 description 1
- 235000010773 Cajanus indicus Nutrition 0.000 description 1
- 244000105627 Cajanus indicus Species 0.000 description 1
- 101000909256 Caldicellulosiruptor bescii (strain ATCC BAA-1888 / DSM 6725 / Z-1320) DNA polymerase I Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 description 1
- 241000208809 Carthamus Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 241000723418 Carya Species 0.000 description 1
- 102100032616 Caspase-2 Human genes 0.000 description 1
- 108090000552 Caspase-2 Proteins 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 241000208328 Catharanthus Species 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- 241000632385 Celastrales Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000227752 Chaetoceros Species 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 108091092236 Chimeric RNA Proteins 0.000 description 1
- 241000195597 Chlamydomonas reinhardtii Species 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- 108010062745 Chloride Channels Proteins 0.000 description 1
- 102000011045 Chloride Channels Human genes 0.000 description 1
- 241000180279 Chlorococcum Species 0.000 description 1
- 108700031407 Chloroplast Genes Proteins 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 241000233652 Chytridiomycota Species 0.000 description 1
- 240000006740 Cichorium endivia Species 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 241000219109 Citrullus Species 0.000 description 1
- 244000241235 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 244000248349 Citrus limon Species 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000723370 Cocculus Species 0.000 description 1
- 241000737241 Cocos Species 0.000 description 1
- 240000004270 Colocasia esculenta var. antiquorum Species 0.000 description 1
- 241000233971 Commelinales Species 0.000 description 1
- 241000134970 Cornales Species 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 244000168525 Croton tiglium Species 0.000 description 1
- KCYOZNARADAZIZ-PPBBKLJYSA-N Cryptochrome Natural products O[C@@H]1CC(C)(C)C=2[C@@](C)(O[C@H](/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(\C)/[C@H]3O[C@@]4(C)C(C(C)(C)CCC4)=C3)/C)\C)/C)C=2)C1 KCYOZNARADAZIZ-PPBBKLJYSA-N 0.000 description 1
- 108010037139 Cryptochromes Proteins 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 235000009847 Cucumis melo var cantalupensis Nutrition 0.000 description 1
- 235000010071 Cucumis prophetarum Nutrition 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 241000219122 Cucurbita Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- 241000219130 Cucurbita pepo subsp. pepo Species 0.000 description 1
- 235000003954 Cucurbita pepo var melopepo Nutrition 0.000 description 1
- 241001116468 Cunninghamia Species 0.000 description 1
- 241000186690 Cupressales Species 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 241000196114 Cycadales Species 0.000 description 1
- 241001147476 Cyclotella Species 0.000 description 1
- 241000206743 Cylindrotheca Species 0.000 description 1
- 244000019459 Cynara cardunculus Species 0.000 description 1
- 235000019106 Cynara scolymus Nutrition 0.000 description 1
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102100023419 Cystic fibrosis transmembrane conductance regulator Human genes 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102100026139 DNA damage-inducible transcript 4 protein Human genes 0.000 description 1
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 1
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 241000208175 Daucus Species 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000618813 Dilleniales Species 0.000 description 1
- 241000199914 Dinophyceae Species 0.000 description 1
- 235000002723 Dioscorea alata Nutrition 0.000 description 1
- 235000007056 Dioscorea composita Nutrition 0.000 description 1
- 235000009723 Dioscorea convolvulacea Nutrition 0.000 description 1
- 235000005362 Dioscorea floribunda Nutrition 0.000 description 1
- 235000004868 Dioscorea macrostachya Nutrition 0.000 description 1
- 235000005361 Dioscorea nummularia Nutrition 0.000 description 1
- 235000005360 Dioscorea spiculiflora Nutrition 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 241000207977 Dipsacales Species 0.000 description 1
- 101100273028 Drosophila melanogaster Caf1-55 gene Proteins 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 241001162696 Duguetia Species 0.000 description 1
- 241000195634 Dunaliella Species 0.000 description 1
- 108010053101 ELAV Proteins Proteins 0.000 description 1
- 102000016662 ELAV Proteins Human genes 0.000 description 1
- 101150031726 ERS1 gene Proteins 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 1
- 241000512897 Elaeis Species 0.000 description 1
- 235000001942 Elaeis Nutrition 0.000 description 1
- 235000001950 Elaeis guineensis Nutrition 0.000 description 1
- 244000127993 Elaeis melanococca Species 0.000 description 1
- 241000218671 Ephedra Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000218182 Eschscholzia Species 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 241000195620 Euglena Species 0.000 description 1
- 102000012858 Eukaryotic Initiation Factor-4G Human genes 0.000 description 1
- 108010057192 Eukaryotic Initiation Factor-4G Proteins 0.000 description 1
- 241000224472 Eustigmatophyceae Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241001247262 Fabales Species 0.000 description 1
- 235000010099 Fagus sylvatica Nutrition 0.000 description 1
- 240000000731 Fagus sylvatica Species 0.000 description 1
- 102000018825 Fanconi Anemia Complementation Group C protein Human genes 0.000 description 1
- 241000234642 Festuca Species 0.000 description 1
- 241000218218 Ficus <angiosperm> Species 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 241000223221 Fusarium oxysporum Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000702463 Geminiviridae Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 241000208326 Gentianales Species 0.000 description 1
- 241000134874 Geraniales Species 0.000 description 1
- 241000208152 Geranium Species 0.000 description 1
- 241000218790 Ginkgoales Species 0.000 description 1
- 241000557129 Glaucium Species 0.000 description 1
- 241001583499 Glomeromycotina Species 0.000 description 1
- 102100030651 Glutamate receptor 2 Human genes 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 241000218664 Gnetales Species 0.000 description 1
- 241000219146 Gossypium Species 0.000 description 1
- 235000009438 Gossypium Nutrition 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 102220491568 Heat shock 70 kDa protein 1B_D10A_mutation Human genes 0.000 description 1
- 241000208818 Helianthus Species 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000258937 Hemiptera Species 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000959437 Homo sapiens Beta-2 adrenergic receptor Proteins 0.000 description 1
- 101000912753 Homo sapiens DNA damage-inducible transcript 4 protein Proteins 0.000 description 1
- 101000865408 Homo sapiens Double-stranded RNA-specific adenosine deaminase Proteins 0.000 description 1
- 101100446641 Homo sapiens FKBP1A gene Proteins 0.000 description 1
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 1
- 101000833167 Homo sapiens Poly(A) RNA polymerase GLD2 Proteins 0.000 description 1
- 101000780643 Homo sapiens Protein argonaute-2 Proteins 0.000 description 1
- 101000807859 Homo sapiens Vasopressin V2 receptor Proteins 0.000 description 1
- 101000744745 Homo sapiens YTH domain-containing family protein 2 Proteins 0.000 description 1
- 101000795753 Homo sapiens mRNA decay activator protein ZFP36 Proteins 0.000 description 1
- 241000724309 Hordeivirus Species 0.000 description 1
- 241000208278 Hyoscyamus Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000008607 Integrin beta3 Human genes 0.000 description 1
- 108010020950 Integrin beta3 Proteins 0.000 description 1
- 102100039060 Interleukin enhancer-binding factor 2 Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000006350 Ipomoea batatas var. batatas Nutrition 0.000 description 1
- 241001501885 Isochrysis Species 0.000 description 1
- 241000235644 Issatchenkia Species 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 241001247355 Landolphia Species 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 241000218652 Larix Species 0.000 description 1
- 235000005590 Larix decidua Nutrition 0.000 description 1
- 241000218194 Laurales Species 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000209499 Lemna Species 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000283960 Leporidae Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 241000234269 Liliales Species 0.000 description 1
- 241000208204 Linum Species 0.000 description 1
- 235000012854 Litsea cubeba Nutrition 0.000 description 1
- 240000002262 Litsea cubeba Species 0.000 description 1
- 241000209082 Lolium Species 0.000 description 1
- 241000219745 Lupinus Species 0.000 description 1
- 235000002262 Lycopersicon Nutrition 0.000 description 1
- 241000702489 Maize streak virus Species 0.000 description 1
- 241000121629 Majorana Species 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 241000134966 Malvales Species 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 241000219823 Medicago Species 0.000 description 1
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108091007780 MiR-122 Proteins 0.000 description 1
- 241000243190 Microsporidia Species 0.000 description 1
- 241000013738 Monochrysis Species 0.000 description 1
- 241001478792 Monoraphidium Species 0.000 description 1
- 241000235575 Mortierella Species 0.000 description 1
- 101100144701 Mus musculus Drosha gene Proteins 0.000 description 1
- 101100078999 Mus musculus Mx1 gene Proteins 0.000 description 1
- 101100046352 Mus musculus Tjap1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- 241000134886 Myrtales Species 0.000 description 1
- VQAYFKKCNSOZKM-IOSLPCCCSA-N N(6)-methyladenosine Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VQAYFKKCNSOZKM-IOSLPCCCSA-N 0.000 description 1
- VQAYFKKCNSOZKM-UHFFFAOYSA-N NSC 29409 Natural products C1=NC=2C(NC)=NC=NC=2N1C1OC(CO)C(O)C1O VQAYFKKCNSOZKM-UHFFFAOYSA-N 0.000 description 1
- 241000196305 Nannochloris Species 0.000 description 1
- 241001494793 Nanovirus Species 0.000 description 1
- 235000017879 Nasturtium officinale Nutrition 0.000 description 1
- 240000005407 Nasturtium officinale Species 0.000 description 1
- 241000502321 Navicula Species 0.000 description 1
- 241000760367 Neocallimastigomycetes Species 0.000 description 1
- 241001442227 Nephroselmis Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102100024014 Nestin Human genes 0.000 description 1
- 108700021638 Neuro-Oncological Ventral Antigen Proteins 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 241000221961 Neurospora crassa Species 0.000 description 1
- 241000180701 Nitzschia <flatworm> Species 0.000 description 1
- 241000059630 Nodularia <Cyanobacteria> Species 0.000 description 1
- 241000192656 Nostoc Species 0.000 description 1
- 108700031302 Nuclear Factor 45 Proteins 0.000 description 1
- 241000039470 Nymphaeales Species 0.000 description 1
- 241000795633 Olea <sea slug> Species 0.000 description 1
- 241000514008 Oocystis Species 0.000 description 1
- 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 description 1
- 241000209094 Oryza Species 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 241000209117 Panicum Species 0.000 description 1
- 235000006443 Panicum miliaceum subsp. miliaceum Nutrition 0.000 description 1
- 235000009037 Panicum miliaceum subsp. ruderale Nutrition 0.000 description 1
- 235000011096 Papaver Nutrition 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- 241001495454 Parthenium Species 0.000 description 1
- AVFIYMSJDDGDBQ-UHFFFAOYSA-N Parthenium Chemical compound C1C=C(CCC(C)=O)C(C)CC2OC(=O)C(=C)C21 AVFIYMSJDDGDBQ-UHFFFAOYSA-N 0.000 description 1
- 240000004370 Pastinaca sativa Species 0.000 description 1
- 235000017769 Pastinaca sativa subsp sativa Nutrition 0.000 description 1
- 241000206766 Pavlova Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 108010085186 Peroxisomal Targeting Signals Proteins 0.000 description 1
- 241000218196 Persea Species 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 244000062780 Petroselinum sativum Species 0.000 description 1
- 240000007377 Petunia x hybrida Species 0.000 description 1
- 241000206731 Phaeodactylum Species 0.000 description 1
- 241000219833 Phaseolus Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 241000746981 Phleum Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 235000009230 Physalis pubescens Nutrition 0.000 description 1
- 240000001558 Physalis viscosa Species 0.000 description 1
- 235000002491 Physalis viscosa Nutrition 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 241000186704 Pinales Species 0.000 description 1
- 235000005205 Pinus Nutrition 0.000 description 1
- 241000218602 Pinus <genus> Species 0.000 description 1
- 241000758713 Piperales Species 0.000 description 1
- 241000543704 Pistacia Species 0.000 description 1
- 235000003445 Pistacia Nutrition 0.000 description 1
- 235000003447 Pistacia vera Nutrition 0.000 description 1
- 240000006711 Pistacia vera Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 108700001094 Plant Genes Proteins 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 241000139306 Platt Species 0.000 description 1
- 241000722208 Pleurochrysis Species 0.000 description 1
- 241000209048 Poa Species 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 241000500034 Podostemaceae Species 0.000 description 1
- 102100024380 Poly(A) RNA polymerase GLD2 Human genes 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 241000710007 Potexvirus Species 0.000 description 1
- 241001135217 Prevotella buccae Species 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000617410 Proteales Species 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 102100034207 Protein argonaute-2 Human genes 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 241000220299 Prunus Species 0.000 description 1
- 235000011432 Prunus Nutrition 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 241001290151 Prunus avium subsp. avium Species 0.000 description 1
- 235000006029 Prunus persica var nucipersica Nutrition 0.000 description 1
- 244000017714 Prunus persica var. nucipersica Species 0.000 description 1
- 241000192511 Pseudanabaena Species 0.000 description 1
- 241000218683 Pseudotsuga Species 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 241001509341 Pyramimonas Species 0.000 description 1
- 101000902592 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) DNA polymerase Proteins 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 235000016976 Quercus macrolepis Nutrition 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 241001128129 Rafflesiaceae Species 0.000 description 1
- 241000133533 Ranunculales Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 101000866288 Rattus norvegicus Excitatory amino acid transporter 1 Proteins 0.000 description 1
- 101710146873 Receptor-binding protein Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 101710137011 Retinol-binding protein 4 Proteins 0.000 description 1
- 241000589180 Rhizobium Species 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 240000005384 Rhizopus oryzae Species 0.000 description 1
- 235000013752 Rhizopus oryzae Nutrition 0.000 description 1
- 235000003846 Ricinus Nutrition 0.000 description 1
- 241000322381 Ricinus <louse> Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 102100024544 SURP and G-patch domain-containing protein 1 Human genes 0.000 description 1
- 241000235343 Saccharomycetales Species 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 241000134968 Sapindales Species 0.000 description 1
- 241000208437 Sarraceniaceae Species 0.000 description 1
- 241000134890 Saxifragales Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 101100204733 Schizosaccharomyces pombe (strain 972 / ATCC 24843) gus1 gene Proteins 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- 241000780602 Senecio Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 description 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 1
- 241000220261 Sinapis Species 0.000 description 1
- 241001643412 Sinomenium Species 0.000 description 1
- 235000002634 Solanum Nutrition 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241001330502 Stephania Species 0.000 description 1
- 241001148696 Stichococcus Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 102000000551 Syk Kinase Human genes 0.000 description 1
- 108010016672 Syk Kinase Proteins 0.000 description 1
- 241000192707 Synechococcus Species 0.000 description 1
- 241000192584 Synechocystis Species 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 241000196321 Tetraselmis Species 0.000 description 1
- 241001491691 Thalassiosira Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 240000006909 Tilia x europaea Species 0.000 description 1
- 241000948318 Tobacco leaf curl virus Species 0.000 description 1
- 241000723573 Tobacco rattle virus Species 0.000 description 1
- 241000723717 Tobravirus Species 0.000 description 1
- 241000702295 Tomato golden mosaic virus Species 0.000 description 1
- 241001135990 Tomato leaf curl virus Species 0.000 description 1
- 241000283907 Tragelaphus oryx Species 0.000 description 1
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 1
- 101710195626 Transcriptional activator protein Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 241000499912 Trichoderma reesei Species 0.000 description 1
- 241000192118 Trichodesmium Species 0.000 description 1
- 241001312519 Trigonella Species 0.000 description 1
- 235000019714 Triticale Nutrition 0.000 description 1
- 241000569574 Trochodendrales Species 0.000 description 1
- 101710176279 Tubulin beta-2 chain Proteins 0.000 description 1
- 108091026838 U1 spliceosomal RNA Proteins 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 241001106462 Ulmus Species 0.000 description 1
- 241000306282 Umbelopsis isabellina Species 0.000 description 1
- 102100037108 Vasopressin V2 receptor Human genes 0.000 description 1
- 241000219873 Vicia Species 0.000 description 1
- 240000006677 Vicia faba Species 0.000 description 1
- 235000010749 Vicia faba Nutrition 0.000 description 1
- 235000002098 Vicia faba var. major Nutrition 0.000 description 1
- 241000219977 Vigna Species 0.000 description 1
- 235000010726 Vigna sinensis Nutrition 0.000 description 1
- 244000042314 Vigna unguiculata Species 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 241000702302 Wheat dwarf virus Species 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 102100039644 YTH domain-containing family protein 2 Human genes 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- 241000235015 Yarrowia lipolytica Species 0.000 description 1
- 241000209149 Zea Species 0.000 description 1
- 241000482268 Zea mays subsp. mays Species 0.000 description 1
- 241000907316 Zika virus Species 0.000 description 1
- 241000234675 Zingiberales Species 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 244000193174 agave Species 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000009418 agronomic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 102000009899 alpha Karyopherins Human genes 0.000 description 1
- 108010077099 alpha Karyopherins Proteins 0.000 description 1
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000016520 artichoke thistle Nutrition 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000000778 atheroprotective effect Effects 0.000 description 1
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical group NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 1
- KCYOZNARADAZIZ-XZOHMNSDSA-N beta-cryptochrome Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C1OC2(C)CC(O)CC(C)(C)C2=C1)C=CC=C(/C)C3OC4(C)CCCC(C)(C)C4=C3 KCYOZNARADAZIZ-XZOHMNSDSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 101150049515 bla gene Proteins 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 235000003733 chicria Nutrition 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000011088 chloroplast localization Effects 0.000 description 1
- 229920003211 cis-1,4-polyisoprene Polymers 0.000 description 1
- VJKUPQSHOVKBCO-RYVYVXLVSA-N cocculus solid Chemical compound O([C@@H]1C[C@]2(O)[C@@]34C)C14C(=O)O[C@@H]3[C@@H]1[C@H](C(=C)C)[C@H]2C(=O)O1.O([C@@H]1C[C@]2(O)[C@@]34C)C14C(=O)O[C@@H]3[C@@H]1[C@H](C(C)(O)C)[C@H]2C(=O)O1 VJKUPQSHOVKBCO-RYVYVXLVSA-N 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 108010031180 cypridina luciferase Proteins 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 1
- 230000001819 effect on gene Effects 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 230000037442 genomic alteration Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 108010089305 glutamate receptor type B Proteins 0.000 description 1
- 108010033706 glycylserine Proteins 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000055209 human FKBP1A Human genes 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 101150095658 ilf2 gene Proteins 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 108700032552 influenza virus INS1 Proteins 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 241000238565 lobster Species 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 230000012976 mRNA stabilization Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000005739 manihot Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 108091051828 miR-122 stem-loop Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 210000000337 motor cortex Anatomy 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000012223 nuclear import Effects 0.000 description 1
- 210000004492 nuclear pore Anatomy 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 235000012162 pavlova Nutrition 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000003415 peat Substances 0.000 description 1
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 1
- 108010043655 penetratin Proteins 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 208000022177 perioral myoclonia with absences Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000020233 pistachio Nutrition 0.000 description 1
- 108010056274 polo-like kinase 1 Proteins 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000003946 protein process Effects 0.000 description 1
- 238000001273 protein sequence alignment Methods 0.000 description 1
- 235000014774 prunus Nutrition 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000014639 sexual reproduction Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000005783 single-strand break Effects 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 235000020354 squash Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000002311 subsequent effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 108010066762 sweet arrow peptide Proteins 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 238000011311 validation assay Methods 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 241000441614 x Festulolium Species 0.000 description 1
- 241000228158 x Triticosecale Species 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
Definitions
- the present invention generally relates to systems, methods and compositions used for the control of gene expression involving sequence targeting, such as perturbation of gene transcripts or nucleic acid editing, that may use vector systems related to Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and components thereof.
- sequence targeting such as perturbation of gene transcripts or nucleic acid editing
- CRISPR Clustered Regularly Interspaced Short Palindromic Repeats
- the CRISPR-CRISPR associated (Cas) systems of bacterial and archaeal adaptive immunity are some such systems that show extreme diversity of protein composition and genomic loci architecture.
- the CRISPR-Cas system loci has more than 50 gene families and there is no strictly universal genes indicating fast evolution and extreme diversity of loci architecture. So far, adopting a multi-pronged approach, there is comprehensive cas gene identification of about 395 profiles for 93 Cas proteins. Classification includes signature gene profiles plus signatures of locus architecture.
- a new classification of CRISPR-Cas systems is proposed in which these systems are broadly divided into two classes, Class 1 with multisubunit effector complexes and Class 2 with single-subunit effector modules exemplified by the Cas9 protein.
- Novel effector proteins associated with Class 2 CRISPR-Cas systems may be developed as powerful genome engineering tools and the prediction of putative novel effector proteins and their engineering and optimization is important.
- Smargon et al., (2017, 65(4):618-630) disclose CRISPR/cas systems comprising a Cas13b effector protein from Bergey/la zoohelcum or Prevotella buccae. Novel Cas13b orthologues and uses thereof are desirable.
- Effector proteins include two subgroups, Type VI-B1 and Type VI-B2, and include members which are RNA-programmable nucleases, RNA-interfering and may be involved in bacterial adoptive immunity against RNA phages.
- a Cas13b system can comprise a large single effector (approximately 1100 amino acids in length), and one or none of two small putative accessory proteins (approximately 200 amino acids in length) nearby a CRISPR array. Based on the nearby small protein, the system is bifurcated into two Loci A and B. No additional proteins out to 25 kilobase pairs upstream or downstream from the array are conserved across species with each locus.
- the CRISPR array comprises direct repeat sequences 36 nucleotides in length and spacer sequences 30 nucleotides in length.
- the direct repeat is generally well conserved, especially at the ends, with a GTTG/GUUG at the 5' end reverse complementary to a CAAC at the 3' end. This conservation suggests strong base pairing for an RNA loop structure that potentially interacts with the protein(s) in the locus.
- a motif search complementary to the direct repeats revealed no candidate tracrRNAs nearby the arrays, possibly indicative of a single crRNA like that found in the Cpf1 locus.
- a Type VI-B system comprises a novel Cas13b effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A and optionally a small accessory protein encoded upstream or downstream of the Cas13b effector protein.
- the small accessory protein enhances the Cas13b effector's ability to target RNA.
- the invention provides a non-naturally occurring or engineered composition comprising
- a non-naturally occurring or engineered composition of the invention may comprise an accessory protein that enhances Type VI-B CRISPR-Cas effector protein activity.
- the accessory protein that enhances Cas13b effector protein activity is a csx28 protein.
- the Type VI-B CRISPR-Cas effector protein and the Type VI-B CRISPR-Cas accessory protein may be from the same source or from a different source.
- a non-naturally occurring or engineered composition of the invention comprises an accessory protein that represses Cas13b effector protein activity.
- a non-naturally occurring or engineered composition of the invention comprises two or more crRNAs.
- a non-naturally occurring or engineered composition of the invention comprises a guide sequence that hybridizes to a target RNA sequence in a prokaryotic cell.
- a non-naturally occurring or engineered composition of the invention comprises a guide sequence that hybridizes to a target RNA sequence in a eukaryotic cell.
- the Cas13b effector protein comprises one or more nuclear localization signals (NLSs).
- NLSs nuclear localization signals
- the Cas13b effector protein of the invention is, or in, or comprises, or consists essentially of, or consists of, or involves or relates to such a Cas13b effector protein from Bacteroidetes bacterium GWA2_31_9 as set forth in Table 1.
- the compositions, vector systems, delivery systems and in vitro or ex vivo methods of invention is intended to provide, or relate to, or involve, or comprise, or consist essentially of, or consist of, a Cas13b effector protein from Bacteroidetes bacterium GWA2_31_9 as set forth in Table 1, including mutations or alterations thereof as set forth herein.
- a non-naturally occurring or engineered composition of the invention comprises a functional domain cleaves the target RNA sequence.
- nucleotide sequence encoding the Type VI-B CRISPR-Cas effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A and/or the nucleotide sequence encoding the Type VI-B CRISPR-Cas accessory protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A is codon optimized for expression in a eukaryotic cell.
- nucleotide sequences encoding the Cas13b effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A and the accessory protein are codon optimized for expression in a eukaryotic cell.
- the non-naturally occurring or engineered composition of the invention is for use in a therapeutic method of treatment or in a research program.
- the non-naturally occurring or engineered vector system of the invention is for use in a therapeutic method of treatment or in a research program.
- the invention provides a method of modifying expression of a target gene of interest, the method comprising contacting a target RNA with one or more non-naturally occurring or engineered compositions comprising
- the method of modifying expression of a target gene of interest further comprises contacting the the target RNA with an accessory protein that enhances Cas13b effector protein activity.
- the method of modifying expression of a target gene of interest further comprises contacting the the target RNA with an accessory protein that represses Cas13b effector protein activity.
- the method of modifying expression of a target gene of interest comprises cleaving the target RNA.
- the method of modifying expression of a target gene of interest comprises increasing or decreasing expression of the target RNA.
- the target gene is in a prokaryotic cell.
- the target gene is in a eukaryotic cell.
- the disclosure provides a cell comprising a modified target of interest, wherein the target of interest has been modified according to any of the method disclosed herein.
- the cell is a prokaryotic cell.
- the cell is a eukaryotic cell.
- modification of the target of interest in a cell results in:
- the disclosure provides a multicellular organism comprising one or more cells disclosed herein or one or more cells modified according to any of the methods disclosed herein.
- the disclosure provides a plant or animal model comprising one or more cells disclosed herein or one or more cells modified according to any of the methods disclosed herein.
- the disclosure provides a gene product from a cell or the cell line or the organism or the plant or animal model disclosed herein.
- the invention provides an isolated nucleic acid encoding the Cas13b effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A which is a DNA sequence and further comprises a sequence encoding a crRNA.
- the invention provides an isolated eukaryotic cell comprising the the nucleic acid encoding the Cas13b effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A.
- Cas13b effector protein from from Bacteroidetes bacterium GWA2_31_9 of Table 1A
- “Cas13b effector protein” or “effector protein” or “Cas” or “Cas protein” or “RNA targeting effector protein” or “RNA targeting protein” or like expressions is to be understood with reference to Table 1 and can be read as a Table 1 Cas13b effector protein
- expressions such as "RNA targeting CRISPR system” are to be understood with reference to Table 1 and can be read as a Table 1 Cas13b effector protein CRISPR system
- references to guide RNA or sgRNA are to be read in conjunction with the herein-discussion of the Cas13b system crRNA, e.g., that which is sgRNA in other systems may be considered as or akin to crRNA in the instant invention.
- the host cell is a bacterial host cell.
- the step of co-introducing the plasmids is by electroporation and the host cell is an electro-competent host cell.
- the invention provides an in vitro or ex vivo method of modifying sequences associated with or at a target locus of interest, the method comprising delivering to said locus a non-naturally occurring or engineered composition comprising a Cas13b effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A and one or more nucleic acid components, wherein the effector protein forms a complex with the one or more nucleic acid components and upon binding of the said complex to the locus of interest the effector protein induces the modification of the sequences associated with or at the target locus of interest.
- the modification is the introduction of a strand break.
- the sequences associated with or at the target locus of interest comprises RNA or consists of RNA.
- the disclosure provides a method of modifying sequences associated with or at a target locus of interest, the method comprising delivering to said sequences associated with or at the locus a non-naturally occurring or engineered composition comprising a Cas13b loci effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A and one or more nucleic acid components, wherein the Cas13b effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A forms a complex with the one or more nucleic acid components and upon binding of the said complex to the locus of interest the effector protein induces the modification of sequences associated with or at the target locus of interest.
- the modification is the introduction of a strand break.
- the nucleic acid component of the complex may comprise a guide sequence linked to a direct repeat sequence, wherein the direct repeat sequence comprises one or more stem loops or optimized secondary structures.
- the direct repeat may be a short DR or a long DR (dual DR).
- the direct repeat may be modified to comprise one or more protein-binding RNA aptamers.
- one or more aptamers may be included such as part of optimized secondary structure. Such aptamers may be capable of binding a bacteriophage coat protein.
- the invention provides methods of in vitro or ex vivo modifying sequences associated with or at a target locus of interest wherein the method comprises introducing a Cas13b complex into any desired cell type, prokaryotic or eukaryotic cell, whereby the Cas13b effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A complex effectively functions to interfere with RNA in the eukaryotic or prokaryotic cell.
- the cell is a eukaryotic cell and the RNA is transcribed from a mammalian genome or is present in a mammalian cell.
- the target locus of interest may be comprised within a RNA molecule.
- the target locus of interest may be comprised in a RNA molecule in vitro.
- the invention provides an in vitro or ex vivo method of modifying a target locus of interest, the method comprising delivering to said locus a non-naturally occurring or engineered composition comprising a Cas13b effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A and one or more nucleic acid components, wherein the effector protein forms a complex with the one or more nucleic acid components and upon binding of the said complex to the locus of interest the effector protein induces the modification of the target locus of interest.
- the modification is the introduction of a strand break.
- the target locus of interest may be a genomic or epigenomic locus of interest.
- the complex may be delivered with multiple guides for multiplexed use.
- more than one protein(s) may be used.
- the nucleic acid components may comprise a CRISPR RNA (crRNA) sequence.
- the effector protein is a Cas13b effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A
- the nucleic acid components may comprise a CRISPR RNA (crRNA) sequence and generally may not comprise any trans-activating crRNA (tracr RNA) sequence.
- the one or more polynucleotide molecules may be comprised in a delivery system, or the one or more vectors may be comprised in a delivery system.
- non-naturally occurring or engineered composition may be delivered via liposomes, particles including nanoparticles, exosomes, microvesicles, a gene-gun or one or more viral vectors.
- the disclosure also provides a non-naturally occurring or engineered composition which is a composition having the characteristics as discussed herein or defined in any of the herein described methods.
- the invention thus provides a non-naturally occurring or engineered composition, such as particularly a composition capable of or configured to modify a target locus of interest, said composition comprising a Cas13b effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A and one or more nucleic acid components, wherein the effector protein forms a complex with the one or more nucleic acid components and upon binding of the said complex to the locus of interest the effector protein induces the modification of the target locus of interest.
- a non-naturally occurring or engineered composition such as particularly a composition capable of or configured to modify a target locus of interest, said composition comprising a Cas13b effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A and one or more nucleic acid components, wherein the effector protein forms a complex with the one or more nucleic acid components and upon binding of the said complex to the locus of interest the effector protein induces the modification of the target locus of interest.
- the invention also provides in a further aspect a non-naturally occurring or engineered composition, such as particularly a composition capable of or configured to modify a target locus of interest, said composition comprising: (a) a guide RNA molecule (or a combination of guide RNA molecules, e.g., a first guide RNA molecule and a second guide RNA molecule) or a nucleic acid encoding the guide RNA molecule (or one or more nucleic acids encoding the combination of guide RNA molecules); (b) a Cas13b effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A.
- a guide RNA molecule or a combination of guide RNA molecules, e.g., a first guide RNA molecule and a second guide RNA molecule
- a nucleic acid encoding the guide RNA molecule or one or more nucleic acids encoding the combination of guide RNA molecules
- a Cas13b effector protein from Bacteroidetes
- the invention also provides in a further aspect a non-naturally occurring or engineered composition
- a non-naturally occurring or engineered composition comprising: (I.) one or more CRISPR-Cas system polynucleotide sequences comprising (a) a guide sequence capable of hybridizing to a target sequence in a polynucleotide locus, (b) a tracr mate sequence, and (c) a tracrRNA sequence, and (II.) a second polynucleotide sequence encoding a Cas13b effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A, wherein when transcribed, the tracr mate sequence hybridizes to the tracrRNA sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the CRISPR complex comprises the Cas13b effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A complexed with (1) the
- a tracrRNA may not be required.
- the invention also provides in certain embodiments a non-naturally occurring or engineered composition comprising: (I.) one or more CRISPR-Cas system polynucleotide sequences comprising (a) a guide sequence capable of hybridizing to a target sequence in a polynucleotide locus, and (b) a direct repeat sequence, and (II.) a second polynucleotide sequence encoding a Cas13b effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A, wherein when transcribed, the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the CRISPR complex comprises the Cas13b effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the direct repeat sequence.
- the direct repeat sequence may comprise secondary structure that is sufficient for crRNA loading onto the effector protein.
- such secondary structure may comprise, consist essentially of or consist of a stem loop (such as one or more stem loops) within the direct repeat.
- the disclosure also provides a vector system comprising one or more vectors, the one or more vectors comprising one or more polynucleotide molecules encoding components of a non-naturally occurring or engineered composition which is a composition having the characteristics as defined in any of the herein described methods.
- the disclosure also provides a delivery system comprising one or more vectors or one or more polynucleotide molecules, the one or more vectors or polynucleotide molecules comprising one or more polynucleotide molecules encoding components of a non-naturally occurring or engineered composition which is a composition having the characteristics discussed herein or as defined in any of the herein described methods.
- the disclosure also provides a non-naturally occurring or engineered composition, or one or more polynucleotides encoding components of said composition, or vector or delivery systems comprising one or more polynucleotides encoding components of said composition for use in a therapeutic method of treatment.
- the therapeutic method of treatment may comprise gene or genome editing, or gene therapy.
- the one or more amino acid residues are modified in the Cas13b effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A, e.g., an engineered or non-naturally-occurring Cas 13 b effector protein.
- the effector protein comprises one or more HEPN domains.
- the effector protein comprises two HEPN domains.
- the effector protein comprises one HEPN domain at the C-terminus and another HEPN domain at the N-terminus of the protein.
- the one or more mutations or the two or more mutations may be in a catalytically active domain of the effector protein comprising a HEPN domain, or a catalytically active domain which is homologous to a HEPN domain.
- the effector protein comprises one or more of the following mutations: R116A, H121A, R1177A, H1182A (wherein amino acid positions correspond to amino acid positions of Group 29 protein originating from Bergeyella zoohelcum ATCC 43767). The skilled person will understand that corresponding amino acid positions in different Cas13b proteins may be mutated to the same effect.
- one or more mutations abolish catalytic activity of the protein completely or partially (e.g.
- the effector protein as described herein is a "dead" effector protein, such as a dead Cas13b effector protein (i.e. dCas13b) from Bacteroidetes bacterium GWA2_31_9 of Table 1A.
- the effector protein has one or more mutations in HEPN domain 1.
- the effector protein has one or more mutations in HEPN domain 2.
- the effectyor protein has one or more mutations in HEPN domain 1 and HEPN domain 2.
- the effector protein may comprise one or more heterologous functional domains.
- the one or more heterologous functional domains may comprise one or more nuclear localization signal (NLS) domains.
- the one or more heterologous functional domains may comprise at least two or more NLS domains.
- the one or more NLS domain(s) may be positioned at or near or in proximity to a terminus of the effector protein (e.g., Cas13b effector protein) and if two or more NLSs, each of the two may be positioned at or near or in proximity to a terminus of the effector protein (e.g., Cas13b effector protein).
- the one or more heterologous functional domains may comprise one or more transcriptional activation domains.
- the transcriptional activation domain may comprise VP64.
- the one or more heterologous functional domains may comprise one or more transcriptional repression domains.
- the transcriptional repression domain comprises a KRAB domain or a SID domain (e.g. SID4X).
- the one or more heterologous functional domains may comprise one or more nuclease domains.
- a nuclease domain comprises Fok1.
- the one or more heterologous functional domains described above mayhave one or more of the following activities: methylase activity, demethylase activity, transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, nuclease activity, single-strand RNA cleavage activity, double-strand RNA cleavage activity, single-strand DNA cleavage activity, double-strand DNA cleavage activity and nucleic acid binding activity.
- At least one or more heterologous functional domains may be at or near the amino-terminus of the effector protein and/or wherein at least one or more heterologous functional domains is at or near the carboxy-terminus of the effector protein.
- the one or more heterologous functional domains may be fused to the effector protein.
- the one or more heterologous functional domains may be tethered to the effector protein.
- the one or more heterologous functional domains may be linked to the effector protein by a linker moiety.
- the Cas13b effector proteins from Bacteroidetes bacterium GWA2_31_9 of Table 1A may be associated with a locus comprising short CRISPR repeats between 30 and 40 bp long, more typically between 34 and 38 bp long, even more typically between 36 and 37 bp long, e.g., 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 bp long.
- the CRISPR repeats are long or dual repeats between 80 and 350 bp long such as between 80 and 200 bp long, even more typically between 86 and 88 bp long, e.g., 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, or 90 bp long
- a protospacer adjacent motif (PAM) or PAM-like motif directs binding of the effector protein (e.g. a Cas13b effector protein) complex as disclosed herein to the target locus of interest.
- the PAM may be a 5' PAM (i.e., located upstream of the 5' end of the protospacer).
- the PAM may be a 3' PAM (i.e., located downstream of the 5' end of the protospacer).
- both a 5' PAM and a 3' PAM are required.
- a PAM or PAM-like motif may not be required for directing binding of the effector protein (e.g.
- a 5' PAM is D (i.e. A, G, or U). In certain embodiments, a 5' PAM is D for Cas13b effectors.
- cleavage at repeat sequences may generate crRNAs (e.g. short or long crRNAs) containing a full spacer sequence flanked by a short nucleotide (e.g. 5, 6, 7, 8, 9, or 10 nt or longer if it is a dual repeat) repeat sequence at the 5' end (this may be referred to as a crRNA "tag”) and the rest of the repeat at the 3'end.
- crRNAs e.g. short or long crRNAs
- Cas13b effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A is engineered and can comprise one or more mutations that reduce or eliminate nuclease activity, thereby reducing or eliminating RNA interfering activity. Mutations can also be made at neighboring residues, e.g., at amino acids near those that participate in the nuclease activity.
- one or more putative catalytic nuclease domains are inactivated and the effector protein complex lacks cleavage activity and functions as an RNA binding complex.
- the resulting RNA binding complex may be linked with one or more functional domains as described herein.
- the one or more functional domains are controllable, i.e. inducible.
- the guide RNA or mature crRNA comprises, consists essentially of, or consists of a direct repeat sequence and a guide sequence or spacer sequence. In certain embodiments, the guide RNA or mature crRNA comprises, consists essentially of, or consists of a direct repeat sequence linked to a guide sequence or spacer sequence. In preferred embodiments of the invention, the mature crRNA comprises a stem loop or an optimized stem loop structure or an optimized secondary structure. In preferred embodiments the mature crRNA comprises a stem loop or an optimized stem loop structure in the direct repeat sequence, wherein the stem loop or optimized stem loop structure is important for cleavage activity. In certain embodiments, the mature crRNA preferably comprises a single stem loop.
- the methods make use of chemically modified guide RNAs.
- guide RNA chemical modifications include, without limitation, incorporation of 2'-O-methyl (M), 2'-O-methyl 3'phosphorothioate (MS), or 2'-O-methyl 3'thioPACE (MSP) at one or more terminal nucleotides.
- M 2'-O-methyl
- MS 2'-O-methyl 3'phosphorothioate
- MSP 2'-O-methyl 3'thioPACE
- Such chemically modified guide RNAs can comprise increased stability and increased activity as compared to unmodified guide RNAs, though on-target vs. off-target specificity is not predictable. (See, Hendel, 2015, Nat Biotechnol. 33(9):985-9, doi: 10.1038/nbt.3290, published online 29 June 2015 ).
- the bacteriophage coat protein may be selected from the group comprising Q ⁇ , F2, GA, fr, JP501, MS2, M12, R17, BZ13, JP34, JP500, KU1, M11, MX1, TW18, VK, SP, FI, ID2, NL95, TW19, AP205, ⁇ Cb5, ⁇ Cb8r, ⁇ Cb12r, ⁇ Cb23r, 7s and PRR1.
- the bacteriophage coat protein is MS2.
- the invention also provides for the nucleic acid component of the complex being 30 or more, 40 or more or 50 or more nucleotides in length.
- an isolated eukaryotic cell comprising a modified target locus of interest, wherein the target locus of interest has been modified according to in any of the herein described methods.
- a further aspect provides a cell line of said cell.
- the modification of the target locus of interest may result in: the eukaryotic cell comprising altered expression of at least one gene product; the eukaryotic cell comprising altered expression of at least one gene product, wherein the expression of the at least one gene product is increased; the eukaryotic cell comprising altered expression of at least one gene product, wherein the expression of the at least one gene product is decreased; or the eukaryotic cell comprising an edited genome.
- the eukaryotic cell may be a mammalian cell or a human cell.
- non-naturally occurring or engineered compositions, the vector systems, or the delivery systems as described in the present specification may be used for: site-specific gene knockout; site-specific genome editing; RNA sequence-specific interference; or multiplexed genome engineering.
- the amount of gene product expressed may be greater than or less than the amount of gene product from a cell that does not have altered expression or edited genome.
- the gene product may be altered in comparison with the gene product from a cell that does not have altered expression or edited genome.
- a method for identifying novel nucleic acid modifying effectors comprising: identifying putative nucleic acid modifying loci from a set of nucleic acid sequences encoding the putative nucleic acid modifying enzyme loci that are within a defined distance from a conserved genomic element of the loci, that comprise at least one protein above a defined size limit, or both; grouping the identified putative nucleic acid modifying loci into subsets comprising homologous proteins; identifying a final set of candidate nucleic acid modifying loci by selecting nucleic acid modifying loci from one or more subsets based on one or more of the following; subsets comprising loci with putative effector proteins with low domain homology matches to known protein domains relative to loci in other subsets, subsets comprising putative proteins with minimal distances to the conserved genomic element relative to loci in other subsets, subsets with loci comprising large effector proteins having a same orientations as putative adjacent accessory
- the defined distance from the conserved genomic element is between 1 kb and 25 kb.
- the conserved genomic element comprises a repetitive element, such as a CRISPR array.
- the defined distance from the conserved genomic element is within 10 kb of the CRISPR array.
- the conserved genomic elements are identified using a repeat or pattern finding analysis of the set of nucleic acids, such as PILER-CR.
- the grouping step of the method described herein is based, at least in part, on results of a domain homology search or an HHpred protein domain homology search.
- the defined threshold is a BLAST nearest-neighbor cut-off value of 0 to 1e-7.
- the method described described but not claimed herein further comprises a filtering step that includes only loci with putative proteins between 900 and 1800 amino acids.
- the method described but not claimed herein further comprises experimental validation of the nucleic acid modifying function of the candidate nucleic acid modifying effectors comprising generating a set of nucleic acid constructs encoding the nucleic acid modifying effectors and performing one or more biochemical validation assays, such as through the use of PAM validation in bacterial colonies, in vitro cleavage assays, the Surveyor method, experiments in mammalian cells, PFS validation, or a combination thereof.
- the method described but not claimed herein further comprises preparing a non-naturally occurring or engineered composition comprising one or more proteins from the identified nucleic acid modifying loci.
- the single large effector protein is greater than 900, or greater than 1100 amino acids in length, or comprises at least one HEPN domain.
- the at least one HEPN domain is near a N- or C-terminus of the effector protein, or is located in an interior position of the effector protein.
- the single large effector protein comprises a HEPN domain at the N- and C-terminus and two HEPN domains internal to the protein.
- the identified loci further comprise one or two small putative accessory proteins within 2 kb to 10 kb of the CRISPR array.
- a small accessory protein is less than 700 amino acids. In one embodiment, the small accessory protein is from 50 to 300 amino acids in length.
- the small accessory protein comprises multiple predicted transmembrane domains, or comprises four predicted transmembrane domains, or comprises at least one HEPN domain.
- the small accessory protein comprises at least one HEPN domain and at least one transmembrane domain.
- the loci comprise no additional proteins out to 25 kb from the CRISPR array.
- the CRISPR array comprises direct repeat sequences comprising about 36 nucleotides in length.
- the direct repeat comprises a GTTG/GUUG at the 5' end that is reverse complementary to a CAAC at the 3' end.
- the CRISPR array comprises spacer sequences comprising about 30 nucleotides in length.
- the identified loci lack a small accessory protein.
- Also described but not claimed herein is a method of identifying novel CRISPR effectors, comprising: a) identifying sequences in a genomic or metagenomic database encoding a CRISPR array; b) identifying one or more Open Reading Frames (ORFs) in said selected sequences within 10 kb of the CRISPR array; c) selecting loci based on the presence of a putative CRISPR effector protein between 900-1800 amino acids in size, d) selecting loci encoding a putative accessory protein of 50-300 amino acids; and e) identifying loci encoding a putative CRISPR effector and CRISPR accessory proteins and optionally classifying them based on structure analysis.
- ORFs Open Reading Frames
- the CRISPR effector is a Type VI CRISPR effector.
- step (a) comprises i) comparing sequences in a genomic and/or metagenomic database with at least one pre-identified seed sequence that encodes a CRISPR array, and selecting sequences comprising said seed sequence; or ii) identifying CRISPR arrays based on a CRISPR algorithm.
- step (d) comprises identifying nuclease domains. In an embodiment, step (d) comprises identifying RuvC, HPN, and/or HEPN domains.
- no ORF encoding Cas1 or Cas2 is present within 10 kb of the CRISPR array
- an ORF in step (b) encodes a putative accessory protein of 50-300 amino acids.
- putative novel CRISPR effectors obtained in step (d) are used as seed sequences for further comparing genomic and/or metagenomics sequences and subsequent selecting loci of interest as described in steps a) to d) of claim 1.
- the pre-identified seed sequence is obtained by a method comprising: (a) identifying CRISPR motifs in a genomic or metagenomic database, (b) extracting multiple features in said identified CRISPR motifs, (c) classifying the CRISPR loci using unsupervised learning, (d) identifying conserved locus elements based on said classification, and (e) selecting therefrom a putative CRISPR effector suitable as seed sequence.
- the features include protein elements, repeat structure, repeat sequence, spacer sequence and spacer mapping.
- the genomic and metagenomic databases are bacterial and/or archaeal genomes.
- the genomic and metagenomic sequences are obtained from the Ensembl and/or NCBI genome databases.
- the structure analysis in step (d) is based on secondary structure prediction and/or sequence alignments.
- step (d) is achieved by clustering of the remaining loci based on the proteins they encode and manual curation of the obtained clusters.
- RNA(s) as that term is herein used (e.g., RNA(s) to guide Cas, such as Cas9, e.g. CRISPR RNA and transactivating (tracr) RNA or a single guide RNA (sgRNA) (chimeric RNA)) or other sequences and transcripts from a CRISPR locus.
- Cas9 e.g. CRISPR RNA and transactivating (tracr) RNA or a single guide RNA (sgRNA) (chimeric RNA)
- a CRISPR system is characterized by elements that promote the formation of a CRISPR complex at the site of a target sequence (also referred to as a protospacer in the context of an endogenous CRISPR system).
- a tracrRNA is not required.
- the direct repeat may encompass naturally-occuring sequences or nonnaturally-occurring sequences.
- the direct repeat of the invention is not limited to naturally occurring lengths and sequences.
- a direct repeat can be 36nt in length, but a longer or shorter direct repeat can vary.
- a direct repeat can be 30nt or longer, such as 30-100 nt or longer.
- target sequence refers to a sequence to which a guide sequence is designed to have complementarity, where hybridization between a target sequence and a guide sequence promotes the formation of a CRISPR complex.
- a target sequence may comprise any polynucleotide, such as DNA or RNA polynucleotides.
- a target sequence is located in the nucleus or cytoplasm of a cell.
- direct repeats may be identified in silico by searching for repetitive motifs that fulfill any or all of the following criteria: 1. found in a 2Kb window of genomic sequence flanking the type II CRISPR locus; 2. span from 20 to 50 bp; and 3. interspaced by 20 to 50 bp. In some embodiments, 2 of these criteria may be used, for instance 1 and 2, 2 and 3, or 1 and 3. In some embodiments, all 3 criteria may be used.
- RNA capable of guiding the Cas13b effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A to a target locus
- a guide sequence or spacer sequence is any polynucleotide sequence having sufficient complementarity with a target polynucleotide sequence to hybridize with the target sequence and direct sequence-specific binding of a CRISPR complex to the target sequence.
- the components of a CRISPR system sufficient to form a CRISPR complex may be provided to a host cell having the corresponding target sequence, such as by transfection with vectors encoding the components of the CRISPR sequence, followed by an assessment of preferential cleavage within the target sequence, such as by Surveyor assay as described herein.
- cleavage of a target polynucleotide sequence may be evaluated in a test tube by providing the target sequence, components of a CRISPR complex, including the guide sequence to be tested and a control guide sequence different from the test guide sequence, and comparing binding or rate of cleavage at the target sequence between the test and control guide sequence reactions.
- Other assays are possible, and will occur to those skilled in the art.
- Cas13b-s1 accessory protein Cas13b-s1 protein, Cas13b-s1, Csx27, and Csx27 protein are used interchangeably and the terms Cas13b-s2 accessory protein, Cas13b-s2 protein, Cas13b-S2, Csx28, and Csx28 protein are used interchangeably.
- the degree of complementarity between a guide sequence and its corresponding target sequence can be about or more than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or 100%;
- a guide or RNA or crRNA can be about or more than about 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75, or more nucleotides in length; or guide or RNA or crRNA can be less than about 75, 50, 45, 40, 35, 30, 25, 20, 15, 12, or fewer nucleotides in length; and advantageously tracr RNA is 30 or 50 nucleotides in length.
- an aspect of the invention is to reduce off-target interactions, e.g., reduce the guide interacting with a target sequence having low complementarity.
- the invention involves mutations that result in the CRISPR-Cas system being able to distinguish between target and off-target sequences that have greater than 80% to about 95% complementarity, e.g., 83%-84% or 88-89% or 94-95% complementarity (for instance, distinguishing between a target having 18 nucleotides from an off-target of 18 nucleotides having 1, 2 or 3 mismatches).
- Off target is less than 100% or 99.9% or 99.5% or 99% or 99% or 98.5% or 98% or 97.5% or 97% or 96.5% or 96% or 95.5% or 95% or 94.5% or 94% or 93% or 92% or 91% or 90% or 89% or 88% or 87% or 86% or 85% or 84% or 83% or 82% or 81% or 80% complementarity between the sequence and the guide, with it advantageous that off target is 100% or 99.9% or 99.5% or 99% or 99% or 98.5% or 98% or 97.5% or 97% or 96.5% or 96% or 95.5% or 95% or 94.5% complementarity between the sequence and the guide.
- the guide RNA (capable of guiding Cas to a target locus) may comprise (1) a guide sequence capable of hybridizing to a target locus (a polynucleotide target locus, such as an RNA target locus) in the eukaryotic cell; (2) a direct repeat (DR) sequence) which reside in a single RNA, i.e. an sgRNA (arranged in a 5' to 3' orientation) or crRNA.
- a target locus a polynucleotide target locus, such as an RNA target locus
- a direct repeat (DR) sequence which reside in a single RNA, i.e. an sgRNA (arranged in a 5' to 3' orientation) or crRNA.
- the wildtype Cas13b effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A has RNA binding and cleaving function.
- the mutations can include the introduction, deletion, or substitution of 1-75 nucleotides at each target sequence of said cell(s) via the guide(s) RNA(s) or sgRNA(s) or crRNA(s).
- the mutations can include the introduction, deletion, or substitution of 1, 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, or 75 nucleotides at each target sequence of said cell(s) via the guide(s) RNA(s) or sgRNA(s) or crRNA(s).
- the mutations can include the introduction, deletion, or substitution of 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, or 75 nucleotides at each target sequence of said cell(s) via the guide(s) RNA(s) or sgRNA(s) or crRNA(s).
- the mutations can include the introduction, deletion, or substitution of 40, 45, 50, 75, 100, 200, 300, 400 or 500 nucleotides at each target sequence of said cell(s) via the guide(s) RNA(s) or sgRNA(s) or crRNAs.
- the methods as described herein may comprise providing a Cas13b transgenic cell in which one or more nucleic acids encoding one or more guide RNAs are provided or introduced operably connected in the cell with a regulatory element comprising a promoter of one or more gene of interest.
- a Cast 3b transgenic cell refers to a cell, such as a eukaryotic cell, in which the Cas13b gene from Bacteroidetes bacterium GWA2_31_9 of Table 1A has been genomically integrated. The nature, type, or origin of the cell are not particularly limiting according to the present invention.
- the Cas13b sequence from Bacteroidetes bacterium GWA2_31_9 of Table 1A is fused to one or more nuclear localization sequences (NLSs), such as about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs.
- NLSs nuclear localization sequences
- the Cas13b comprises about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs at or near the amino-terminus, about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs at or near the carboxy-terminus, or a combination of these (e.g. zero or at least one or more NLS at the amino-terminus and zero or at one or more NLS at the carboxy terminus).
- the Cas13b comprises at most 6 NLSs.
- an NLS is considered near the N- or C-terminus when the nearest amino acid of the NLS is within about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50, or more amino acids along the polypeptide chain from the N- or C-terminus.
- Non-limiting examples of NLSs include an NLS sequence derived from: the NLS of the SV40 virus large T-antigen, having the amino acid sequence PKKKRKV(SEQ ID NO: X); the NLS from nucleoplasmin (e.g.
- nucleoplasmin bipartite NLS with the sequence KRPAATKKAGQAKKKK) (SEQ ID NO: X); the c-myc NLS having the amino acid sequence PAAKRVKLD (SEQ ID NO: X) or RQRRNELKRSP(SEQ ID NO: X); the hRNPA1 M9 NLS having the sequence NQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGY(SEQ ID NO: X); the sequence RMRIZFKNKGKDTAELRRRRVEVSVELRKAKKDEQILKRRNV (SEQ ID NO: X) of the IBB domain from importin-alpha; the sequences VSRKRPRP (SEQ ID NO: X) and PPKKARED (SEQ ID NO: X) of the myoma T protein; the sequence POPKKKPL (SEQ ID NO: X) of human p53; the sequence SALIKKKKKMAP (SEQ ID NO: X) of mouse c
- Cell nuclei may also be isolated from cells, the contents of which may then be analyzed by any suitable process for detecting protein, such as immunohistochemistry, Western blot, or enzyme activity assay. Accumulation in the nucleus may also be determined indirectly, such as by an assay for the effect of CRISPR complex formation (e.g. assay for DNA cleavage or mutation at the target sequence, or assay for altered gene expression activity affected by CRISPR complex formation and/or Cas enzyme activity), as compared to a control no exposed to the Cas or complex, or exposed to a Cas lacking the one or more NLSs.
- an assay for the effect of CRISPR complex formation e.g. assay for DNA cleavage or mutation at the target sequence, or assay for altered gene expression activity affected by CRISPR complex formation and/or Cas enzyme activity
- the invention involves vectors, e.g. for delivering or introducing in a cell Cas13b from Bacteroidetes bacterium GWA2_31_9 of Table 1A and/or RNA capable of guiding Cas13b to a target locus (i.e. guide RNA), but also for propagating these components (e.g. in prokaryotic cells).
- a "vector” is a tool that allows or facilitates the transfer of an entity from one environment to another. It is a replicon, such as a plasmid, phage, or cosmid, into which another DNA segment may be inserted so as to bring about the replication of the inserted segment.
- a vector is capable of replication when associated with the proper control elements.
- the term "vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
- Vectors include, but are not limited to, nucleic acid molecules that are single-stranded, double-stranded, or partially double-stranded; nucleic acid molecules that comprise one or more free ends, no free ends (e.g. circular); nucleic acid molecules that comprise DNA, RNA, or both; and other varieties of polynucleotides known in the art.
- vector refers to a circular double stranded DNA loop into which additional DNA segments can be inserted, such as by standard molecular cloning techniques.
- viral vector wherein virally-derived DNA or RNA sequences are present in the vector for packaging into a virus (e.g. retroviruses, replication defective retroviruses, adenoviruses, replication defective adenoviruses, and adeno-associated viruses (AAVs)).
- viruses e.g. retroviruses, replication defective retroviruses, adenoviruses, replication defective adenoviruses, and adeno-associated viruses (AAVs)
- Viral vectors also include polynucleotides carried by a virus for transfection into a host cell. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g.
- bacterial vectors having a bacterial origin of replication and episomal mammalian vectors.
- Other vectors e.g., non-episomal mammalian vectors
- certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as "expression vectors.”
- Common expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.
- Recombinant expression vectors can comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory elements, which may be selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed.
- "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory element(s) in a manner that allows for expression of the nucleotide sequence (e.g. in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).
- the vector(s) can include the regulatory element(s), e.g., promoter(s).
- the vector(s) can comprise Cas13b encoding sequence(s), and/or a single, but possibly also can comprise at least 2, 3 or 8 or 16 or 32 or 48 or 50 guide RNA(s) (e.g., crRNAs) encoding sequences, such as 1-2, 1-3, 1-4 1-5, 3-6, 3-7, 3-8, 3-9, 3-10, 3-8, 3-16, 3-30, 3-32, 3-48, 3-50 RNA(s) (e.g., crRNAs).
- guide RNA(s) e.g., crRNAs
- RNA(s) there can be a promoter for each RNA (e.g., crRNA(s)), advantageously when there are up to about 16 RNA(s) (e.g., crRNA(s)s); and, when a single vector provides for more than 16 RNA(s) (e.g., crRNA(s)s), one or more promoter(s) can drive expression of more than one of the RNA(s) (e.g., crRNA(s)s), e.g., when there are 32 RNA(s) (e.g., sgRNAs or crRNA(s)), each promoter can drive expression of two RNA(s) (e.g., sgRNAs or crRNA(s)), and when there are 48 RNA(s) (e.g., sgRNAs or crRNA(s)), each promoter can drive expression of three RNA(s) (e.g., sgRNAs or crRNA(s)).
- RNA(s) e.g
- RNA(s) e.g., sgRNA(s) or crRNA(s)for a suitable exemplary vector such as AAV
- a suitable promoter such as the U6 promoter, e.g., U6-sgRNAs or -crRNA(s).
- the packaging limit of AAV is ⁇ 4.7 kb.
- the skilled person can readily fit about 12-16, e.g., 13 U6-sgRNA or crRNA(s) cassettes in a single vector.
- the skilled person can also use a tandem guide strategy to increase the number of U6-sgRNAs or -crRNA(s)by approximately 1.5 times, e.g., to increase from 12-16, e.g., 13 to approximately 18-24, e.g., about 19 U6-sgRNAs or -crRNA(s).
- the guide RNA(s), e.g., sgRNA(s) or crRNA(s) encoding sequences and/or Cas13b encoding sequences, can be functionally or operatively linked to regulatory element(s) and hence the regulatory element(s) drive expression.
- the promoter(s) can be constitutive promoter(s) and/or conditional promoter(s) and/or inducible promoter(s) and/or tissue specific promoter(s).
- the promoter can be selected from the group consisting of RNA polymerases, pol I, pol II, pol III, T7, U6, H1, retroviral Rous sarcoma virus (RSV) LTR promoter, the cytomegalovirus (CMV) promoter, the SV40 promoter, the dihydrofolate reductase promoter, the ⁇ -actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EF1 ⁇ promoter.
- RSV Rous sarcoma virus
- CMV cytomegalovirus
- SV40 promoter the dihydrofolate reductase promoter
- ⁇ -actin promoter the phosphoglycerol kinase (PGK) promoter
- PGK phosphoglycerol kinase
- EF1 ⁇ promoter EF1 ⁇ promoter.
- An advantageous promoter is the promoter is U6.
- the effector protein may be used to control or bind to molecules comprising or consisting of RNA, such as ribozymes, ribosomes or riboswitches.
- RNA such as ribozymes, ribosomes or riboswitches.
- the RNA guide can recruit the effector protein to these molecules so that the effector protein is able to bind to them.
- rRNA Ribosomal RNA
- the effector protein may also be used, together with a suitable guide, to target gene expression, including via control of RNA processing.
- the control of RNA processing may include RNA processing reactions such as RNA splicing, including alternative splicing, via targeting of RNApol; viral replication (in particular of satellite viruses, bacteriophages and retroviruses, such as HBV, HBC and HIV and others listed herein) including virioids in plants; and tRNA biosynthesis.
- the effector protein and suitable guide may also be used to control RNAactivation (RNAa).
- RNAa leads to the promotion of gene expression, so control of gene expression may be achieved that way through disruption or reduction of RNAa and thus less promotion of gene expression.
- the target-specific RNAse from Bacteroidetes bacterium GWA2_31_9 of Table 1A provided herein allows for very specific cutting of a target RNA.
- the interference at RNA level allows for modulation both spatially and temporally and in a non-invasive way, as the genome is not modified.
- RNA targeting can also be used to impact specific aspects of the RNA processing within the cell, which may allow a more subtle modulation of gene expression.
- modulation can for instance be mediated by interfering with binding of proteins to the RNA, such as for instance blocking binding of proteins, or recruiting RNA binding proteins.
- modulations can be ensured at different levels such as splicing, transport, localization, translation and turnover of the mRNA.
- it can be envisaged to address (pathogenic) malfunctioning at each of these levels by using RNA-specific targeting molecules.
- splice variants may be targeted, while other splice variants will not be targeted
- RNA targeting effector proteins of the present invention can be used to correct malfunctioning RNA modification.
- Polyadenylation of an mRNA is important for nuclear transport, translation efficiency and stability of the mRNA, and all of these, as well as the process of polyadenylation, depend on specific RBPs. Most eukaryotic mRNAs receive a 3' poly(A) tail of about 200 nucleotides after transcription. Polyadenylation involves different RNA-binding protein complexes which stimulate the activity of a poly(A)polymerase ( Minvielle-Sebastia L et al. Curr Opin Cell Biol. 1999;11:352-7 ). It is envisaged that the RNA-targeting effector proteins provided herein can be used to interfere with or promote the interaction between the RNA-binding proteins and RNA.
- OPMD oculopharyngeal muscular dystrophy
- mRNA localization ensures spatially regulated protein production. Localization of transcripts to a specific region of the cell can be ensured by localization elements.
- the effector proteins described herein can be used to target localization elements to the RNA of interest.
- the effector proteins can be designed to bind the target transcript and shuttle them to a location in the cell determined by its peptide signal tag. More particularly for instance, a RNA targeting effector protein fused to a nuclear localization signal (NLS) can be used to alter RNA localization.
- NLS nuclear localization signal
- localization signals include the zipcode binding protein (ZBP1) which ensures localization of ⁇ -actin to the cytoplasm in several asymmetric cell types, KDEL retention sequence (localization to endoplasmic reticulum), nuclear export signal (localization to cytoplasm), mitochondrial targeting signal (localization to mitochondria), peroxisomal targeting signal (localization to peroxisome) and m6A marking/YTHDF2 (localization to p-bodies).
- ZBP1 zipcode binding protein
- KDEL retention sequence localization to endoplasmic reticulum
- nuclear export signal localization to cytoplasm
- mitochondrial targeting signal localization to mitochondria
- peroxisomal targeting signal localization to peroxisome
- m6A marking/YTHDF2 localization to p-bodies.
- Other approaches that are envisaged are fusion of the RNA targeting effector protein with proteins of known localization (for instance membrane, synapse).
- the effector protein according to the invention may for instance be used in localization-dependent knockdown.
- the effector protein By fusing the effector protein to a appropriate localization signal, the effector is targeted to a particular cellular compartment. Only target RNAs residing in this compartment will effectively be targeted, whereas otherwise identical targets, but residing in a different cellular compartment will not be targeted, such that a localization dependent knockdown can be established.
- RNA targeting effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A described herein can be used to enhance or repress translation. It is envisaged that upregulating translation is a very robust way to control cellular circuits. Further, for functional studies a protein translation screen can be favorable over transcriptional upregulation screens, which have the shortcoming that upregulation of transcript does not translate into increased protein production.
- RNA targeting effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A described herein can be used to bring translation initiation factors, such as EIF4G in the vicinity of the 5' untranslated repeat (5'UTR) of a messenger RNA of interest to drive translation (as described in De Gregorio et al. EMBO J. 1999;18(17):4865-74 for a non-reprogrammable RNA binding protein).
- a cytoplasmic poly(A) polymerase can be recruited to the target mRNA by an RNA targeting effector protein. This would allow for directed polyadenylation of the target mRNA thereby stimulating translation.
- RNA targeting effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A envisaged herein can be used to block translational repressors of mRNA, such as ZBP1 ( Huttelmaier S, et al. Nature. 2005;438:512-5 ). By binding to translation initiation site of a target RNA, translation can be directly affected.
- RNA targeting effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A to a protein that stabilizes mRNAs, e.g. by preventing degradation thereof such as RNase inhibitors, it is possible to increase protein production from the transcripts of interest.
- RNA targeting effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A described herein can be used to repress translation by binding in the 5' UTR regions of a RNA transcript and preventing the ribosome from forming and beginning translation.
- RNA targeting effector protein can be used to recruit Caf1, a component of the CCR4-NOT deadenylase complex, to the target mRNA, resulting in deadenylation or the target transcript and inhibition of protein translation.
- the RNA targeting effector protein of the invention can be used to increase or decrease translation of therapeutically relevant proteins.
- Examples of therapeutic applications wherein the RNA targeting effector protein can be used to downregulate or upregulate translation are in amyotrophic lateral sclerosis (ALS) and cardiovascular disorders.
- ALS amyotrophic lateral sclerosis
- Reduced levels of the glial glutamate transporter EAAT2 have been reported in ALS motor cortex and spinal cord, as well as multiple abnormal EAAT2 mRNA transcripts in ALS brain tissue. Loss of the EAAT2 protein and function thought to be the main cause of excitotoxicity in ALS. Restoration of EAAT2 protein levels and function may provide therapeutic benefit.
- the RNA targeting effector protein can be beneficially used to upregulate the expression of EAAT2 protein, e.g. by blocking translational repressors or stabilizing mRNA as described above.
- Apolipoprotein A1 is the major protein component of high density lipoprotein (HDL) and ApoA1 and HDL are generally considered as atheroprotective. It is envisages that the RNA targeting effector protein can be beneficially used to upregulate the expression of ApoA1, e.g. by blocking translational repressors or stabilizing mRNA as described above.
- Translation is tightly coupled to mRNA turnover and regulated mRNA stability.
- Specific proteins have been described to be involved in the stability of transcripts (such as the ELAV/Hu proteins in neurons, Keene JD, 1999, Proc Natl Acad Sci U S A. 96:5-7 ) and tristetraprolin (TTP). These proteins stabilize target mRNAs by protecting the messages from degradation in the cytoplasm ( Peng SS et al., 1988, EMBO J. 17:3461-70 ).
- RNA-targeting effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A of the present invention can be used to interfere with or to promote the activity of proteins acting to stabilize mRNA transcripts, such that mRNA turnover is affected.
- recruitment of human TTP to the target RNA using the RNA targeting effector protein would allow for adenylate-uridylate-rich element (AU-rich element) mediated translational repression and target degradation.
- AU-rich elements are found in the 3' UTR of many mRNAs that code for proto-oncogenes, nuclear transcription factors, and cytokines and promote RNA stability.
- RNA targeting effector protein can be fused to HuR, another mRNA stabilization protein ( Hinman MN and Lou H, Cell Mol Life Sci 2008;65:3168-81 ), and recruit it to a target transcript to prolong its lifetime or stabilize short-lived mRNA.
- RNA-targeting effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A described herein can be used to promote degradation of target transcripts.
- m6A methyltransferase can be recruited to the target transcript to localize the transcript to P-bodies leading to degradation of the target.
- an RNA targeting effector protein as described herein can be fused to the non-specific endonuclease domain PilT N-terminus (PIN), to recruit it to a target transcript and allow degradation thereof.
- PIN non-specific endonuclease domain
- RNA-targeting effector proteins of the present invention can be used to interfere with the binding of auto-antibodies to mRNA transcripts.
- DM1 dystrophy type 1
- DMPK dystrophia myotonica-protein kinase
- RNA adopts a defined structure in order to perform its biological activities. Transitions in conformation among alternative tertiary structures are critical to most RNA-mediated processes. However, RNA folding can be associated with several problems. For instance, RNA may have a tendency to fold into, and be upheld in, improper alternative conformations and/or the correct tertiary structure may not be sufficiently thermodynamically favored over alternative structures.
- the RNA targeting effector protein, in particular a cleavage-deficient or dead RNA targeting protein, of the invention may be used to direct folding of (m)RNA and/or capture the correct tertiary structure thereof.
- the non-naturally occurring or engineered composition, vector system, or delivery systems as derscribed herein are used for or are for use in induction of cell dormancy. In certain embodiments, the non-naturally occurring or engineered composition, vector system, or delivery systems as derscribed herein are used for or are for use in induction of cell cycle arrest. In certain embodiments, the non-naturally occurring or engineered composition, vector system, or delivery systems as derscribed herein are used for or are for use in reduction of cell growth and/or cell proliferation, In certain embodiments, the non-naturally occurring or engineered composition, vector system, or delivery systems as derscribed herein are used for or are for use in induction of cell anergy.
- the non-naturally occurring or engineered composition, vector system, or delivery systems as derscribed herein are used for or are for use in induction of cell apoptosis. In certain embodiments, the non-naturally occurring or engineered composition, vector system, or delivery systems as derscribed herein are used for or are for use in incuction of cell necrosis. In certain embodiments, the non-naturally occurring or engineered composition, vector system, or delivery systems as derscribed herein are used for or are for use in induction of cell death. In certain embodiments, the non-naturally occurring or engineered composition, vector system, or delivery systems as derscribed herein are used for or are for use in induction of programmed cell death.
- the disclosure relates to a method for induction of cell anergy comprising introducing or inducing the non-naturally occurring or engineered composition, vector system, or delivery systems as derscribed herein.
- the disclosure relates to a method for induction of cell apoptosis comprising introducing or inducing the non-naturally occurring or engineered composition, vector system, or delivery systems as derscribed herein.
- the disclosure relates to a method for induction of cell necrosis comprising introducing or inducing the non-naturally occurring or engineered composition, vector system, or delivery systems as derscribed herein.
- the disclosure relates to a method for treating a pathological condition characterized by the presence of undersirable cells (host cells), comprising introducing or inducing the non-naturally occurring or engineered composition, vector system, or delivery systems as derscribed herein.
- the disclosure relates the use of the non-naturally occurring or engineered composition, vector system, or delivery systems as derscribed herein for treating a pathological condition characterized by the presence of undersirable cells (host cells).
- the disclosure relates the non-naturally occurring or engineered composition, vector system, or delivery systems as derscribed herein for use in treating a pathological condition characterized by the presence of undersirable cells (host cells).
- the disclosure relates to the use of the non-naturally occurring or engineered composition, vector system, or delivery systems as derscribed herein for treating, preventing, or alleviating cancer.
- the disclosure relates to the non-naturally occurring or engineered composition, vector system, or delivery systems as derscribed herein for use in treating, preventing, or alleviating cancer.
- the disclosure relates to a method for treating, preventing, or alleviating cancer comprising introducing or inducing the non-naturally occurring or engineered composition, vector system, or delivery systems as derscribed herein.
- the disclosure relates to the use of the non-naturally occurring or engineered composition, vector system, or delivery systems as derscribed herein for treating, preventing, or alleviating infection of cells by a pathogen. In certain embodiments, the disclosure relates to the non-naturally occurring or engineered composition, vector system, or delivery systems as derscribed herein for use in treating, preventing, or alleviating infection of cells by a pathogen.
- the disclosure relates to a method for treating, preventing, or alleviating infection of cells by a pathogen comprising introducing or inducing the non-naturally occurring or engineered composition, vector system, or delivery systems as derscribed herein. It is to be understood that preferably the CRISPR-Cas system targets a target specific for the cells infected by the pathogen (e.g. a pathogen derived target). In certain embodiments, the disclosure relates to the use of the non-naturally occurring or engineered composition, vector system, or delivery systems as derscribed herein for treating, preventing, or alleviating an autoimmune disorder.
- the disclosure relates to the non-naturally occurring or engineered composition, vector system, or delivery systems as derscribed herein for use in treating, preventing, or alleviating an autoimmune disorder.
- the disclosure relates to a method for treating, preventing, or alleviating an autoimmune disorder comprising introducing or inducing the non-naturally occurring or engineered composition, vector system, or delivery systems as derscribed herein. It is to be understood that preferably the CRISPR-Cas system targets a target specific for the cells responsible for the autoimmune disorder (e.g. specific immune cells).
- RNA targeting effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A can be used in Northern blot assays.
- Northern blotting involves the use of electrophoresis to separate RNA samples by size.
- the RNA targeting effector protein can be used to specifically bind and detect the target RNA sequence.
- a RNA targeting effector protein can be fused to a fluorescent protein (such as GFP) and used to track RNA localization in living cells. More particularly, the RNA targeting effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A can be inactivated in that it no longer cleaves RNA.
- a split RNA targeting effector protein can be used, whereby the signal is dependent on the binding of both subproteins, in order to ensure a more precise visualization.
- a split fluorescent protein can be used that is reconstituted when multiple RNA targeting effector protein complexes bind to the target transcript. It is further envisaged that a transcript is targeted at multiple binding sites along the mRNA so the fluorescent signal can amplify the true signal and allow for focal identification.
- the fluorescent protein can be reconstituted form a split intein.
- RNA targeting effector proteins are for instance suitably used to determine the localization of the RNA or specific splice variants, the level of mRNA transcript, up- or down-regulation of transcripts and disease-specific diagnosis.
- the RNA targeting effector protein can be used for visualization of RNA in (living) cells using e.g. fluorescent microscopy or flow cytometry, such as fluorescence-activated cell sorting (FACS) which allows for high-throughput screening of cells and recovery of living cells following cell sorting. Further, expression levels of different transcripts can be assessed simultaneously under stress, e.g. inhibition of cancer growth using molecular inhibitors or hypoxic conditions on cells. Another application would be to track localization of transcripts to synaptic connections during a neural stimulus using two photon microscopy.
- the components or complexes according to the invention comprising an RNA targeting effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A as described herein can be used in multiplexed error-robust fluorescence in situ hybridization (MERFISH; Chen et al. Science; 2015; 348(6233 )), such as for instance with (fluorescently) labeled Cas13b effectors.
- MEFISH error-robust fluorescence in situ hybridization
- RNA targeting effector protein of the invention can for instance be used to target a probe to a selected RNA sequence.
- RNA origami refers to nanoscale folded structures for creating two-dimensional or three-dimensional structures using RNA as integrated template.
- the folded structure is encoded in the RNA and the shape of the resulting RNA is thus determined by the synthesized RNA sequence ( Geary, et al. 2014. Science, 345 (6198). pp. 799-804 ).
- the RNA origami may act as scaffold for arranging other components, such as proteins, into complexes.
- the RNA targeting effector protein of the invention can for instance be used to target proteins of interest to the RNA origami using a suitable guide RNA.
- RNA targeting effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A when complexed to RNA can be used to isolate and/or purify the RNA.
- the RNA targeting effector protein can for instance be fused to an affinity tag that can be used to isolate and/or purify the RNA-RNA targeting effector protein complex.
- affinity tag can be used to isolate and/or purify the RNA-RNA targeting effector protein complex.
- the RNA targeting effector protein can be used to target a specific noncoding RNA (ncRNA) thereby blocking its activity, providing a useful functional probe.
- the effector protein as described herein may be used to specifically enrich for a particular RNA (including but not limited to increasing stability, etc.), or alternatively to specifically deplete a particular RNA (such as without limitation for instance particular splice variants, isoforms, etc.).
- RNA knockdown strategies such as siRNA have the disadvantage that they are mostly limited to targeting cytosolic transcripts since the protein machinery is cytosolic.
- the advantage of a RNA targeting effector protein of the present invention an exogenous system that is not essential to cell function, is that it can be used in any compartment in the cell. By fusing a NLS signal to the RNA targeting effector protein, it can be guided to the nucleus, allowing nuclear RNAs to be targeted. It is for instance envisaged to probe the function of lincRNAs. Long intergenic non-coding RNAs (lincRNAs) are a vastly underexplored area of research. Most lincRNAs have as of yet unknown functions which could be studies using the RNA targeting effector protein of the invention.
- RNA targeting effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A can be designed to recruit a biotin ligase to a specific transcript in order to label locally bound proteins with biotin. The proteins can then be pulled down and analyzed by mass spectrometry to identify them.
- RNA targeting effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A can further be used to assemble complexes on RNA. This can be achieved by functionalizing the RNA targeting effector protein with multiple related proteins (e.g. components of a particular synthesis pathway). Alternatively, multiple RNA targeting effector proteins can be functionalized with such different related proteins and targeted to the same or adjacent target RNA. Useful application of assembling complexes on RNA are for instance facilitating substrate shuttling between proteins.
- RNA targeting effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A can be used fused to split proteins of toxic domains for targeted cell death, for instance using cancer-linked RNA as target transcript.
- pathways involving protein-protein interaction can be influenced in synthetic biological systems with e.g. fusion complexes with the appropriate effectors such as kinases or other enzymes.
- Protein splicing is a post-translational process in which an intervening polypeptide, referred to as an intein, catalyzes its own excision from the polypeptides flacking it, referred to as exteins, as well as subsequent ligation of the exteins.
- the assembly of two or more RNA targeting effector proteins as described herein on a target transcript could be used to direct the release of a split intein ( Topilina and Mills Mob DNA. 2014 Feb 4;5(1):5 ), thereby allowing for direct computation of the existence of a mRNA transcript and subsequent release of a protein product, such as a metabolic enzyme or a transcription factor (for downstream actuation of transcription pathways).
- This application may have significant relevance in synthetic biology (see above) or large-scale bioproduction (only produce product under certain conditions).
- fusion complexes comprising the RNA targeting effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A and an effector component are designed to be inducible, for instance light inducible or chemically inducible. Such inducibility allows for activation of the effector component at a desired moment in time.
- Light inducibility is for instance achieved by designing a fusion complex wherein CRY2PHR/CIBN pairing is used for fusion. This system is particularly useful for light induction of protein interactions in living cells ( Konermann S, et al. Nature. 2013;500:472-476 ).
- Chemical inducibility is for instance provided for by designing a fusion complex wherein FKBP/FRB (FK506 binding protein / FKBP rapamycin binding) pairing is used for fusion. Using this system rapamycin is required for binding of proteins ( Zetsche et al. Nat Biotechnol. 2015;33(2): 139-42 describes the use of this system for Cas9).
- FKBP/FRB FK506 binding protein / FKBP rapamycin binding
- the RNA targeting effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A can be modulated by inducible promoters, such as tetracycline or doxycycline controlled transcriptional activation (Tet-On and Tet-Off expression system), hormone inducible gene expression system such as for instance an ecdysone inducible gene expression system and an arabinose-inducible gene expression system.
- inducible promoters such as tetracycline or doxycycline controlled transcriptional activation (Tet-On and Tet-Off expression system)
- hormone inducible gene expression system such as for instance an ecdysone inducible gene expression system and an arabinose-inducible gene expression system.
- expression of the RNA targeting effector protein can be modulated via a riboswitch, which can sense a small molecule like tetracycline (as described in Goldfless et al. Nucleic Acids Res. 2012;40
- the delivery of the RNA targeting effector protein of the invention can be modulated to change the amount of protein or crRNA in the cell, thereby changing the magnitude of the desired effect or any undesired off-target effects.
- the RNA targeting effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A described herein can be designed to be self-inactivating.
- RNA either mRNA or as a replication RNA therapeutic ( Wrobleska et al Nat Biotechnol. 2015 Aug; 33(8): 839-841 )
- they can self-inactivate expression and subsequent effects by destroying the own RNA, thereby reducing residency and potential undesirable effects.
- RNA targeting effector proteins as described herein, reference is made to Mackay JP et al (Nat Struct Mol Biol. 2011 Mar;18(3):256-61 ), Nelles et al (Bioessays. 2015 Jul;37(7):732-9 ) and Abil Z and Zhao H (Mol Biosyst. 2015 Oct;11(10):2658-65 ).
- the following applications are envisaged in certain embodiments of the invention, preferably in certain embodiments by using catalytically inactive Cast3b: enhancing translation (e.g. Cast3b - translation promotion factor fusions (e.g. eIF4 fusions)); repressing translation (e.g.
- gRNA targeting ribosome binding sites exon skipping (e.g. gRNAs targeting splice donor and/or acceptor sites); exon inclusion (e.g. gRNA targeting a particular exon splice donor and/or acceptor site to be included or Cas13b fused to or recruiting spliceosome components (e.g. U1 snRNA)); accessing RNA localization (e.g. Cas13b - marker fusions (e.g.EGFP fusions)); altering RNA localization (e.g. Cas13b - localization signal fusions (e.g.
- RNA degradation in this case no catalytically inactive Cas13b is to be used if relied on the activity of Cas13b, alternatively and for increased specificity, a split Cas13b may be used
- inhibition of non-coding RNA function e.g. miRNA
- miRNA non-coding RNA function
- Cas13b function is robust to 5' or 3' extensions of the crRNA and to extension of the crRNA loop. It is therefore envisages that MS2 loops and other recruitment domains can be added to the crRNA without affecting complex formation and binding to target transcripts. Such modifications to the crRNA for recruitment of various effector domains are applicable in the uses of a RNA targeted effector proteins described above.
- Cas13b is capable of mediating resistance to RNA phages. It is therefore envisaged that Cas13b can be used to immunize, e.g. animals, humans and plants, against RNA-only pathogens, including but not limited to Ebola virus and Zika virus.
- Cas13b can process (cleave) its own array. This applies to both the wildtype Cas13b protein and the mutated Cas13b protein containing one or more mutated amino acid residues as herein-discussed. It is therefore envisaged that multiple crRNAs designed for different target transcripts and/or applications can be delivered as a single pre-crRNA or as a single transcript driven by one promotor. Such method of delivery has the advantages that it is substantially more compact, easier to synthesize and easier to delivery in viral systems. It will be understood that exact amino acid positions may vary for orthologues of a herein Cas13b can be adequately determined by protein alignment, as is known in the art, and as described herein elsewhere.
- compositions and systems described herein in genome engineering, e.g. for altering or manipulating the expression of one or more genes or the one or more gene products, in prokaryotic or eukaryotic cells, in vitro, in vivo or ex vivo.
- the invention provides methods and compositions for modulating, e.g., reducing, expression of a target RNA in cells.
- a Cas13b system of the invention is provided that interferes with transcription, stability, and / or translation of an RNA.
- an effective amount of Cas13b system is used to cleave RNA or otherwise inhibit RNA expression.
- the system has uses similar to siRNA and shRNA, thus can also be substituted for such methods.
- the method includes, without limitation, use of a Cas13b system as a substitute for e.g., an interfering ribonucleic acid (such as an siRNA or shRNA) or a transcription template thereof, e.g., a DNA encoding an shRNA.
- the Cas13b system is introduced into a target cell, e.g., by being administered to a mammal that includes the target cell.
- a Cas13b system of the invention is specific.
- interfering ribonucleic acid such as an siRNA or shRNA
- a Cas13b system of the invention can be designed with high specificity.
- the effector protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A as described herein is associated with or fused to a destabilization domain (DD).
- the DD is ER50.
- a corresponding stabilizing ligand for this DD is, in some embodiments, 4HT.
- one of the at least one DDs is ER50 and a stabilizing ligand therefor is 4HT or CMP8.
- the DD is DHFR50.
- a corresponding stabilizing ligand for this DD is, in some embodiments, TMP.
- one of the at least one DDs is DHFR50 and a stabilizing ligand therefor is TMP.
- the DD is ER50.
- a corresponding stabilizing ligand for this DD is, in some embodiments, CMP8.
- CMP8 may therefore be an alternative stabilizing ligand to 4HT in the ER50 system. While it may be possible that CMP8 and 4HT can/should be used in a competitive matter, some cell types may be more susceptible to one or the other of these two ligands, and from this disclosure and the knowledge in the art the skilled person can use CMP8 and/or 4HT.
- one or two DDs may be fused to the N- terminal end of the Cas13b with one or two DDs fused to the C- terminal of the Cas13b.
- the at least two DDs are associated with the Cas13b and the DDs are the same DD, i.e. the DDs are homologous.
- both (or two or more) of the DDs could be ER50 DDs. This is preferred in some embodiments.
- both (or two or more) of the DDs could be DHFR50 DDs. This is also preferred in some embodiments.
- the at least two DDs are associated with the Cas13b and the DDs are different DDs, i.e. the DDs are heterologous.
- one of the DDS could be ER50 while one or more of the DDs or any other DDs could be DHFR50. Having two or more DDs which are heterologous may be advantageous as it would provide a greater level of degradation control.
- a tandem fusion of more than one DD at the N or C-term may enhance degradation; and such a tandem fusion can be, for example ER50-ER50-Cas13b or DHFR-DHFR-Cas13b It is envisaged that high levels of degradation would occur in the absence of either stabilizing ligand, intermediate levels of degradation would occur in the absence of one stabilizing ligand and the presence of the other (or another) stabilizing ligand, while low levels of degradation would occur in the presence of both (or two of more) of the stabilizing ligands. Control may also be imparted by having an N-terminal ER50 DD and a C-terminal DHFR50 DD.
- the fusion of the Cas13b with the DD comprises a linker between the DD and the Cas13b.
- the linker is a GlySer linker.
- the DD-Cas13b further comprises at least one Nuclear Export Signal (NES).
- the DD- Cas13b comprises two or more NESs.
- the DD- Cas13b comprises at least one Nuclear Localization Signal (NLS). This may be in addition to an NES.
- the Cas13b comprises or consists essentially of or consists of a localization (nuclear import or export) signal as, or as part of, the linker between the Cas13b and the DD.
- HA or Flag tags are also within the ambit of the invention as linkers. Applicants use NLS and/or NES as linker and also use Glycine Serine linkers as short as GS up to (GGGGS)3.
- Destabilizing domains have general utility to confer instability to a wide range of proteins; see, e.g., Miyazaki, J Am Chem Soc. Mar 7, 2012; 134(9): 3942-3945 .
- CMP8 or 4-hydroxytamoxifen can be destabilizing domains. More generally, A temperature-sensitive mutant of mammalian DHFR (DHFRts), a destabilizing residue by the N-end rule, was found to be stable at a permissive temperature but unstable at 37 °C. The addition of methotrexate, a high-affinity ligand for mammalian DHFR, to cells expressing DHFRts inhibited degradation of the protein partially.
- methotrexate a high-affinity ligand for mammalian DHFR
- a rapamycin derivative was used to stabilize an unstable mutant of the FRB domain of mTOR (FRB*) and restore the function of the fused kinase, GSK-3 ⁇ .6,7
- FRB* FRB domain of mTOR
- GSK-3 ⁇ .6,7 This system demonstrated that ligand-dependent stability represented an attractive strategy to regulate the function of a specific protein in a complex biological environment.
- a system to control protein activity can involve the DD becoming functional when the ubiquitin complementation occurs by rapamycin induced dimerization of FK506-binding protein and FKBP12.
- Mutants of human FKBP12 or ecDHFR protein can be engineered to be metabolically unstable in the absence of their high-affinity ligands, Shield-1 or trimethoprim (TMP), respectively. These mutants are some of the possible destabilizing domains (DDs) useful in the practice of the invention and instability of a DD as a fusion with a Cas13b confers to the Cas13b degradation of the entire fusion protein by the proteasome. Shield-1 and TMP bind to and stabilize the DD in a dose-dependent manner.
- the estrogen receptor ligand binding domain (ERLBD, residues 305-549 of ERS1) can also be engineered as a destabilizing domain.
- the mutant ERLBD can be fused to a Cas13b and its stability can be regulated or perturbed using a ligand, whereby the Cas13b has a DD.
- Another DD can be a 12-kDa (107-amino-acid) tag based on a mutated FKBP protein, stabilized by Shield1 ligand; see, e.g., Nature Methods 5, (2008 ).
- a DD can be a modified FK506 binding protein 12 (FKBP12) that binds to and is reversibly stabilized by a synthetic, biologically inert small molecule, Shield-1; see, e.g., Banaszynski LA, Chen LC, Maynard-Smith LA, Ooi AG, Wandless TJ. A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules. Cell. 2006;126:995-1004 ; Banaszynski LA, Sellmyer MA, Contag CH, Wandless TJ, Thorne SH. Chemical control of protein stability and function in living mice. Nat Med.
- FKBP12 modified FK506 binding protein 12
- the knowledge in the art includes a number of DDs, and the DD can be associated with, e.g., fused to, advantageously with a linker, to a Cas13b, whereby the DD can be stabilized in the presence of a ligand and when there is the absence thereof the DD can become destabilized, whereby the Cas13b is entirely destabilized, or the DD can be stabilized in the absence of a ligand and when the ligand is present the DD can become destabilized; the DD allows the Cas13b and hence the CRISPR-Cas13b complex or system to be regulated or controlled-turned on or off so to speak, to thereby provide means for regulation or control of the system, e.g., in an in vivo or in vitro environment.
- a protein of interest when expressed as a fusion with the DD tag, it is destabilized and rapidly degraded in the cell, e.g., by proteasomes. Thus, absence of stabilizing ligand leads to a D associated Cas being degraded.
- a new DD When fused to a protein of interest, its instability is conferred to the protein of interest, resulting in the rapid degradation of the entire fusion protein. Peak activity for Cas is sometimes beneficial to reduce off-target effects. Thus, short bursts of high activity are preferred.
- the present invention is able to provide such peaks. In some senses the system is inducible. In some other senses, the system repressed in the absence of stabilizing ligand and de-repressed in the presence of stabilizing ligand.
- the effecteorprotein (CRISPR enzyme; Cas13; effector protein) from Bacteroidetes bacterium GWA2_31_9 of Table 1A as described herein is a catalytically inactive or dead Cas13 effector protein (dCas13).
- the dCas13 effector comprises mutations in the nuclease domain.
- the dCas13 effector protein has been truncated. To reduce the size of a fusion protein of the Cas13 effector and the one or more functional domains, the C-terminus of the Cas13 effector can be truncated while still maintaining its RNA binding function.
- Cas13 truncations include C-terminal ⁇ 984-1090, C-terminal ⁇ 1026-1090, and C-terminal ⁇ 1053-1090, C-terminal ⁇ 934-1090, C-terminal ⁇ 884-1090, C-terminal ⁇ 834-1090, C-terminal ⁇ 784-1090, and C-terminal ⁇ 734-1090, wherein amino acid positions correspond to amino acid positions of Prevotella sp. P5-125 Cas13b protein. See Fig. 28 .
- the invention provides accessory proteins that modulate CRISPR protein function.
- the accessory protein modulates catalytic activity of a CRISPR protein.
- an accessory protein modulates targeted, or sequence specific, nuclease activity.
- an accessory protein modulates collateral nuclease activity.
- an accessory protein modulates binding to a target nucleic acid.
- the nuclease activity to be modulated can be directed against nucleic acids comprising or consisting of RNA, including without limitation mRNA, miRNA, siRNA and nucleic acids comprising cleavable RNA linkages along with nucleotide analogs.
- the nuclease activity to be modulated can be directed against nucleic acids comprising or consisting of DNA, including without limitation nucleic acids comprising cleavable DNA linkages and nucleic acid analogs.
- an accessory protein enhances an activity of a CRISPR protein.
- the accessory protein comprises a HEPN domain and enhances RNA cleavage.
- the accessory protein inhibits an activity of a CRISPR protein.
- the accessory protein comprises an inactivated HEPN domain or lacks an HEPN domain altogether.
- Naturally occurring accessory proteins of Type VI CRISPR systems comprise small proteins encoded at or near a CRISPR locus that function to modify an activity of a CRISPR protein.
- a CRISPR locus can be identified as comprising a putative CRISPR array and/or encoding a putative CRISPR effector protein.
- an effector protein can be from 800 to 2000 amino acids, or from 900 to 1800 amino acids, or from 950 to 1300 amino acids.
- an accessory protein can be encoded within 25 kb, or within 20 kb or within 15 kb, or within 10 kb of a putative CRISPR effector protein or array, or from 2 kb to 10 kb from a putative CRISPR effector protein or array.
- an accessory protein is from 50 to 300 amino acids, or from 100 to 300 amino acids or from 150 to 250 amino acids or about 200 amino acids.
- accessory proteins include the csx27 and csx28 proteins identified herein.
- CRISPR accessory protein of the invention is independent of CRISPR effector protein classification.
- Accessory proteins of the invention can be found in association with or engineered to function with a variety of CRISPR effector proteins.
- Examples of accessory proteins identified and used herein are representative of CRISPR effector proteins generally. It is understood that CRISPR effector protein classification may involve homology, feature location (e.g., location of REC domains, NUC domains, HEPN sequences), nucleic acid target (e.g. DNA or RNA), absence or presence of tracr RNA, location of guide / spacer sequence 5' or 3' of a direct repeat, or other criteria.
- accessory protein identification and use transcend such classifications.
- the Cas proteins In type VI CRISPR-Cas systems that target RNA, the Cas proteins usually comprise two conserved HEPN domains which are involved in RNA cleavage.
- the Cas protein processes crRNA to generate mature crRNA.
- the guide sequence of the crRNA recognizes target RNA with a complementary sequence and the Cas protein degrades the target strand. More particularly, in certain embodiments, upon target binding, the Cas protein undergoes a structural rearrangement that brings two HEPN domains together to form an active HEPN catalytic site and the target RNA is then cleaved. The location of the catalytic site near the surface of the Cas protein allows non-specific collateral ssRNA cleavage.
- accessory proteins are instrumental in increasing or reducing target and/or collateral RNA cleavage.
- an accessory protein that activates CRISPR activity e.g., a csx28 protein or ortholog or variant comprising a HEPN domain
- an inhibitory accessory protein e.g. csx27 with lacks an HEPN domain
- enhancing activity of a Type VI Cas protein or complex thereof comprises contacting the Type VI Cas protein or complex thereof with an accessory protein from the same organism that activates the Cas protein.
- enhancing activity of a Type VI Cas protein of complex thereof comprises contacting the Type VI Cas protein or complex thereof with an activator accessory protein from a different organism within the same subclass (e.g., Type VI-b).
- enhancing activity of a Type VI Cas protein or complex thereof comprises contacting the Type VI Cas protein or complex thereof with an accessory protein not within the subclass (e.g., a Type VI Cas protein other than Type VI-b with a Type VI-b accessory protein or vice-versa).
- repressing activity of a Type VI Cas protein or complex thereof comprises contacting the Type VI Cas protein or complex thereof with an accessory protein from the same organism that represses the Cas protein.
- repressing activity of a Type VI Cas protein or complex thereof comprises contacting the Type VI Cas protein or complex thereof with an repressor accessory protein from a different organism within the same subclass (e.g., Type VI-b).
- repressing activity of a Type VI Cas protein or complex thereof comprises contacting the Type VI Cas protein or complex thereof with an repressor accessory protein not within the subclass (e.g., a Type VI Cas protein other than Type VI-b with a Type VI-b repressor accessory protein or vice-versa).
- an repressor accessory protein not within the subclass (e.g., a Type VI Cas protein other than Type VI-b with a Type VI-b repressor accessory protein or vice-versa).
- the two proteins will function together in an engineered CRISPR system. In certain embodiments, it will be desirable to alter the function of the engineered CRISPR system, for example by modifying either or both of the proteins or their expression. In embodiments where the Type VI Cas protein and the Type VI accessory protein are from different organisms which may be within the same class or different classes, the proteins may function together in an engineered CRISPR system but it will often be desired or necessary to modify either or both of the proteins to function together.
- either or both of the Cas protein from Bacteroidetes bacterium GWA2_31_9 of Table 1A and an accessory protein may be modified to adjust aspects of protein-protein interactions between the Cas protein and accessory protein.
- either or both of a Cas protein and an accessory protein may be modified to adjust aspects of protein-nucleic acid interactions. Ways to adjust protein-protein interactions and protein-nucleic acid interaction include without limitation, fitting molecular surfaces, polar interactions, hydrogen bonds, and modulating van der Waals interactions.
- adjusting protein-protein interactions or protein-nucleic acid binding comprises increasing or decreasing binding interactions.
- adjusting protein-protein interactions or protein-nucleic acid binding comprises modifications that favor or disfavor a conformation of the protein or nucleic acid.
- fitting is meant determining including by automatic, or semi-automatic means, interactions between one or more atoms of a Cas13 protein and at least one atoms of a Cas13 accessory protein, or between one or more atoms of a Cas13 protein and one or more atoms of a nucleic acid, or between one or more atoms of a Cas13 accessory protein and a nucleic acid, and calculating the extent to which such interactions are stable. Interactions include attraction and repulsion, brought about by charge, steric considerations and the like.
- Type VI CRISPR protein or complex thereof or a Type VI CRISPR accessory protein or complex thereof provides in the context of the instant invention an additional tool for identifying additional mutations in orthologs of Cas 13.
- the crystal structure can also be basis for the design of new and specific Cas 13s and Cas13 accessory proteins.
- Various computer-based methods for fitting are described further. Binding interactions of Cas13s, accessory proteins, and nucleic acids can be examined through the use of computer modeling using a docking program. Docking programs are known; for example GRAM, DOCK or AUTODOCK (see Walters et al. Drug Discovery Today, vol. 3, no. 4 (1998), 160-178 , and Dunbrack et al. Folding and Design 2 (1997), 27-42 ).
- This procedure can include computer fitting to ascertain how well the shape and the chemical structure of the binding partners.
- Computer-assisted, manual examination of the active site or binding site of a Type VI system may be performed.
- Programs such as GRID ( P. Goodford, J. Med. Chem, 1985, 28, 849-57 )-a program that determines probable interaction sites between molecules with various functional groups-may also be used to analyze the active site or binding site to predict partial structures of binding compounds.
- Computer programs can be employed to estimate the attraction, repulsion or steric hindrance of the two binding partners, e.g., components of a Type VI CRISPR system, or a nucleic acid molecule and a component of a Type VI CRISPR system.
- Amino acid substitutions may be made on the basis of differences or similarities in amino acid properties (such as polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues) and it is therefore useful to group amino acids together in functional groups. Amino acids may be grouped together based on the properties of their side chains alone. In comparing orthologs, ther are likely to be residues conserved for structural or catalytic reasons. These sets may be described in the form of a Venn diagram ( Livingstone C.D. and Barton G.J. (1993) "Protein sequence alignments: a strategy for the hierarchical analysis of residue conservation" Comput. Appl. Biosci.
- modification may comprise modification of one or more amino acid residues of the Cas 13 protein and/or may comprise modification of one or more amino acid residues of the Cas13 accessory protein.
- modification may comprise modification of one or more amino acid residues located in a region which comprises residues which are positively charged in the unmodified Cast3 protein and/or Cas13 accessory protein.
- modification may comprise modification of one or more amino acid residues which are positively charged in the unmodified Cast3 protein and/or Cas13 accessory protein.
- modification may comprise modification of one or more amino acid residues which are not positively charged in the unmodified Cas13 protein and/or Cas13 accessory protein.
- the modification may comprise modification of one or more amino acid residues which are uncharged in the unmodified Cas13 protein and/or Cas13 accessory protein.
- the modification may comprise modification of one or more amino acid residues which are negatively charged in the unmodified Cas13 protein and/or Cas13 accessory protein.
- the modification may comprise modification of one or more amino acid residues which are hydrophobic in the unmodified Cas13 protein and/or Cas13 accessory protein.
- the modification may comprise modification of one or more amino acid residues which are polar in the unmodified Cas13 protein and/or Cas13 accessory protein.
- the modification may comprise substitution of a hydrophobic amino acid or polar amino acid with a charged amino acid, which can be a negatively charged or positively charged amino acid.
- the modification may comprise substitution of a negatively charged amino acid with a positively charged or polar or hydrophobic amino acid.
- the modification may comprise substitution of a positively charged amino acid with a negatively charged or polar or hydrophobic amino acid.
- Embodiments of the invention include compositions, vector systems, isolated nucleic acids comprising sequences (either polynucleotide or polypeptide) which may comprise homologous substitution (substitution and replacement are both used herein to mean the interchange of an existing amino acid residue or nucleotide, with an alternative residue or nucleotide) that may occur i.e., like-for-like substitution in the case of amino acids such as basic for basic, acidic for acidic, polar for polar, etc.
- Non-homologous substitution may also occur i.e., from one class of residue to another or alternatively involving the inclusion of unnatural amino acids such as ornithine (hereinafter referred to as Z), diaminobutyric acid ornithine (hereinafter referred to as B), norleucine ornithine (hereinafter referred to as O), pyriylalanine, thienylalanine, naphthylalanine and phenylglycine.
- Z ornithine
- B diaminobutyric acid ornithine
- O norleucine ornithine
- pyriylalanine pyriylalanine
- thienylalanine thienylalanine
- naphthylalanine phenylglycine
- Variant amino acid sequences may include suitable spacer groups that may be inserted between any two amino acid residues of the sequence including alkyl groups such as methyl, ethyl or propyl groups in addition to amino acid spacers such as glycine or ⁇ -alanine residues.
- alkyl groups such as methyl, ethyl or propyl groups
- amino acid spacers such as glycine or ⁇ -alanine residues.
- a further form of variation which involves the presence of one or more amino acid residues in peptoid form, may be well understood by those skilled in the art.
- the peptoid form is used to refer to variant amino acid residues wherein the ⁇ -carbon substituent group is on the residue's nitrogen atom rather than the ⁇ -carbon.
- Structural alignment is further used to identify both close and remote structural neighbours by considering global and local geometric relationships. Whenever two neighbors of the structural representatives form a complex reported in the Protein Data Bank, this defines a template for modelling the interaction between the two query proteins. Models of a complex are created by superimposing the representative structures on their corresponding structural neighbour in the template. This approach is in Dey et al., 2013 (Prot Sci; 22: 359-66 ).
- plant relates to any various photosynthetic, eukaryotic, unicellular or multicellular organism of the kingdom Plantae characteristically growing by cell division, containing chloroplasts, and having cell walls comprised of cellulose.
- the term plant encompasses monocotyledonous and dicotyledonous plants.
- the plants are intended to comprise without limitation angiosperm and gymnosperm plants such as acacia, alfalfa, amaranth, apple, apricot, artichoke, ash tree, asparagus, avocado, banana, barley, beans, beet, birch, beech, blackberry, blueberry, broccoli, Brussel's sprouts, cabbage, canola, cantaloupe, carrot, cassava, cauliflower, cedar, a cereal, celery, chestnut, cherry, Chinese cabbage, citrus, clementine, clover, coffee, corn, cotton, cowpea, cucumber, cypress, eggplant, elm, endive, eucalyptus, fennel, figs, fir, geranium, grape, grapefruit, groundnuts, ground cherry, gum hemlock, hickory, kale, kiwifruit, kohlrabi, larch, lettuce, leek, lemon, lime, locust, pine, maidenhair, mai
- RNA targeting system as described herein can be used to confer desired traits on essentially any plant.
- a wide variety of plants and plant cell systems may be engineered for the desired physiological and agronomic characteristics described herein using the nucleic acid constructs of the present disclosure and the various transformation methods mentioned above.
- target plants and plant cells for engineering include, but are not limited to, those monocotyledonous and dicotyledonous plants, such as crops including grain crops (e.g., wheat, maize, rice, millet, barley), fruit crops (e.g., tomato, apple, pear, strawberry, orange), forage crops (e.g., alfalfa), root vegetable crops (e.g., carrot, potato, sugar beets, yam), leafy vegetable crops (e.g., lettuce, spinach); flowering plants (e.g., petunia, rose, chrysanthemum), conifers and pine trees (e.g., pine fir, spruce); plants used in phytoremediation (e.g., heavy metal accumulating plants); oil crops (e.g., sunflower, rape seed) and plants used for experimental purposes (e.g., Arabidopsis ) .
- crops including grain crops (e.g., wheat, maize, rice, millet, barley
- the methods and CRISPR-Cas systems can be used over a broad range of plants, such as for example with dicotyledonous plants belonging to the orders Magniolales, Illiciales, Laurales, Piperales, Aristochiales, Nymphaeales, Ranunculales, Papeverales, Sarraceniaceae, Trochodendrales, Hamamelidales, Eucomiales, Leitneriales, Myricales, Fagales, Casuarinales, Caryophyllales, Batales, Polygonales, Plumbaginales, Dilleniales, Theales, Malvales, Urticales, Lecythidales, Violales, Salicales, Capparales, Ericales, Diapensales, Ebenales, Primulales, Rosales, Fabales, Podostemales, Haloragales, Myrtales, Cornales, Proteales, San tales, Rafflesiales, Celastrales, Euphorbiales, Rhamnales, Sapindales, Ju
- RNA targeting CRISPR systems and methods of use described herein can be used over a broad range of plant species, included in the non-limitative list of dicot, monocot or gymnosperm genera hereunder: Atropa, Alseodaphne, Anacardium, Arachis, Beilschmiedia, Brassica, Carthamus, Cocculus, Croton, Cucumis, Citrus, Citrullus, Capsicum, Catharanthus, Cocos, Coffea, Cucurbita, Daucus, Duguetia, Eschscholzia, Ficus, Fragaria, Glaucium, Glycine, Gossypium, Helianthus, Hevea, Hyoscyamus, Lactuca, Landolphia, Linum, Litsea, Lycopersicon, Lupinus, Manihot, Majorana, Malus, Medicago, Nicotiana, Olea, Parthenium, Papaver, Persea, Phaseolus, Pistacia,
- RNA targeting CRISPR systems and methods of use can also be used over a broad range of "algae” or “algae cells”; including for example algea selected from several eukaryotic phyla, including the Rhodophyta (red algae), Chlorophyta (green algae), Phaeophyta (brown algae), Bacillariophyta (diatoms), Eustigmatophyta and dinoflagellates as well as the prokaryotic phylum Cyanobacteria (blue-green algae).
- algea selected from several eukaryotic phyla including the Rhodophyta (red algae), Chlorophyta (green algae), Phaeophyta (brown algae), Bacillariophyta (diatoms), Eustigmatophyta and dinoflagellates as well as the prokaryotic phylum Cyanobacteria (blue-green algae).
- algae includes for example algae selected from : Amphora, Anabaena, Anikstrodesmis, Botryococcus, Chaetoceros, Chlamydomonas, Chlorella, Chlorococcum, Cyclotella, Cylindrotheca, Dunaliella, Emiliana, Euglena, Hematococcus, Isochrysis, Monochrysis, Monoraphidium, Nannochloris, Nannnochloropsis, Navicula, Nephrochloris, Nephroselmis, Nitzschia, Nodularia, Nostoc, Oochromonas, Oocystis, Oscillartoria, Pavlova, Phaeodactylum, Playtmonas, Pleurochrysis, Porhyra, Pseudoanabaena, Pyramimonas, Stichococcus, Synechococcus, Synechocystis, Tetrasel
- Plant tissue A part of a plant, i.e., a "plant tissue” may be treated according to the methods of the present invention to produce an improved plant.
- Plant tissue also encompasses plant cells.
- plant cell refers to individual units of a living plant, either in an intact whole plant or in an isolated form grown in in vitro tissue cultures, on media or agar, in suspension in a growth media or buffer or as a part of higher organized unites, such as, for example, plant tissue, a plant organ, or a whole plant.
- a "protoplast” refers to a plant cell that has had its protective cell wall completely or partially removed using, for example, mechanical or enzymatic means resulting in an intact biochemical competent unit of living plant that can reform their cell wall, proliferate and regenerate grow into a whole plant under proper growing conditions.
- plant host refers to plants, including any cells, tissues, organs, or progeny of the plants.
- plant tissues or plant cells can be transformed and include, but are not limited to, protoplasts, somatic embryos, pollen, leaves, seedlings, stems, calli, stolons, microtubers, and shoots.
- a plant tissue also refers to any clone of such a plant, seed, progeny, propagule whether generated sexually or asexually, and descendents of any of these, such as cuttings or seed.
- the term "transformed” as used herein, refers to a cell, tissue, organ, or organism into which a foreign DNA molecule, such as a construct, has been introduced.
- the introduced DNA molecule may be integrated into the genomic DNA of the recipient cell, tissue, organ, or organism such that the introduced DNA molecule is transmitted to the subsequent progeny.
- the "transformed” or “transgenic” cell or plant may also include progeny of the cell or plant and progeny produced from a breeding program employing such a transformed plant as a parent in a cross and exhibiting an altered phenotype resulting from the presence of the introduced DNA molecule.
- the transgenic plant is fertile and capable of transmitting the introduced DNA to progeny through sexual reproduction.
- progeny such as the progeny of a transgenic plant
- the introduced DNA molecule may also be transiently introduced into the recipient cell such that the introduced DNA molecule is not inherited by subsequent progeny and thus not considered “transgenic”.
- a non-transgenic plant or plant cell is a plant which does not contain a foreign DNA stably integrated into its genome.
- plant promoter is a promoter capable of initiating transcription in plant cells, whether or not its origin is a plant cell.
- exemplary suitable plant promoters include, but are not limited to, those that are obtained from plants, plant viruses, and bacteria such as Agrobacterium or Rhizobium which comprise genes expressed in plant cells.
- fungal cell refers to any type of eukaryotic cell within the kingdom of fungi. Phyla within the kingdom of fungi include Ascomycota, Basidiomycota, Blastocladiomycota, Chytridiomycota, Glomeromycota, Microsporidia, and Neocallimastigomycota. Fungal cells may include yeasts, molds, and filamentous fungi. In some embodiments, the fungal cell is a yeast cell.
- yeast cell refers to any fungal cell within the phyla Ascomycota and Basidiomycota.
- Yeast cells may include budding yeast cells, fission yeast cells, and mold cells. Without being limited to these organisms, many types of yeast used in laboratory and industrial settings are part of the phylum Ascomycota.
- the yeast cell is an S. cerervisiae, Kluyveromyces marxianus, or Issatchenkia orientalis cell.
- Other yeast cells may include without limitation Candida spp. (e.g., Candida albicans), Yarrowia spp. (e.g., Yarrowia lipolytica), Pichia spp.
- the fungal cell is a filamentous fungal cell.
- filamentous fungal cell refers to any type of fungal cell that grows in filaments, i.e., hyphae or mycelia.
- filamentous fungal cells may include without limitation Aspergillus spp. (e.g., Aspergillus niger), Trichoderma spp. (e.g., Trichoderma reesei), Rhizopus spp. (e.g., Rhizopus oryzae), and Mortierella spp. (e.g., Mortierella isabellina).
- the fungal cell is an industrial strain.
- industrial strain refers to any strain of fungal cell used in or isolated from an industrial process, e.g., production of a product on a commercial or industrial scale.
- Industrial strain may refer to a fungal species that is typically used in an industrial process, or it may refer to an isolate of a fungal species that may be also used for non-industrial purposes (e.g., laboratory research).
- Examples of industrial processes may include fermentation (e.g., in production of food or beverage products), distillation, biofuel production, production of a compound, and production of a polypeptide.
- industrial strains may include, without limitation, JAY270 and ATCC4124.
- the fungal cell is a polyploid cell.
- a "polyploid" cell may refer to any cell whose genome is present in more than one copy.
- a polyploid cell may refer to a type of cell that is naturally found in a polyploid state, or it may refer to a cell that has been induced to exist in a polyploid state (e.g., through specific regulation, alteration, inactivation, activation, or modification of meiosis, cytokinesis, or DNA replication).
- a polyploid cell may refer to a cell whose entire genome is polyploid, or it may refer to a cell that is polyploid in a particular genomic locus of interest.
- the abundance of guideRNA may more often be a rate-limiting component in genome engineering of polyploid cells than in haploid cells, and thus the methods using the Cas13b CRISPR system described herein may take advantage of using a certain fungal cell type.
- the fungal cell is a diploid cell.
- a diploid cell may refer to any cell whose genome is present in two copies.
- a diploid cell may refer to a type of cell that is naturally found in a diploid state, or it may refer to a cell that has been induced to exist in a diploid state (e.g., through specific regulation, alteration, inactivation, activation, or modification of meiosis, cytokinesis, or DNA replication).
- the S. cerevisiae strain S228C may be maintained in a haploid or diploid state.
- a diploid cell may refer to a cell whose entire genome is diploid, or it may refer to a cell that is diploid in a particular genomic locus of interest.
- the fungal cell is a haploid cell.
- a "haploid" cell may refer to any cell whose genome is present in one copy.
- a haploid cell may refer to a type of cell that is naturally found in a haploid state, or it may refer to a cell that has been induced to exist in a haploid state (e.g., through specific regulation, alteration, inactivation, activation, or modification of meiosis, cytokinesis, or DNA replication). For example, the S.
- a haploid cell may refer to a cell whose entire genome is haploid, or it may refer to a cell that is haploid in a particular genomic locus of interest.
- yeast expression vector refers to a nucleic acid that contains one or more sequences encoding an RNA and/or polypeptide and may further contain any desired elements that control the expression of the nucleic acid(s), as well as any elements that enable the replication and maintenance of the expression vector inside the yeast cell.
- yeast expression vectors and features thereof are known in the art; for example, various vectors and techniques are illustrated in in Yeast Protocols, 2nd edition, Xiao, W., ed. (Humana Press, New York, 2007 ) and Buckholz, R.G. and Gleeson, M.A. (1991) Biotechnology (NY) 9(11): 1067-72 .
- Yeast vectors may contain, without limitation, a centromeric (CEN) sequence, an autonomous replication sequence (ARS), a promoter, such as an RNA Polymerase III promoter, operably linked to a sequence or gene of interest, a terminator such as an RNA polymerase III terminator, an origin of replication, and a marker gene (e.g., auxotrophic, antibiotic, or other selectable markers).
- CEN centromeric
- ARS autonomous replication sequence
- a promoter such as an RNA Polymerase III promoter
- a terminator such as an RNA polymerase III terminator
- an origin of replication e.g., auxotrophic, antibiotic, or other selectable markers
- marker gene e.g., auxotrophic, antibiotic, or other selectable markers.
- expression vectors for use in yeast may include plasmids, yeast artificial chromosomes, 2 ⁇ plasmids, yeast integrative plasmids, yeast replicative plasmids, shuttle vectors, and
- RNA targeting CRISP system components in the genome of plants and plant cells
- the polynucleotides encoding the components of the RNA targeting CRISPR system are introduced for stable integration into the genome of a plant cell.
- the design of the transformation vector or the expression system can be adjusted depending on when, where and under what conditions the guide RNA and/or the RNA targeting gene(s) are expressed.
- RNA targeting CRISPR system stably into the genomic DNA of a plant cell.
- RNA targeting CRISPR system for stable integration into the DNA of a plant organelle such as, but not limited to a plastid, e mitochondrion or a chloroplast.
- the expression system for stable integration into the genome of a plant cell may contain one or more of the following elements: a promoter element that can be used to express the guide RNA and/or RNA targeting enzyme in a plant cell; a 5' untranslated region to enhance expression ; an intron element to further enhance expression in certain cells, such as monocot cells; a multiple-cloning site to provide convenient restriction sites for inserting the one or more guide RNAs and/or the RNA targeting gene sequences and other desired elements; and a 3' untranslated region to provide for efficient termination of the expressed transcript.
- a promoter element that can be used to express the guide RNA and/or RNA targeting enzyme in a plant cell
- a 5' untranslated region to enhance expression an intron element to further enhance expression in certain cells, such as monocot cells
- a multiple-cloning site to provide convenient restriction sites for inserting the one or more guide RNAs and/or the RNA targeting gene sequences and other desired elements
- a 3' untranslated region to provide for efficient
- the elements of the expression system may be on one or more expression constructs which are either circular such as a plasmid or transformation vector, or non-circular such as linear double stranded DNA.
- RNA targeting CRISPR expression system comprises at least:
- DNA construct(s) containing the components of the RNA targeting CRISPR system may be introduced into the genome of a plant, plant part, or plant cell by a variety of conventional techniques.
- the process generally comprises the steps of selecting a suitable host cell or host tissue, introducing the construct(s) into the host cell or host tissue, and regenerating plant cells or plants therefrom.
- the DNA construct may be introduced into the plant cell using techniques such as but not limited to electroporation, microinjection, aerosol beam injection of plant cell protoplasts, or the DNA constructs can be introduced directly to plant tissue using biolistic methods, such as DNA particle bombardment (see also Fu et al., Transgenic Res. 2000 Feb;9(1): 11-9 ).
- the basis of particle bombardment is the acceleration of particles coated with gene/s of interest toward cells, resulting in the penetration of the protoplasm by the particles and typically stable integration into the genome. (see e.g. Klein et al, Nature (1987 ), Klein et a1, Bio/Technology (1992 ), Casas et a1, Proc. Natl. Acad. Sci. USA (1993 ).).
- the DNA constructs containing components of the RNA targeting CRISPR system may be introduced into the plant by Agrobacterium -mediated transformation.
- the DNA constructs may be combined with suitable T-DNA flanking regions and introduced into a conventional Agrobacterium tumefaciens host vector.
- the foreign DNA can be incorporated into the genome of plants by infecting the plants or by incubating plant protoplasts with Agrobacterium bacteria, containing one or more Ti (tumor-inducing) plasmids. (see e.g. Fraley et al., (1985), Rogers et al., (1987) and U.S. Pat. No. 5,563,055 ).
- the components of the Cas13b CRISPR system described herein are typically placed under control of a plant promoter, i.e. a promoter operable in plant cells.
- a plant promoter i.e. a promoter operable in plant cells.
- the use of different types of promoters is envisaged.
- a constitutive plant promoter is a promoter that is able to express the open reading frame (ORF) that it controls in all or nearly all of the plant tissues during all or nearly all developmental stages of the plant (referred to as "constitutive expression").
- ORF open reading frame
- One non-limiting example of a constitutive promoter is the cauliflower mosaic virus 35S promoter.
- the present invention envisages methods for modifying RNA sequences and as such also envisages regulating expression of plant biomolecules. In particular embodiments of the present invention it is thus advantageous to place one or more elements of the RNA targeting CRISPR system under the control of a promoter that can be regulated.
- RNA targeting CRISPR components are expressed under the control of a constitutive promoter, such as the cauliflower mosaic virus 35S promoter issue-preferred promoters can be utilized to target enhanced expression in certain cell types within a particular plant tissue, for instance vascular cells in leaves or roots or in specific cells of the seed.
- promoters for use in the RNA targeting CRISPR system- are found in Kawamata et al., (1997) Plant Cell Physiol 38:792-803 ; Yamamoto et al., (1997) Plant J 12:255-65 ; Hire et al, (1992) Plant Mol Biol 20:207-18 , Kuster et al, (1995) Plant Mol Biol 29:759-72 , and Capana et al., (1994) Plant Mol Biol 25:681 -91 .
- promoters that are inducible and that allow for spatiotemporal control of gene editing or gene expression may use a form of energy.
- the form of energy may include but is not limited to sound energy, electromagnetic radiation, chemical energy and/or thermal energy.
- inducible systems include tetracycline inducible promoters (Tet-On or Tet-Off), small molecule two-hybrid transcription activations systems (FKBP, ABA, etc), or light inducible systems (Phytochrome, LOV domains, or cryptochrome)., such as a Light Inducible Transcriptional Effector (LITE) that direct changes in transcriptional activity in a sequence-specific manner.
- LITE Light Inducible Transcriptional Effector
- the components of a light inducible system may include a RNA targeting Cas13b, a light-responsive cytochrome heterodimer (e.g. from Arabidopsis thaliana), and a transcriptional activation/repression domain.
- transient or inducible expression can be achieved by using, for example, chemical-regulated promoters, i.e. whereby the application of an exogenous chemical induces gene expression. Modulating of gene expression can also be obtained by a chemical-repressible promoter, where application of the chemical represses gene expression.
- Chemical-inducible promoters include, but are not limited to, the maize ln2-2 promoter, activated by benzene sulfonamide herbicide safeners ( De Veylder et al., (1997) Plant Cell Physiol 38:568-77 ), the maize GST promoter (GST-ll-27, WO93/01294 ), activated by hydrophobic electrophilic compounds used as pre-emergent herbicides, and the tobacco PR-1 a promoter ( Ono et al., (2004) Biosci Biotechnol Biochem 68:803-7 ) activated by salicylic acid.
- Promoters which are regulated by antibiotics such as tetracycline-inducible and tetracycline-repressible promoters ( Gatz et al., (1991 ) Mol Gen Genet 227:229-37 ; U.S. Patent Nos. 5,814,618 and 5,789,156 ) can also be used herein.
- the expression system may comprise elements for translocation to and/or expression in a specific plant organelle.
- the RNA targeting CRISPR system is used to specifically modify expression and/or translation of chloroplast genes or to ensure expression in the chloroplast.
- use is made of chloroplast transformation methods or proximityalization of the RNA targeting CRISPR components to the chloroplast.
- the introduction of genetic modifications in the plastid genome can reduce biosafety issues such as gene flow through pollen.
- Methods of chloroplast transformation include Particle bombardment, PEG treatment, and microinjection. Additionally, methods involving the translocation of transformation cassettes from the nuclear genome to the plastid can be used as described in WO2010061186 .
- RNA targeting CRISPR components it is envisaged to target one or more of the RNA targeting CRISPR components to the plant chloroplast.
- This is achieved by incorporating in the expression construct a sequence encoding a chloroplast transit peptide (CTP) or plastid transit peptide, operably linked to the 5' region of the sequence encoding the RNA targeting protein.
- CTP chloroplast transit peptide
- the CTP is removed in a processing step during translocation into the chloroplast.
- Chloroplast targeting of expressed proteins is well known to the skilled artisan (see for instance Protein Transport into Chloroplasts, 2010, Annual Review of Plant Biology,Vol. 61: 157-180 ) .
- Transgenic algae may be particularly useful in the production of vegetable oils or biofuels such as alcohols (especially methanol and ethanol) or other products. These may be engineered to express or overexpress high levels of oil or alcohols for use in the oil or biofuel industries.
- RNA targeting protein and guide RNA(s) are introduced in algae expressed using a vector that expresses RNA targeting protein under the control of a constitutive promoter such as Hsp70A-Rbc S2 or Beta2 -tubulin.
- Guide RNA is optionally delivered using a vector containing T7 promoter.
- RNA targeting mRNA and in vitro transcribed guide RNA can be delivered to algal cells. Electroporation protocols are available to the skilled person such as the standard recommended protocol from the GeneArt Chlamydomonas Engineering kit.
- the invention relates to the use of the RNA targeting CRISPR system for RNA editing in yeast cells.
- Methods for transforming yeast cells which can be used to introduce polynucleotides encoding the RNA targeting CRISPR system components are well known to the artisan and are reviewed by Kawai et al., 2010, Bioeng Bugs. 2010 Nov-Dec; 1(6): 395-403 ).
- Non-limiting examples include transformation of yeast cells by lithium acetate treatment (which may further include carrier DNA and PEG treatment), bombardment or by electroporation.
- the guide RNA and/or RNA targeting gene are transiently expressed in the plant cell.
- the RNA targeting CRISPR system can ensure modification of RNA target molecules only when both the guide RNA and the RNA targeting protein is present in a cell, such that gene expression can further be controlled.
- the expression of the RNA targeting enzyme is transient, plants regenerated from such plant cells typically contain no foreign DNA.
- the RNA targeting enzyme is stably expressed by the plant cell and the guide sequence is transiently expressed.
- the RNA targeting CRISPR system components can be introduced in the plant cells using a plant viral vector ( Scholthof et al. 1996, Annu Rev Phytopathol. 1996;34:299-323 ).
- said viral vector is a vector from a DNA virus.
- geminivirus e.g., cabbage leaf curl virus, bean yellow dwarf virus, wheat dwarf virus, tomato leaf curl virus, maize streak virus, tobacco leaf curl virus, or tomato golden mosaic virus
- nanovirus e.g., Faba bean necrotic yellow virus.
- said viral vector is a vector from an RNA virus.
- tobravirus e.g., tobacco rattle virus, tobacco mosaic virus
- potexvirus e.g., potato virus X
- hordeivirus e.g., barley stripe mosaic virus
- the vector used for transient expression of RNA targeting CRISPR constructs is for instance a pEAQ vector, which is tailored for Agrobacterium-mediated transient expression ( Sainsbury F. et al., Plant Biotechnol J. 2009 Sep;7(7):682-93 ) in the protoplast. Precise targeting of genomic locations was demonstrated using a modified Cabbage Leaf Curl virus (CaLCuV) vector to express gRNAs in stable transgenic plants expressing a Cas13b (see Scientific Reports 5, Article number: 14926 (2015), doi:10.1038/srep14926 ).
- CaLCuV Cabbage Leaf Curl virus
- double-stranded DNA fragments encoding the guide RNA or crRNA and/or the RNA targeting gene can be transiently introduced into the plant cell.
- the introduced double-stranded DNA fragments are provided in sufficient quantity to modify RNA molecule(s) in the cell but do not persist after a contemplated period of time has passed or after one or more cell divisions.
- Methods for direct DNA transfer in plants are known by the skilled artisan (see for instance Davey et al. Plant Mol Biol. 1989 Sep;13(3):273-85 .)
- an RNA polynucleotide encoding the RNA targeting protein is introduced into the plant cell, which is then translated and processed by the host cell generating the protein in sufficient quantity to modify the RNA molecule(s) cell (in the presence of at least one guide RNA) but which does not persist after a contemplated period of time has passed or after one or more cell divisions.
- Methods for introducing mRNA to plant protoplasts for transient expression are known by the skilled artisan (see for instance in Gallie, Plant Cell Reports (1993), 13;119-122 ). Combinations of the different methods described above are also envisaged.
- RNA targeting CRISPR components Delivery of RNA targeting CRISPR components to the plant cell
- RNA targeting CRISPR system it is of interest to deliver one or more components of the RNA targeting CRISPR system directly to the plant cell. This is of interest, inter alia, for the generation of non-transgenic plants.
- one or more of the RNA targeting components is prepared outside the plant or plant cell and delivered to the cell.
- the RNA targeting protein is prepared in vitro prior to introduction to the plant cell.
- RNA targeting protein can be prepared by various methods known by one of skill in the art and include recombinant production. After expression, the RNA targeting protein is isolated, refolded if needed, purified and optionally treated to remove any purification tags, such as a His-tag. Once crude, partially purified, or more completely purified RNA targeting protein is obtained, the protein may be introduced to the plant cell.
- the RNA targeting protein is mixed with guide RNA targeting the RNA of interest to form a pre-assembled ribonucleoprotein.
- the individual components or pre-assembled ribonucleoprotein can be introduced into the plant cell via electroporation, by bombardment with RNA targeting -associated gene product coated particles, by chemical transfection or by some other means of transport across a cell membrane.
- transfection of a plant protoplast with a pre-assembled CRISPR ribonucleoprotein has been demonstrated to ensure targeted modification of the plant genome (as described by Woo et al. Nature Biotechnology, 2015; DOI: 10.1038/nbt.3389 ). These methods can be modified to achieve targeted modification of RNA molecules in the plants.
- the RNA targeting CRISPR system components are introduced into the plant cells using nanoparticles.
- the components either as protein or nucleic acid or in a combination thereof, can be uploaded onto or packaged in nanoparticles and applied to the plants (such as for instance described in WO 2008042156 and US 20130185823 ).
- embodiments of the invention comprise nanoparticles uploaded with or packed with DNA molecule(s) encoding the RNA targeting protein, DNA molecules encoding the guide RNA and/or isolated guide RNA as described in WO2015089419 .
- RNA targeting CRISPR system comprises compositions comprising a cell penetrating peptide linked to an RNA targeting protein.
- an RNA targeting protein and/or guide RNA(s) is coupled to one or more CPPs to effectively transport them inside plant protoplasts ( Ramakrishna (2014, Genome Res. 2014 Jun;24(6): 1020-7 for Cas9 in human cells).
- the RNA targeting gene and/or guide RNA(s) are encoded by one or more circular or non-circular DNA molecule(s) which are coupled to one or more CPPs for plant protoplast delivery.
- the plant protoplasts are then regenerated to plant cells and further to plants.
- CPPs are generally described as short peptides of fewer than 35 amino acids either derived from proteins or from chimeric sequences which are capable of transporting biomolecules across cell membrane in a receptor independent manner.
- CPP can be cationic peptides, peptides having hydrophobic sequences, amphipatic peptides, peptides having proline-rich and antimicrobial sequence, and chimeric or bipartite peptides (Pooga and Langel 2005).
- CPPs are able to penetrate biological membranes and as such trigger the movement of various biomolecules across cell membranes into the cytoplasm and to improve their intracellular routing, and hence facilitate interaction of the biolomolecule with the target.
- Examples of CPP include amongst others: Tat, a nuclear transcriptional activator protein required for viral replication by HIV type1, penetratin, Kaposi fibroblast growth factor (FGF) signal peptide sequence, integrin ⁇ 3 signal peptide sequence; polyarginine peptide Args sequence, Guanine rich-molecular transporters, sweet arrow peptide, etc...
- the target RNA i.e. the RNA of interest
- the target RNA is the RNA to be targeted by the present invention leading to the recruitment to, and the binding of the RNA targeting protein at, the target site of interest on the target RNA.
- the target RNA may be any suitable form of RNA. This may include, in some embodiments, mRNA.
- the target RNA may include transfer RNA (tRNA) or ribosomal RNA (rRNA).
- the target RNA may include interfering RNA (RNAi), microRNA (miRNA), microswitches, microzymes, satellite RNAs and RNA viruses.
- the target RNA may be located in the cytoplasm of the plant cell, or in the cell nucleus or in a plant cell organelle such as a mitochondrion, chloroplast or plastid.
- the RNA targeting CRISPR system is used to cleave RNA or otherwise inhibit RNA expression.
- RNA targeting CRISPR system for modulating plant gene expression via RNA modulation
- the RNA targeting protein may also be used, together with a suitable guide RNA, to target gene expression, via control of RNA processing.
- the control of RNA processing may include RNA processing reactions such as RNA splicing, including alternative splicing; viral replication (in particular of plant viruses, including virioids in plants and tRNA biosynthesis.
- the RNA targeting protein in combination with a suitable guide RNA may also be used to control RNA activation (RNAa).
- RNAa leads to the promotion of gene expression, so control of gene expression may be achieved that way through disruption or reduction of RNAa and thus less promotion of gene expression.
- the RNA targeting effector protein of the invention can further be used for antiviral activity in plants, in particular against RNA viruses.
- the effector protein can be targeted to the viral RNA using a suitable guide RNA selective for a selected viral RNA sequence.
- the effector protein may be an active nuclease that cleaves RNA, such as single stranded RNA. provided is therefore the use of an RNA targeting effector protein of the invention as an antiviral agent.
- viruses that can be counteracted in this way include, but are not limited to, Tobacco mosaic virus (TMV), Tomato spotted wilt virus (TSWV), Cucumber mosaic virus (CMV), Potato virus Y (PVY), Cauliflower mosaic virus (CaMV) (RT virus), Plum pox virus (PPV), Brome mosaic virus (BMV) and Potato virus X (PVX).
- TMV Tobacco mosaic virus
- TSWV Tomato spotted wilt virus
- CMV Cucumber mosaic virus
- PVY Potato virus Y
- CaMV Cauliflower mosaic virus
- PV Plum pox virus
- BMV Brome mosaic virus
- PVX Potato virus X
- RNA expression in plants, algae or fungi examples of modulating RNA expression in plants, algae or fungi, as an alternative of targeted gene modification are described herein further.
- regulated control of gene expression through regulated cleavage of mRNA. This can be achieved by placing elements of the RNA targeting under the control of regulated promoters as described herein.
- RNA targeting CRISPR system Use of the RNA targeting CRISPR system to restore the functionality of tRNA molecules.
- RNA editing in plant mitochondria and chloroplasts that alters mRNA sequences to code for different proteins than the DNA.
- the elements of the RNA targeting CRISPR system specifically targetting mitochondrial and chloroplast mRNA can be introduced in a plant or plant cell to express different proteins in such plant cell organelles mimicking the processes occuring in vivo.
- RNA targeting CRISPR system as an alternative to RNA interference to inhibit RNA expression.
- RNA targeting CRISPR system has uses similar to RNA inhibition or RNA interference, thus can also be substituted for such methods.
- the methods of the present invention include the use of the RNA targeting CRISPR as a substitute for e.g. an interfering ribonucleic acid (such as an siRNA or shRNA or a dsRNA). Examples of inhibition of RNA expression in plants, algae or fungi as an alternative of targeted gene modification are described herein further.
- the target RNA may include interfering RNA, i.e. RNA involved in an RNA interference pathway, such as shRNA, siRNA and so forth.
- the target RNA may include microRNA (miRNA) or double stranded RNA (dsRNA).
- RNA targeting protein and suitable guide RNA(s) are selectively expressed (for example spatially or temporally under the control of a regulated promoter, for example a tissue- or cell cycle-specific promoter and/or enhancer) this can be used to 'protect' the cells or systems ( in vivo or in vitro ) from RNAi in those cells.
- a regulated promoter for example a tissue- or cell cycle-specific promoter and/or enhancer
- the RNA targeting protein may be used to control or bind to molecules comprising or consisting of RNA, such as ribozymes, ribosomes or riboswitches.
- the guide RNA can recruit the RNA targeting protein to these molecules so that the RNA targeting protein is able to bind to them.
- RNA targeting CRISPR system of the invention can be applied in areas of inplanta RNAi technologies, without undue experimentation, from this disclosure, including insect pest management, plant disease management and management of herbicide resistance, as well as in plant assay and for other applications (see, for instance Kim et al., in Pesticide Biochemistry and Physiology (Impact Factor: 2.01). 01/2015; 120. DOI: 10.1016/j.pestbp.2015.01.002 ; Sharma et al. in Academic Journals (2015), Vol.12(18) pp2303-2312 ); Green J.M, inPest Management Science, Vol 70(9), pp 1351-1357 ), because the present application provides the foundation for informed engineering of the system.
- RNA targeting CRISPR system to modify riboswitches and control metabolic regulation in Plants, Algae and Fungi
- Riboswitches are regulatory segments of messenger RNA that bind small molecules and in turn regulate gene expression. This mechanism allows the cell to sense the intracellular concentration of these small molecules.
- a particular riboswitch typically regulates its adjacent gene by altering the transcription, the translation or the splicing of this gene.
- control of riboswitch activity is envisaged through the use of the RNA targeting protein in combination with a suitable guide RNA to target the riboswitch. This may be through cleavage of, or binding to, the riboswitch. In particular embodiments, reduction of riboswitch activity is envisaged.
- TPP thiamin pyrophosphate
- RNA targeting CRISPR system described herein may be used to manipulate the endogenous riboswitch activity in plants, algae or fungi and as such alter the expression of downstream genes controlled by it.
- the RNA targeting CRISP system may be used in assaying riboswitch function in vivo or in vitro and in studying its relevance for the metabolic network.
- the RNA targeting CRISPR system may potentially be used for engineering of riboswitches as metabolite sensors in plants and platforms for gene control.
- RNA targeting CRISPR system Screens for plants, algae or fungi
- RNAi screens Identifying gene products whose knockdown is associated with phenotypic changes, biological pathways can be interrogated and the constituent parts identified, via RNAi screens.
- control may also be exerted over or during these screens by use of the Guide 29 or Guide 30 protein and suitable guide RNA described herein to remove or reduce the activity of the RNAi in the screen and thus reinstate the activity of the (previously interfered with) gene product (by removing or reducing the interference/repression).
- RNA targeting proteins for visualization of RNA molecules in vivo and in vitro
- the invention provides a nucleic acid binding system.
- In situ hybridization of RNA with complementary probes is a powerful technique.
- fluorescent DNA oligonucleotides are used to detect nucleic acids by hybridization.
- Increased efficiency has been attained by certain modifications, such as locked nucleic acids (LNAs), but there remains a need for efficient and versatile alternatives.
- LNAs locked nucleic acids
- labelled elements of the RNA targeting system can be used as an alternative for efficient and adaptable system for in situ hybridization
- biofuel is an alternative fuel made from plant and plant-derived resources. Renewable biofuels can be extracted from organic matter whose energy has been obtained through a process of carbon fixation or are made through the use or conversion of biomass. This biomass can be used directly for biofuels or can be converted to convenient energy containing substances by thermal conversion, chemical conversion, and biochemical conversion. This biomass conversion can result in fuel in solid, liquid, or gas form.
- biofuels There are two types of biofuels: bioethanol and biodiesel.
- Bioethanol is mainly produced by the sugar fermentation process of cellulose (starch), which is mostly derived from maize and sugar cane.
- Biodiesel on the other hand is mainly produced from oil crops such as rapeseed, palm, and soybean. Biofuels are used mainly for transportation.
- the methods using the RNA targeting CRISPR system as described herein are used to alter the properties of the cell wall in order to facilitate access by key hydrolysing agents for a more efficient release of sugars for fermentation.
- the biosynthesis of cellulose and/or lignin are modified.
- Cellulose is the major component of the cell wall.
- the biosynthesis of cellulose and lignin are co-regulated. By reducing the proportion of lignin in a plant the proportion of cellulose can be increased.
- the methods described herein are used to downregulate lignin biosynthesis in the plant so as to increase fermentable carbohydrates.
- the methods described herein are used to downregulate at least a first lignin biosynthesis gene selected from the group consisting of 4-coumarate 3-hydroxylase (C3H), phenylalanine ammonia-lyase (PAL), cinnamate 4-hydroxylase (C4H), hydroxycinnamoyl transferase (HCT), caffeic acid O-methyltransferase (COMT), caffeoyl CoA 3-O-methyltransferase (CCoAOMT), ferulate 5- hydroxylase (F5H), cinnamyl alcohol dehydrogenase (CAD), cinnamoyl CoA-reductase (CCR), 4- coumarate-CoA ligase (4CL), monolignol-lignin-specific glycosyltransferase, and aldehyde dehydrogenase (ALDH) as disclosed in WO 2008064289 A2 .
- C3H 4-coumarate 3-hydroxylase
- PAL
- the methods described herein are used to produce plant mass that produces lower levels of acetic acid during fermentation (see also WO 2010096488 ).
- RNA targeting enzymes are used for bioethanol production by recombinant micro-organisms.
- RNA targeting enzymes can be used to engineer micro-organisms, such as yeast, to generate biofuel or biopolymers from fermentable sugars and optionally to be able to degrade plant-derived lignocellulose derived from agricultural waste as a source of fermentable sugars.
- the invention provides methods whereby the RNA targeting CRISPR complex is used to modify the expression of endogenous genes required for biofuel production and/or to modify endogenous genes why may interfere with the biofuel synthesis.
- the methods involve stimulating the expression in a micro-organism such as a yeast of one or more nucleotide sequence encoding enzymes involved in the conversion of pyruvate to ethanol or another product of interest.
- a micro-organism such as a yeast of one or more nucleotide sequence encoding enzymes involved in the conversion of pyruvate to ethanol or another product of interest.
- the methods ensure the stimulation of expression of one or more enzymes which allows the micro-organism to degrade cellulose, such as a cellulase.
- the RNA targeting CRISPR complex is used to suppress endogenous metabolic pathways which compete with the biofuel production pathway.
- Transgenic algae or other plants such as rape may be particularly useful in the production of vegetable oils or biofuels such as alcohols (especially methanol and ethanol), for instance. These may be engineered to express or overexpress high levels of oil or alcohols for use in the oil or biofuel industries.
- alcohols especially methanol and ethanol
- RNA targeting effetor protein and guide RNA are introduced in algae expressed using a vector that expresses the RNA targeting effector protein under the control of a constitutive promoter such as Hsp70A-Rbc S2 or Beta2 -tubulin.
- Guide RNA will be delivered using a vector containing T7 promoter.
- in vitro transcribed guide RNA can be delivered to algae cells. Electroporation protocol follows standard recommended protocol from the GeneArt Chlamydomonas Engineering kit.
- present invention can be used as a therapy for virus removal in plant systems as it is able to cleave viral RNA.
- Previous studies in human systems have demonstrated the success of utilizing CRISPR in targeting the single strand RNA virus, hepatitis C ( A. Price, et al., Proc. Natl. Acad. Sci, 2015 ). These methods may also be adapted for using the RNA targeting CRISPR system in plants.
- the present invention also provides plants and yeast cells obtainable and obtained by the methods provided herein.
- the improved plants obtained by the methods described herein may be useful in food or feed production through the modified expression of genes which, for instance ensure tolerance to plant pests, herbicides, drought, low or high temperatures, excessive water, etc.
- improved plants obtained by the methods described herein, especially crops and algae may be useful in food or feed production through expression of, for instance, higher protein, carbohydrate, nutrient or vitamin levels than would normally be seen in the wildtype.
- improved plants, especially pulses and tubers are preferred.
- Improved algae or other plants such as rape may be particularly useful in the production of vegetable oils or biofuels such as alcohols (especially methanol and ethanol), for instance. These may be engineered to express or overexpress high levels of oil or alcohols for use in the oil or biofuel industries.
- alcohols especially methanol and ethanol
- Plant parts include, but are not limited to, leaves, stems, roots, tubers, seeds, endosperm, ovule, and pollen. Plant parts as envisaged herein may be viable, nonviable, regeneratable, and/or non- regeneratable.
- Plant cells and plants generated according to the methods of the invention are also included within the scope of the present invention.
- Such plants may contain a heterologous or foreign DNA sequence inserted at or instead of a target sequence.
- Such plants may contain only an alteration (mutation, deletion, insertion, substitution) in one or more nucleotides. As such, such plants will only be different from their progenitor plants by the presence of the particular modification.
- a Cas13b system is used to engineer pathogen resistant plants, for example by creating resistance against diseases caused by bacteria, fungi or viruses.
- pathogen resistance can be accomplished by engineering crops to produce a Cas13b system that wil be ingested by an insect pest, leading to mortality.
- a Cas13b system is used to engineer abiotic stress tolerance.
- a Cas13b system is used to engineer drought stress tolerance or salt stress tolerance, or cold or heat stress tolerance.
- Some non-limiting target crops include Arabidops Zea mays is thaliana, Oryza sativa L, Prunus domestica L., Gossypium hirsutum, Nicotiana rustica, Zea mays, Medicago sativa, Nicotiana benthamiana and Arabidopsis thaliana
- a Cas13b system is used for management of crop pests.
- a Cas13b system operable in a crop pest can be expressed from a plant host or transferred directly to the target, for example using a viral vector.
- the invention provides a method of efficiently producing homozygous organisms from a heterozygous non-human starting organism.
- the invention is used in plant breeding.
- the invention is used in animal breeding.
- a homozygous organism such as a plant or animal is made by preventing or suppressing recombination by interfering with at least one target gene involved in double strand breaks, chromosome pairing and/or strand exchange.
- the invention provides a system for specific delivery of functional components to the RNA environment. This can be ensured using the CRISPR systems comprising the RNA targeting effector protein of the present invention which allow specific targeting of different components to RNA. More particularly such components include activators or repressors, such as activators or repressors of RNA translation, degradation, etc. Applications of this system are described elsewhere herein.
- the invention provides non-naturally occurring or engineered composition
- a guide RNA comprising a guide sequence capable of hybridizing to a target sequence in a genomic locus of interest in a cell, wherein the guide RNA is modified by the insertion of one or more distinct RNA sequence(s) that bind an adaptor protein.
- the RNA sequences may bind to two or more adaptor proteins (e.g. aptamers), and wherein each adaptor protein is associated with one or more functional domains.
- the guide RNAs of the Cas13b enzymes described herein are shown to be amenable to modification of the guide sequence.
- the guide RNA is modified by the insertion of distinct RNA sequence(s) 5' of the direct repeat, within the direct repeat, or 3' of the guide sequence.
- the functional domains can be same or different, e.g., two of the same or two different activators or repressors.
- the invention provides a herein-discussed composition, wherein the one or more functional domains are attached to the RNA targeting enzyme so that upon binding to the target RNA the functional domain is in a spatial orientation allowing for the functional domain to function in its attributed function;
- the invention provides a herein-discussed composition, wherein the composition comprises a CRISPR-Cas complex having at least three functional domains, at least one of which is associated with the RNA targeting enzyme and at least two of which are associated with the gRNA.
- the invention provides non-naturally occurring or engineered CRISPR-Cas13b complex composition
- the guide RNA as herein-discussed and a Cas13b which is an RNA targeting enzyme encoding a Cas13b effector protein from Bacteroidetes bacterium GWA2_31_9, wherein optionally the RNA targeting enzyme comprises at least one mutation, such that the RNA targeting enzyme has no more than 5% of the nuclease activity of the enzyme not having the at least one mutation, and optionally one or more comprising at least one or more nuclear localization sequences.
- the guide RNA is additionally or alternatively modified so as to still ensure binding of the RNA targeting enzyme but to prevent cleavage by the RNA targeting enzyme (as detailed elsewhere herein).
- the RNA targeting enzyme is a Cas13b enzyme which has a diminished nuclease activity of at least 97%, or 100% as compared with the Cast 3b enzyme not having the at least one mutation.
- the invention provides a herein-discussed composition, wherein the Cas13b enzyme comprises two or more mutations as otherwise herein-discussed.
- an RNA targeting system comprising two or more functional domains.
- the two or more functional domains are heterologous functional domain.
- the system comprises an adaptor protein which is a fusion protein comprising a functional domain, the fusion protein optionally comprising a linker between the adaptor protein and the functional domain.
- the linker includes a GlySer linker.
- one or more functional domains are attached to the RNA effector protein by way of a linker, optionally a GlySer linker.
- the one or more functional domains are attached to the RNA targeting enzyme through one or both of the HEPN domains.
- the invention provides a herein-discussed composition, wherein the one or more functional domains associated with the adaptor protein or the RNA targeting enzume is a domain capable of activating or repressing RNA translation.
- the invention provides a herein-discussed composition, wherein at least one of the one or more functional domains associated with the adaptor protein have one or more activities comprising methylase activity, demethylase activity, transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, DNA integration activity RNA cleavage activity, DNA cleavage activity or nucleic acid binding activity, or molecular switch activity or chemical inducibility or light inducibility.
- the invention provides a herein-discussed composition comprising an aptamer sequence.
- the aptamer sequence is two or more aptamer sequences specific to the same adaptor protein.
- the invention provides a herein-discussed composition, wherein the aptamer sequence is two or more aptamer sequences specific to different adaptor protein.
- the invention provides a herein-discussed composition, wherein the adaptor protein comprises MS2, PP7, Q ⁇ , F2, GA, fr, JP501, M12, R17, BZ13, JP34, JP500, KU1, M11, MX1, TW18, VK, SP, FI, ID2, NL95, TW19, AP205, ⁇ Cb5, ⁇ Cb8r, ⁇ Cb12r, ⁇ Cb23r, 7s, PRR1.
- the aptamer is selected from a binding protein specifically binding any one of the adaptor proteins listed above.
- the invention provides a herein-discussed composition, wherein the cell is a eukaryotic cell.
- the invention provides a herein-discussed composition, wherein the eukaryotic cell is a mammalian cell, a plant cell or a yeast cell, whereby the mammalian cell is optionally a mouse cell.
- the invention provides a herein-discussed composition, wherein the mammalian cell is a human cell.
- the invention provides a herein above-discussed composition wherein there is more than one guide RNA or gRNA or crRNA, and these target different sequences whereby when the composition is employed, there is multiplexing.
- the invention provides a composition wherein there is more than one guide RNA or gRNA or crRNA modified by the insertion of distinct RNA sequence(s) that bind to one or more adaptor proteins.
- the invention provides a herein-discussed composition wherein one or more adaptor proteins associated with one or more functional domains is present and bound to the distinct RNA sequence(s) inserted into the guide RNA(s).
- the invention provides a herein-discussed composition wherein the guide RNA is modified to have at least one non-coding functional loop; e.g., wherein the at least one non-coding functional loop is repressive; for instance, wherein at least one non-coding functional loop comprises Alu.
- the invention provides a method for modifying gene expression comprising the administration to a host or expression in a host in vivo of one or more of the compositions as herein-discussed.
- the invention provides a herein-discussed method comprising the delivery of the composition or nucleic acid molecule(s) coding therefor, wherein said nucleic acid molecule(s) are operatively linked to regulatory sequence(s) and expressed in vivo.
- the invention provides a herein-discussed method wherein the expression in vivo is via a lentivirus, an adenovirus, or an AAV.
- the invention provides a mammalian cell line of cells as herein-discussed, wherein the cell line is, optionally, a human cell line or a mouse cell line.
- the invention provides a transgenic mammalian model, optionally a mouse, wherein the model has been transformed with a herein-discussed composition or is a progeny of said transformant.
- the invention provides a nucleic acid molecule(s) encoding guide RNA or the RNA targeting CRISPR-Cas13b complex or the composition as herein-discussed.
- the invention provides a vector comprising: a nucleic acid molecule encoding a guide RNA (gRNA) or crRNA comprising a guide sequence capable of hybridizing to an RNA target sequence in a cell, wherein the direct repeat of the gRNA or crRNA is modified by the insertion of distinct RNA sequence(s) that bind(s) to two or more adaptor proteins, and wherein each adaptor protein is associated with one or more functional domains; or, wherein the gRNA is modified to have at least one non-coding functional loop.
- gRNA guide RNA
- crRNA comprising a guide sequence capable of hybridizing to an RNA target sequence in a cell, wherein the direct repeat of the gRNA or crRNA is modified by the insertion of distinct RNA sequence(s) that bind(s) to two or more adaptor proteins,
- the invention provides vector(s) comprising nucleic acid molecule(s) encoding: non-naturally occurring or engineered CRISPR-Cas13b complex composition comprising the gRNA or crRNA herein-discussed, and an RNA targeting enzyme, wherein optionally the RNA targeting enzyme comprises at least one mutation, such that the RNA targeting enzyme has no more than 5% of the nuclease activity of the RNA targeting enzyme not having the at least one mutation, and optionally one or more comprising at least one or more nuclear localization sequences.
- a vector can further comprise regulatory element(s) operable in a eukaryotic cell operably linked to the nucleic acid molecule encoding the guide RNA (gRNA) or crRNA and/or the nucleic acid molecule encoding the RNA targeting enzyme and/or the optional nuclear localization sequence(s).
- regulatory element(s) operable in a eukaryotic cell operably linked to the nucleic acid molecule encoding the guide RNA (gRNA) or crRNA and/or the nucleic acid molecule encoding the RNA targeting enzyme and/or the optional nuclear localization sequence(s).
- kits comprising one or more of the components described herein.
- the kit may comprise a vector system as described herein and instructions for using the kit.
- Also described but not claimed herein is a method of screening for gain of function (GOF) or loss of function (LOF) or for screening non-coding RNAs or potential regulatory regions (e.g. enhancers, repressors) comprising the cell line of as herein-discussed or cells of the model herein-discussed containing or expressing the RNA targeting enzyme and introducing a composition as herein-discussed into cells of the cell line or model, whereby the gRNA or crRNA includes either an activator or a repressor, and monitoring for GOF or LOF respectively as to those cells as to which the introduced gRNA or crRNA includes an activator or as to those cells as to which the introduced gRNA or crRNA includes a repressor.
- GEF gain of function
- LEF loss of function
- non-coding RNAs or potential regulatory regions e.g. enhancers, repressors
- compositions each comprising a RNA targeting CRISPR guide RNA (gRNA) or crRNA comprising a guide sequence capable of hybridizing to a target RNA sequence of interest in a cell, an RNA targeting enzyme, wherein the RNA targeting enzyme comprises at least one mutation, such that the RNA targeting enzyme has no more than 5% of the nuclease activity of the RNA targeting enzyme not having the at least one mutation, wherein the gRNA or crRNA is modified by the insertion of distinct RNA sequence(s) that bind to one or more adaptor proteins, and wherein the adaptor protein is associated with one or more functional domains, wherein the composition comprises one or more or two or more adaptor proteins, wherein the each protein is associated with one or more functional domains, and wherein the gRNAs or crRNAs comprise a genome wide library comprising a plurality of RNA targeting guide RNAs (gRNAs) or crRNAs.
- gRNAs RNA targeting CRISPR guide RNA
- crRNAs comprising a guide sequence capable of hybrid
- the invention provides a library as herein-discussed, wherein the RNA targeting RNA targeting enzyme has a diminished nuclease activity of at least 97%, or 100% as compare with the RNA targeting enzyme not having the at least one mutation.
- the invention provides a library as herein-discussed, wherein the adaptor protein is a fusion protein comprising the functional domain.
- the invention provides a library as herein discussed, wherein the gRNA or crRNA is not modified by the insertion of distinct RNA sequence(s) that bind to the one or two or more adaptor proteins.
- the invention provides a library as herein discussed, wherein the one or two or more functional domains are associated with the RNA targeting enzyme.
- the invention provides a library as herein discussed, wherein the cell population of cells is a population of eukaryotic cells.
- the invention provides a library as herein discussed, wherein the eukaryotic cell is a mammalian cell, a plant cell or a yeast cell.
- the invention provides a library as herein discussed, wherein the mammalian cell is a human cell.
- the invention provides a library as herein discussed, wherein the population of cells is a population of embryonic stem (ES) cells.
- ES embryonic stem
- a library as herein discussed wherein the targeting is of about 100 or more RNA sequences.
- the invention provides a library as herein discussed, wherein the targeting is of about 1000 or more RNA sequences.
- the invention provides a library as herein discussed, wherein the targeting is of about 20,000 or more sequences.
- the invention provides a library as herein discussed, wherein the targeting is of the entire transcriptome.
- the invention provides a library as herein discussed, wherein the targeting is of a panel of target sequences focused on a relevant or desirable pathway.
- the invention provides a library as herein discussed, wherein the pathway is an immune pathway.
- the invention provides a library as herein discussed, wherein the pathway is a cell division pathway.
- a disease gene is any gene associated an increase in the risk of having or developing a disease.
- the method comprises (a) introducing one or more vectors encoding the components of the system described herein above into a eukaryotic cell, and (b) allowing a CRISPR complex to bind to a target polynucleotide so as to modify expression of a gene, thereby generating a model eukaryotic cell comprising modified gene expression.
- the structural information provided herein allows for interrogation of guide RNA or crRNA interaction with the target RNA and the RNA targeting enzyme permitting engineering or alteration of guide RNA structure to optimize functionality of the entire RNA targeting CRISPR-Cas13b system.
- the guide RNA or crRNA may be extended, without colliding with the RNA targeting protein by the insertion of adaptor proteins that can bind to RNA. These adaptor proteins can further recruit effector proteins or fusions which comprise one or more functional domains.
- modifications to the guide RNA or crRNA which allow for binding of the adapter + functional domain but not proper positioning of the adapter + functional domain are modifications which are not intended.
- the one or more modified guide RNA or crRNA may be modified, by introduction of a distinct RNA sequence(s) 5' of the direct repeat, within the direct repeat, or 3' of the guide sequence.
- the modified guide RNA or crRNA, the inactivated RNA targeting enzyme (with or without functional domains), and the binding protein with one or more functional domains may each individually be comprised in a composition and administered to a host individually or collectively. Alternatively, these components may be provided in a single composition for administration to a host. Administration to a host may be performed via viral vectors known to the skilled person or described herein for delivery to a host (e.g. lentiviral vector, adenoviral vector, AAV vector). As explained herein, use of different selection markers (e.g. for lentiviral gRNA or crRNA selection) and concentration of gRNA or crRNA (e.g. dependent on whether multiple gRNAs or crRNAs are used) may be advantageous for eliciting an improved effect.
- compositions may be applied in a wide variety of methods for screening in libraries in cells and functional modeling in vivo (e.g. gene activation of lincRNA and indentification of function; gain-of-function modeling; loss-of-function modeling; the use the compositions of the invention to establish cell lines and transgenic animals for optimization and screening purposes).
- methods for screening in libraries in cells and functional modeling in vivo e.g. gene activation of lincRNA and indentification of function; gain-of-function modeling; loss-of-function modeling; the use the compositions of the invention to establish cell lines and transgenic animals for optimization and screening purposes).
- the current invention comprehends the use of the compositions of the current invention to establish and utilize conditional or inducible CRISPR Cas13b RNA targeting events.
- CRISPR Cas13b RNA targeting events See, e.g., Platt et al., Cell (2014), http://dx.doi.org/10.1016/j.cell.2014.09.014 , or PCT patent publications cited herein, such as WO 2014/093622 ( PCT/US2013/074667 ), which are not believed prior to the present invention or application).
- Guide RNA according to the invention comprising a dead guide sequence
- the invention provides guide sequences which are modified in a manner which allows for formation of the CRISPR Cas13b complex and successful binding to the target, while at the same time, not either allowing for or not allowing for successful nuclease activity (i.e. without nuclease activity / without indel activity).
- modified guide sequences are referred to as "dead guides” or “dead guide sequences”.
- dead guides or dead guide sequences can be thought of as catalytically inactive or conformationally inactive with regard to nuclease activity. Indeed, dead guide sequences may not sufficiently engage in productive base pairing with respect to the ability to promote catalytic activity or to distinguish on-target and off-target binding activity.
- the assay involves synthesizing a CRISPR target RNA and guide RNAs comprising mismatches with the target RNA, combining these with the RNA targeting enzyme and analyzing cleavage based on gels based on the presence of bands generated by cleavage products, and quantifying cleavage based upon relative band intensities.
- the invention provides a non-naturally occurring or engineered composition RNA targeting CRISPR-Cas system comprising a functional RNA targeting enzyme as described herein, and guide RNA (gRNA) or crRNA wherein the gRNA or crRNA comprises a dead guide sequence whereby the gRNA is capable of hybridizing to a target sequence such that the RNA targeting CRISPR-Cas system is directed to a genomic locus of interest in a cell without detectable RNA cleavage activity of a non-mutant RNA targeting enzyme of the system.
- gRNA guide RNA
- crRNA comprises a dead guide sequence whereby the gRNA is capable of hybridizing to a target sequence such that the RNA targeting CRISPR-Cas system is directed to a genomic locus of interest in a cell without detectable RNA cleavage activity of a non-mutant RNA targeting enzyme of the system.
- the ability of a dead guide sequence to direct sequence-specific binding of a CRISPR complex to an RNA target sequence may be assessed by any suitable assay.
- the components of a CRISPR Cas13b system sufficient to form a CRISPR Cas13b complex, including the dead guide sequence to be tested may be provided to a host cell having the corresponding target sequence, such as by transfection with vectors encoding the components of the system, followed by an assessment of preferential cleavage within the target sequence.
- Dead guide sequences can be typically shorter than respective guide sequences which result in active RNA cleavage.
- dead guides are 5%, 10%, 20%, 30%, 40%, 50%, shorter than respective guides directed to the same.
- one aspect of gRNA or crRNA - RNA targeting specificity is the direct repeat sequence, which is to be appropriately linked to such guides.
- Structural data available for validated dead guide sequences may be used for designing Cas13b specific equivalents.
- Structural similarity between, e.g., the orthologous nuclease domains HEPN of two or more Cas13b effector proteins may be used to transfer design equivalent dead guides.
- the dead guide herein may be appropriately modified in length and sequence to reflect such Cas13b specific equivalents, allowing for formation of the CRISPR Cas13b complex and successful binding to the target RNA, while at the same time, not allowing for successful nuclease activity.
- Dead guides allow one to use gRNA or crRNA as a means for gene targeting, without the consequence of nuclease activity, while at the same time providing directed means for activation or repression.
- Guide RNA or crRNA comprising a dead guide may be modified to further include elements in a manner which allow for activation or repression of gene activity, in particular protein adaptors (e.g. aptamers) as described herein elsewhere allowing for functional placement of gene effectors (e.g. activators or repressors of gene activity).
- protein adaptors e.g. aptamers
- gene effectors e.g. activators or repressors of gene activity.
- One example is the incorporation of aptamers, as explained herein and in the state of the art.
- gRNA or crRNA comprising a dead guide to incorporate protein-interacting aptamers
- Konermann et al. "Genome-scale transcription activation by an engineered CRISPR-Cas9 complex," doi:10.1038/nature14136 )
- a guide sequence is any polynucleotide sequence having sufficient complementarity with a target polynucleotide sequence to hybridize with the target sequence and direct sequence-specific binding of a CRISPR complex to the target sequence.
- the degree of complementarity between a guide sequence and its corresponding target sequence when optimally aligned using a suitable alignment algorithm, is about or more than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or more.
- Optimal alignment may be determined with the use of any suitable algorithm for aligning sequences, non-limiting example of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler Transform (e.g., the Burrows Wheeler Aligner), ClustalW, Clustal X, BLAT, Novoalign (Novocraft Technologies; available at www.novocraft.com), ELAND (Illumina, San Diego, CA), SOAP (available at soap.genomics.org.cn), and Maq (available at maq.sourceforge.net).
- any suitable algorithm for aligning sequences include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler Transform (e.g., the Burrows Wheeler Aligner), ClustalW, Clustal X, BLAT, Novoalign (Novocraft Technologies; available at www.novocraft.com), ELAND (Illumina, San
- a guide sequence is about or more than about 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75, or more nucleotides in length. In some embodiments, a guide sequence is less than about 75, 50, 45, 40, 35, 30, 25, 20, 15, 12, or fewer nucleotides in length. Preferably the guide sequence is 10 - 30 nucleotides long, such as 30 nucleotides long. The ability of a guide sequence to direct sequence-specific binding of a CRISPR complex to a target sequence may be assessed by any suitable assay.
- the components of a CRISPR system sufficient to form a CRISPR complex may be provided to a host cell having the corresponding target sequence, such as by transfection with vectors encoding the components of the CRISPR sequence, followed by an assessment of preferential cleavage within the target sequence, such as by Surveyor assay as described herein.
- cleavage of a target polynucleotide sequence may be evaluated in a test tube by providing the target sequence, components of a CRISPR complex, including the guide sequence to be tested and a control guide sequence different from the test guide sequence, and comparing binding or rate of cleavage at the target sequence between the test and control guide sequence reactions.
- a guide sequence may be selected to target any target sequence.
- the target sequence is a sequence within a genome of a cell.
- Exemplary target sequences include those that are unique in the target genome.
- vector refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
- Vectors include, but are not limited to, nucleic acid molecules that are single-stranded, double-stranded, or partially double-stranded; nucleic acid molecules that comprise one or more free ends, no free ends (e.g., circular); nucleic acid molecules that comprise DNA, RNA, or both; and other varieties of polynucleotides known in the art.
- plasmid refers to a circular double stranded DNA loop into which additional DNA segments can be inserted, such as by standard molecular cloning techniques.
- viral vector Another type of vector is a viral vector, wherein virallyderived DNA or RNA sequences are present in the vector for packaging into a virus (e.g., retroviruses, replication defective retroviruses, adenoviruses, replication defective adenoviruses, and adeno-associated viruses).
- Viral vectors also include polynucleotides carried by a virus for transfection into a host cell.
- Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors).
- vectors e.g., non-episomal mammalian vectors
- Other vectors are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome.
- certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as "expression vectors.”
- Vectors for and that result in expression in a eukaryotic cell can be referred to herein as “eukaryotic expression vectors.”
- Common expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.
- Recombinant expression vectors can comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory elements, which may be selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed.
- "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory element(s) in a manner that allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).
- regulatory element is intended to include promoters, enhancers, internal ribosomal entry sites (IRES), and other expression control elements (e.g., transcription termination signals, such as polyadenylation signals and poly-U sequences).
- regulatory elements are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990 ).
- Regulatory elements include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences).
- a tissue-specific promoter may direct expression primarily in a desired tissue of interest, such as muscle, neuron, bone, skin, blood, specific organs (e.g., liver, pancreas), or particular cell types (e.g., lymphocytes). Regulatory elements may also direct expression in a temporal-dependent manner, such as in a cell-cycle dependent or developmental stage-dependent manner, which may or may not also be tissue or cell-type specific.
- a vector comprises one or more pol III promoter (e.g., 1, 2, 3, 4, 5, or more pol III promoters), one or more pol II promoters (e.g., 1, 2, 3, 4, 5, or more pol II promoters), one or more pol I promoters (e.g., 1, 2, 3, 4, 5, or more pol I promoters), or combinations thereof.
- pol III promoters include, but are not limited to, U6 and H1 promoters.
- pol II promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer) [see, e.g., Boshart et al, Cell, 41:521-530 (1985 )], the SV40 promoter, the dihydrofolate reductase promoter, the ⁇ -actin promoter, the phosphoglycerol kinase (PGK) promoter, and the FF1 ⁇ promoter.
- RSV Rous sarcoma virus
- CMV cytomegalovirus
- PGK phosphoglycerol kinase
- enhancer elements such as WPRE; CMV enhancers; the R-U5' segment in LTR of HTLV-I ( Mol. Cell. Biol., Vol. 8(1), p. 466-472, 1988 ); SV40 enhancer; and the intron sequence between exons 2 and 3 of rabbit ⁇ -globin ( Proc. Natl. Acad. Sci. USA., Vol. 78(3), p. 1527-31, 1981 ).
- WPRE WPRE
- CMV enhancers the R-U5' segment in LTR of HTLV-I
- SV40 enhancer SV40 enhancer
- the intron sequence between exons 2 and 3 of rabbit ⁇ -globin Proc. Natl. Acad. Sci. USA., Vol. 78(3), p. 1527-31, 1981 .
- the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression desired, etc.
- a vector can be introduced into host cells to thereby produce transcripts, proteins, or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., clustered regularly interspersed short palindromic repeats (CRISPR) transcripts, proteins, enzymes, mutant forms thereof, fusion proteins thereof, etc.).
- CRISPR clustered regularly interspersed short palindromic repeats
- Advantageous vectors include lentiviruses and adeno-associated viruses, and types of such vectors can also be selected for targeting particular types of cells.
- the CRISPR system as provided herein can make use of a crRNA or analogous polynucleotide comprising a guide sequence, wherein the polynucleotide is an RNA, a DNA or a mixture of RNA and DNA, and/or wherein the polynucleotide comprises one or more nucleotide analogs.
- the sequence can comprise any structure, including but not limited to a structure of a native crRNA, such as a bulge, a hairpin or a stem loop structure.
- the polynucleotide comprising the guide sequence forms a duplex with a second polynucleotide sequence which can be an RNA or a DNA sequence.
- guides of the invention comprise non-naturally occurring nucleic acids and/or non-naturally occurring nucleotides and/or nucleotide analogs, and/or chemically modifications.
- Non-naturally occurring nucleic acids can include, for example, mixtures of naturally and non-naturally occurring nucleotides.
- Non-naturally occurring nucleotides and/or nucleotide analogs may be modified at the ribose, phosphate, and/or base moiety.
- a guide nucleic acid comprises ribonucleotides and non-ribonucleotides.
- a guide comprises one or more ribonucleotides and one or more deoxyribonucleotides.
- the guide comprises one or more non-naturally occurring nucleotide or nucleotide analog such as a nucleotide with phosphorothioate linkage, boranophosphate linkage, a locked nucleic acid (LNA) nucleotides comprising a methylene bridge between the 2' and 4' carbons of the ribose ring, or bridged nucleic acids (BNA).
- LNA locked nucleic acid
- BNA bridged nucleic acids
- modified nucleotides include 2'-O-methyl analogs, 2'-deoxy analogs, 2-thiouridine analogs, N6-methyladenosine analogs, or 2'-fluoro analogs.
- modified bases include, but are not limited to, 2-aminopurine, 5-bromo-uridine, pseudouridine ( ⁇ ), N1-methylpseudouridine (me1 ⁇ ), 5-methoxyuridine(5moU), inosine, 7-methylguanosine.
- guide RNA chemical modifications include, without limitation, incorporation of 2'-O-methyl (M), 2'-O-methyl 3'phosphorothioate (MS), S-constrained ethyl (cEt), or 2'-O-methyl 3'thioPACE (MSP) at one or more terminal nucleotides.
- Such chemically modified guide RNAs can comprise increased stability and increased activity as compared to unmodified guide RNAs, though on-target vs. off-target specificity is not predictable.
- a guide RNA is modified by a variety of functional moieties including fluorescent dyes, polyethylene glycol, cholesterol, proteins, or detection tags.
- a guide comprises ribonucleotides in a region that binds to a target DNA and one or more deoxyribonucletides and/or nucleotide analogs in a region that binds to Cas9, Cpfl, or C2c1.
- deoxyribonucleotides and/or nucleotide analogs are incorporated in engineered guide structures, such as, without limitation, 5' and/or 3' end, stem-loop regions, and the seed region.
- the modification is not in the 5'-handle of the stem-loop regions.
- Chemical modification in the 5'-handle of the stem-loop region of a guide may abolish its function (see Li, et al., Nature Biomedical Engineering, 2017, 1:0066 ).
- at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, or 75 nucleotides of a guide is chemically modified.
- 3-5 nucleotides at either the 3' or the 5' end of a guide is chemically modified.
- only minor modifications are introduced in the seed region, such as 2'-F modifications.
- 2'-F modification is introduced at the 3' end of a guide.
- three to five nucleotides at the 5' and/or the 3' end of the guide are chemicially modified with 2'-O-methyl (M), 2'-O-methyl-3'-phosphorothioate (MS), S-constrained ethyl(cEt), or 2'-O-methyl-3'-thioPACE (MSP).
- M 2'-O-methyl
- MS 2'-O-methyl-3'-phosphorothioate
- cEt S-constrained ethyl
- MSP 2'-O-methyl-3'-thioPACE
- phosphodiester bonds of a guide are substituted with phosphorothioates (PS) for enhancing levels of gene disruption.
- PS phosphorothioates
- more than five nucleotides at the 5' and/or the 3' end of the guide are chemicially modified with 2'-O-Me, 2'-F or S-constrained ethyl(cEt).
- Such chemically modified guide can mediate enhanced levels of gene disruption (see Ragdarm et al., 0215, PNAS, E7110-E7111 ).
- a guide is modified to comprise a chemical moiety at its 3' and/or 5' end.
- Such moieties include, but are not limited to amine, azide, alkyne, thio, dibenzocyclooctyne (DBCO), or Rhodamine.
- the chemical moiety is conjugated to the guide by a linker, such as an alkyl chain.
- the chemical moiety of the modified guide can be used to attach the guide to another molecule, such as DNA, RNA, protein, or nanoparticles.
- Such chemically modified guide can be used to identify or enrich cells generically edited by a CRISPR system (see Lee et al., eLife, 2017, 6:e25312, DOI:10.7554 )
- the guide comprises a modified crRNA for Cpfl, having a 5'-handle and a guide segment further comprising a seed region and a 3'-terminus.
- the modified guide can be used with a Cpfl of any one of Acidaminococcus sp. BV3L6 Cpfl (AsCpf1); Francisella tularensis subsp. Novicida U112 Cpfl (FnCpf1); L.
- bacterium MA2020 Cpfl Lb2Cpf1; Porphyromonas crevioricanis Cpfl (PcCpf1); Porphyromonas macacae Cpfl (PmCpf1); Candidatus Methanoplasma termitum Cpfl (CMtCpf1); Eubacterium eligens Cpfl (EeCpf1); Moraxella bovoculi 237 Cpfl (MbCpf1); Prevotella disiens Cpfl (PdCpf1); or L. bacterium ND2006 Cpfl (LbCpf1).
- the modification to the guide is a chemical modification, an insertion, a deletion or a split.
- the chemical modification includes, but is not limited to, incorporation of 2'-O-methyl (M) analogs, 2'-deoxy analogs, 2-thiouridine analogs, N6-methyladenosine analogs, 2'-fluoro analogs, 2-aminopurine, 5-bromo-uridine, pseudouridine ( ⁇ ), N1-methylpseudouridine (me1 ⁇ ), 5-methoxyuridine(5moU), inosine, 7-methylguanosine, 2'-O-methyl-3'-phosphorothioate (MS), S-constrained ethyl(cEt), phosphorothioate (PS), or 2'-O-methyl-3'-thioPACE (MSP).
- M 2'-O-methyl
- the guide comprises one or more of phosphorothioate modifications. In certain embodiments, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 25 nucleotides of the guide are chemically modified. In certain embodiments, one or more nucleotides in the seed region are chemically modified. In certain embodiments, one or more nucleotides in the 3'-terminus are chemically modified. In certain embodiments, none of the nucleotides in the 5'-handle is chemically modified. In some embodiments, the chemical modification in the seed region is a minor modification, such as incorporation of a 2'-fluoro analog.
- one nucleotide of the seed region is replaced with a 2'-fluoro analog.
- 5 or 10 nucleotides in the 3'-terminus are chemically modified. Such chemical modifications at the 3'-terminus of the Cpfl CrRNA improve gene cutting efficiency (see Li, et al., Nature Biomedical Engineering, 2017, 1:0066 ).
- 5 nucleotides in the 3'-terminus are replaced with 2'-fluoro analogues.
- 10 nucleotides in the 3'-terminus are replaced with 2'-fluoro analogues.
- 5 nucleotides in the 3'-terminus are replaced with 2'- O-methyl (M) analogs.
- the loop of the 5'-handle of the guide is modified. In some embodiments, the loop of the 5'-handle of the guide is modified to have a deletion, an insertion, a split, or chemical modifications. In certain embodiments, the loop comprises 3, 4, or 5 nucleotides. In certain embodiments, the loop comprises the sequence of UCUU, UUUU, UAUU, or UGUU.
- the guide comprises portions that are chemically linked or conjugated via a non-phosphodiester bond.
- the guide comprises, in non-limiting examples, a tracr sequence and a tracr mate sequence portion or a direct repeat and a targeting sequence portion that are chemically linked or conjugated via a non-nucleotide loop.
- the portions are joined via a non-phosphodiester covalent linker.
- covalent linker examples include but are not limited to a chemical moiety selected from the group consisting of carbamates, ethers, esters, amides, imines, amidines, aminotrizines, hydrozone, disulfides, thioethers, thioesters, phosphorothioates, phosphorodithioates, sulfonamides, sulfonates, fulfones, sulfoxides, ureas, thioureas, hydrazide, oxime, triazole, photolabile linkages, C-C bond forming groups such as Diels-Alder cyclo-addition pairs or ring-closing metathesis pairs, and Michael reaction pairs.
- a chemical moiety selected from the group consisting of carbamates, ethers, esters, amides, imines, amidines, aminotrizines, hydrozone, disulfides, thioethers, thioesters, phosphorothioates, phospho
- portions of the guide are first synthesized using the standard phosphoramidite synthetic protocol ( Herdewijn, P., ed., Methods in Molecular Biology Col 288, Oligonucleotide Synthesis: Methods and Applications, Humana Press, New Jersey (2012 )).
- the non-targeting guide portions can be functionalized to contain an appropriate functional group for ligation using the standard protocol known in the art ( Hermanson, G. T., Bioconjugate Techniques, Academic Press (2013 )).
- Examples of functional groups include, but are not limited to, hydroxyl, amine, carboxylic acid, carboxylic acid halide, carboxylic acid active ester, aldehyde, carbonyl, chlorocarbonyl, imidazolylcarbonyl, hydrozide, semicarbazide, thio semicarbazide, thiol, maleimide, haloalkyl, sufonyl, ally, propargyl, diene, alkyne, and azide.
- Examples of chemical bonds include, but are not limited to, those based on carbamates, ethers, esters, amides, imines, amidines, aminotrizines, hydrozone, disulfides, thioethers, thioesters, phosphorothioates, phosphorodithioates, sulfonamides, sulfonates, fulfones, sulfoxides, ureas, thioureas, hydrazide, oxime, triazole, photolabile linkages, C-C bond forming groups such as Diels-Alder cyclo-addition pairs or ring-closing metathesis pairs, and Michael reaction pairs.
- one or more portions of a guide can be chemically synthesized.
- the chemical synthesis uses automated, solid-phase oligonucleotide synthesis machines with 2'-acetoxyethyl orthoester (2'-ACE) ( Scaringe et al., J. Am. Chem. Soc. (1998) 120: 11820-11821 ; Scaringe, Methods Enzymol. (2000) 317: 3-18 ) or 2'-thionocarbamate (2'-TC) chemistry ( Dellinger et al., J. Am. Chem. Soc. (2011) 133: 11540-11546 ; Hendel et al., Nat. Biotechnol. (2015) 33:985-989 ).
- 2'-ACE 2'-acetoxyethyl orthoester
- the guide portions can be covalently linked using various bioconjugation reactions, loops, bridges, and non-nucleotide links via modifications of sugar, internucleotide phosphodiester bonds, purine and pyrimidine residues.
- the guide portions can be covalently linked using click chemistry. In some embodiments, guide portions can be covalently linked using a triazole linker. In some embodiments, guide portions can be covalently linked using Huisgen 1,3-dipolar cycloaddition reaction involving an alkyne and azide to yield a highly stable triazole linker ( He et al., ChemBioChem (2015) 17: 1809-1812 ; WO 2016/186745 ). In some embodiments, guide portions are covalently linked by ligating a 5'-hexyne portion and a 3'-azide portion.
- either or both of the 5'-hexyne guide portion and a 3'-azide guide portion can be protected with 2'-acetoxyethl orthoester (2'-ACE) group, which can be subsequently removed using Dharmacon protocol ( Scaringe etal., J. Am. Chem. Soc. (1998) 120: 11820-11821 ; Scaringe, Methods Enzymol. (2000) 317: 3-18 ).
- 2'-ACE 2'-acetoxyethl orthoester
- guide portions can be covalently linked via a linker (e.g., a non-nucleotide loop) that comprises a moiety such as spacers, attachments, bioconjugates, chromophores, reporter groups, dye labeled RNAs, and non-naturally occurring nucleotide analogues.
- a linker e.g., a non-nucleotide loop
- a moiety such as spacers, attachments, bioconjugates, chromophores, reporter groups, dye labeled RNAs, and non-naturally occurring nucleotide analogues.
- suitable spacers for purposes of this invention include, but are not limited to, polyethers (e.g., polyethylene glycols, polyalcohols, polypropylene glycol or mixtures of efhylene and propylene glycols), polyamines group (e.g., spennine, spermidine and polymeric derivatives thereof), polyesters (e.g., poly(ethyl acrylate)), polyphosphodiesters, alkylenes, and combinations thereof.
- Suitable attachments include any moiety that can be added to the linker to add additional properties to the linker, such as but not limited to, fluorescent labels.
- Suitable bioconjugates include, but are not limited to, peptides, glycosides, lipids, cholesterol, phospholipids, diacyl glycerols and dialkyl glycerols, fatty acids, hydrocarbons, enzyme substrates, steroids, biotin, digoxigenin, carbohydrates, polysaccharides.
- Suitable chromophores, reporter groups, and dye-labeled RNAs include, but are not limited to, fluorescent dyes such as fluorescein and rhodamine, chemiluminescent, electrochemiluminescent, and bioluminescent marker compounds. The design of example linkers conjugating two RNA components are also described in WO 2004/015075 .
- the linker (e.g., a non-nucleotide loop) can be of any length. In some embodiments, the linker has a length equivalent to about 0-16 nucleotides. In some embodiments, the linker has a length equivalent to about 0-8 nucleotides. In some embodiments, the linker has a length equivalent to about 0-4 nucleotides. In some embodiments, the linker has a length equivalent to about 2 nucleotides.
- Example linker design is also described in WO2011/008730 .
- the degree of complementarity when optimally aligned using a suitable alignment algorithm, is about or more than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or more.
- Optimal alignment may be determined with the use of any suitable algorithm for aligning sequences, non-limiting example of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler Transform (e.g., the Burrows Wheeler Aligner), ClustalW, Clustal X, BLAT, Novoalign (Novocraft Technologies; available at www.novocraft.com), ELAND (Illumina, San Diego, CA), SOAP (available at soap.genomics.org.cn), and Maq (available at maq.sourceforge.net).
- any suitable algorithm for aligning sequences non-limiting example of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Whee
- RNA-targeting guide RNA or crRNA The ability of a guide sequence (within a RNA-targeting guide RNA or crRNA) to direct sequence-specific binding of a nucleic acid -targeting complex to a target nucleic acid sequence may be assessed by any suitable assay.
- the components of a RNA-targeting CRISPR Cas13b system sufficient to form a nucleic acid -targeting complex, including the guide sequence to be tested may be provided to a host cell having the corresponding target nucleic acid sequence, such as by transfection with vectors encoding the components of the nucleic acid -targeting complex, followed by an assessment of preferential targeting (e.g., cleavage) within the target nucleic acid sequence, such as by Surveyor assay as described herein.
- preferential targeting e.g., cleavage
- cleavage of a target nucleic acid sequence may be evaluated in a test tube by providing the target nucleic acid sequence, components of a nucleic acid -targeting complex, including the guide sequence to be tested and a control guide sequence different from the test guide sequence, and comparing binding or rate of cleavage at the target sequence between the test and control guide sequence reactions.
- a guide sequence, and hence a RNA-targeting guide RNA or crRNA may be selected to target any target nucleic acid sequence.
- the target sequence may be DNA.
- the target sequence may be any RNA sequence.
- the target sequence may be a sequence within a RNA molecule selected from the group consisting of messenger RNA (mRNA), pre-mRNA, ribosomaal RNA (rRNA), transfer RNA (tRNA), micro-RNA (miRNA), small interfering RNA (siRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), double stranded RNA (dsRNA), non coding RNA (ncRNA), long non-coding RNA (IncRNA), and small cytoplasmatic RNA (scRNA).
- the target sequence may be a sequence within a RNA molecule selected from the group consisting of mRNA, pre-mRNA, and rRNA.
- the target sequence may be a sequence within a RNA molecule selected from the group consisting of ncRNA, and lncRNA. In some more preferred embodiments, the target sequence may be a sequence within an mRNA molecule or a pre-mRNA molecule.
- a RNA-targeting guide RNA or crRNA is selected to reduce the degree secondary structure within the RNA-targeting guide RNA or crRNA. In some embodiments, about or less than about 75%, 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 1%, or fewer of the nucleotides of the RNA-targeting guide RNA participate in self-complementary base pairing when optimally folded. Optimal folding may be determined by any suitable polynucleotide folding algorithm. Some programs are based on calculating the minimal Gibbs free energy. An example of one such algorithm is mFold, as described by Zuker and Stiegler (Nucleic Acids Res. 9 (1981), 133-148 ).
- Another example folding algorithm is the online webserver RNAfold, developed at Institute for Theoretical Chemistry at the University of Vienna, using the centroid structure prediction algorithm (see e.g., A.R. Gruber et al., 2008, Cell 106(1): 23-24 ; and PA Carr and GM Church, 2009, Nature Biotechnology 27(12): 1151-62 ).
- a guide RNA or crRNA may comprise, consist essentially of, or consist of a direct repeat (DR) sequence and a guide sequence or spacer sequence.
- the guide RNA or crRNA may comprise, consist essentially of, or consist of a direct repeat sequence fused or linked to a guide sequence or spacer sequence.
- the direct repeat sequence may be located upstream (i.e., 5') from the guide sequence or spacer sequence.
- the direct repeat sequence may be located downstream (i.e., 3') from the guide sequence or spacer sequence.
- multiple DRs (such as dual DRs) may be present.
- the crRNA comprises a stem loop, preferably a single stem loop.
- the direct repeat sequence forms a stem loop, preferably a single stem loop.
- the spacer length of the guide RNA is from 15 to 35 nt. In certain embodiments, the spacer length of the guide RNA is at least 15 nucleotides. In certain embodiments, the spacer length is from 15 to 17 nt, e.g., 15, 16, or 17 nt, from 17 to 20 nt, e.g., 17, 18, 19, or 20 nt, from 20 to 24 nt, e.g., 20, 21, 22, 23, or 24 nt, from 23 to 25 nt, e.g., 23, 24, or 25 nt, from 24 to 27 nt, e.g., 24, 25, 26, or 27 nt, from 27-30 nt, e.g., 27, 28, 29, or 30 nt, from 30-35 nt, e.g., 30, 31, 32, 33, 34, or 35 nt, or 35 nt or longer.
- the "tracrRNA” sequence or analogous terms includes any polynucleotide sequence that has sufficient complementarity with a crRNA sequence to hybridize.
- degree of complementarity is with reference to the optimal alignment of the sca sequence and tracr sequence, along the length of the shorter of the two sequences.
- Optimal alignment may be determined by any suitable alignment algorithm, and may further account for secondary structures, such as selfcomplementarity within either the sca sequence or tracr sequence.
- the degree of complementarity between the tracr sequence and sca sequence along the length of the shorter of the two when optimally aligned is about or more than about 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97.5%, 99%, or higher.
- the tracrRNA may not be required. Indeed, the Cas13b effector protein from Bergeyella zoohelcum and orthologs thereof do not require a tracrRNA to ensure cleavage of an RNA target.
- the assay is as follows for a RNA target, provided that a PAM sequence is required to direct recognition.
- Two E.coli strains are used in this assay. One carries a plasmid that encodes the endogenous effector protein locus from the bacterial strain. The other strain carries an empty plasmid (e.g. pACYC184, control strain). All possible 7 or 8 bp PAM sequences are presented on an antibiotic resistance plasmid (pUC19 with ampicillin resistance gene). The PAM is located next to the sequence of proto-spacer 1 (the RNA target to the first spacer in the endogenous effector protein locus). Two PAM libraries were cloned.
- One has a 8 random bp 5' of the proto-spacer (e.g. total of 65536 different PAM sequences complexity).
- Plasmid RNA was used as template for PCR amplification and subsequent deep sequencing. Representation of all PAMs in the untransfomed libraries showed the expected representation of PAMs in transformed cells. Representation of all PAMs found in control strains showed the actual representation. Representation of all PAMs in test strain showed which PAMs are not recognized by the enzyme and comparison to the control strain allows extracting the sequence of the depleted PAM.
- the cleavage such as the RNA cleavage is not PAM dependent. Indeed, for the Bergeyella zoohelcum effector protein and its orthologs, RNA target cleavage appears to be PAM independent, and hence the Table 1 Cas13b of the invention may act in a PAM independent fashion.
- RNA-targeting guide RNA For minimization of toxicity and off-target effect, it will be important to control the concentration of RNA-targeting guide RNA delivered.
- Optimal concentrations of nucleic acid - targeting guide RNA can be determined by testing different concentrations in a cellular or non-human eukaryote animal model and using deep sequencing the analyze the extent of modification at potential off-target genomic loci. The concentration that gives the highest level of on-target modification while minimizing the level of off-target modification should be chosen for in vivo delivery.
- the RNA-targeting system is derived advantageously from a CRISPR-Cas13b system.
- one or more elements of a RNA-targeting system is derived from a particular organism comprising an endogenous RNA-targeting system of a Table 1 Cas13b effector protein system as herein-discussed.
- orthologue also referred to as “ortholog” herein
- homologue also referred to as “homolog” herein
- a “homologue” of a protein as used herein is a protein of the same species which performs the same or a similar function as the protein it is a homologue of. Homologous proteins may but need not be structurally related, or are only partially structurally related.
- An “orthologue” of a protein as used herein is a protein of a different species which performs the same or a similar function as the protein it is an orthologue of. Orthologous proteins may but need not be structurally related, or are only partially structurally related.
- the homologue or orthologue of a Cas13b protein as referred to herein has a sequence homology or identity of at least 80%, more preferably at least 85%, even more preferably at least 90%, such as for instance at least 95% with a Cas13b effector protein set forth in Table 1, below.
- the Cas13b effector protein may be of or from an organism identified in Table 1 or the genus to which the organism belongs.
- the Cas13b effector protein is a protein comprising a sequence having at least 70% seqeuence identity with one or more of the sequences consisting of DKHXFGAFLNLARHN (SEQ ID NO:XX), GLLFFVSLFLDK (SEQ ID NO:XX), SKIXGFK (SEQ ID NO:XX), DMLNELXRCP (SEQ ID NO:XX), RXZDRFPYFALRYXD (SEQ ID NO: XX) and LRFQVBLGXY (SEQ ID NO:XX).
- DKHXFGAFLNLARHN SEQ ID NO:XX
- GLLFFVSLFLDK SKIXGFK
- DMLNELXRCP SEQ ID NO:XX
- RXZDRFPYFALRYXD SEQ ID NO: XX
- LRFQVBLGXY LRFQVBLGXY
- the Cas13b effector protein comprises a sequence having at least 70% seqeuence identity at least 2, 3, 4, 5 or all 6 of these sequences. In further particular embodiments, the sequence identity with these sequences is at least 75%, 80%, 85%, 90%, 95% or 100%. In further particular embodiments, the Cas13b effector protein is a protein comprising a sequence having 100% sequence identity with GLLFFVSLFL (SEQ ID NO:XX) and RHQXRFPYF (SEQ ID NO:XX). In further particular embodiments, the Cas13b effector is a Cas13b effector protein comprising a sequence having 100% sequence identity with RHQDRFPY (SEQ ID NO:XX).
- the Cas13b effector protein is a Cas13b effector protein having at least 65%, preferably at least 70%, 75%, 80%, 85%, 90%, 95% or more sequence identity with a Cas13b protein from Prevotella buccae, Porphyromonas gingivales, Prevotella saccharolytica, Riemerella antipestifer.
- the Cas13b effector is selected from the Cas13b protein from Bacteroides pyogenes, Prevotella sp. MA2016, Riemerella anatipestifer, Porphyromonas gulae, Porphyromonas gingivalis, and Porphyromonas sp.COT-0520H4946.
- orthologs of a Table 1 Cas13b enzyme that can be within the invention can include a chimeric enzyme comprising a fragment of a Table 1 Cas13b enzyme multiple orthologs. Examples of such orthologs are described elsewhere herein.
- a chimeric enzyme may comprise a fragment of a Table 1 Cas13b enzyme and a fragment from another CRISPR enzyme, such as an ortholog of a Table 1 Cas13b enzyme of an organism which includes but is not limited to Bergeyella, Prevotella, Porphyromonas, Bacteroides, Alistipes, Riemerella, Myroides, Flavobacterium, Capnocytophaga, Chryseobacterium, Phaeodactylibacter, Paludibacter or Psychroflexus.
- a chimeric enzyme can comprise a first fragment and a second fragment, and the fragments, wherein one of the first and second a fragment is of or from a Table 1 Cas13b enzyme and the other fragment is of or from a CRISPR enzyme ortholog of a different species.
- the Cas13b RNA-targeting Cas13b effector proteins referred to herein also encompasses a functional variant of the effector protein or a homologue or an orthologue thereof.
- a "functional variant" of a protein as used herein refers to a variant of such protein which retains at least partially the activity of that protein. Functional variants may include mutants (which may be insertion, deletion, or replacement mutants), including polymorphs, etc., including as discussed herein in conjunction with Table 1. Also included within functional variants are fusion products of such protein with another, usually unrelated, nucleic acid, protein, polypeptide or peptide. Functional variants may be naturally occurring or may be man-made.
- nucleic acid molecule(s) encoding the Cas13b RNA-targeting effector proteins, or an ortholog or homolog thereof may be codon-optimized for expression in an eukaryotic cell.
- a eukaryote can be as herein discussed.
- Nucleic acid molecule(s) can be engineered or non-naturally occurring.
- the Cas13b RNA-targeting effector protein or an ortholog or homolog thereof may comprise one or more mutations.
- the mutations may be artificially introduced mutations and may include but are not limited to one or more mutations in a catalytic domain, e.g., one or more mutations are introduced ino one or more of the HEPN domains.
- the Cas13b protein or an ortholog or homolog thereof may be used as a generic nucleic acid binding protein with fusion to or being operably linked to a functional domain.
- exemplary functional domains may include but are not limited to translational initiator, translational activator, translational repressor, nucleases, in particular ribonucleases, a spliceosome, beads, a light inducible/controllable domain or a chemically inducible/controllable domain.
- the unmodified RNA-targeting effector protein may have cleavage activity.
- Cas13b may direct cleavage of one or two nucleic acid strands at the location of or near a target sequence, such as within the target sequence and/or within the complement of the target sequence or at sequences associated with the target sequence, e.g., within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500, or more base pairs from the first or last nucleotide of a target sequence.
- the Cas13b protein may direct more than one cleavage (such as one, two three, four, five, or more cleavages) of one or two strands within the target sequence and/or within the complement of the target sequence or at sequences associated with the target sequence and/or within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500, or more base pairs from the first or last nucleotide of a target sequence.
- the cleavage may be blunt, i.e., generating blunt ends.
- the cleavage may be staggered, i.e., generating sticky ends.
- a vector encodes a nucleic acid-targeting Cas13b protein that may be mutated with respect to a corresponding wild-type enzyme such that the mutated nucleic acid-targeting Cas13b protein lacks the ability to cleave one or two strands of a target polynucleotide containing a target sequence, e.g., alteration or mutation in a HEPN domain to produce a mutated Cas13b substantially lacking all RNA cleavage activity, e.g., the RNA cleavage activity of the mutated enzyme is about no more than 25%, 10%, 5%, 1%, 0.1%, 0.01%, or less of the nucleic acid cleavage activity of the non-mutated form of the enzyme; an example can be when the nucleic acid cleavage activity of the mutated form is nil or negligible as compared with the non-mutated form.
- derived enzyme is largely based, in the sense of having a high degree of sequence homology with, a wildtype enzyme, but that it has been mutated (modified) in some way as known in the art or as described herein.
- RNA-targeting complex comprising a guide RNA or crRNA hybridized to a target sequence and complexed with one or more RNA-targeting effector proteins
- cleavage of RNA strand(s) in or near results in cleavage of RNA strand(s) in or near (e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or more base pairs from) the target sequence.
- sequence(s) associated with a target locus of interest refers to sequences near the vicinity of the target sequence (e.g. within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or more base pairs from the target sequence, wherein the target sequence is comprised within a target locus of interest).
- a codon optimized sequence is in this instance a sequence optimized for expression in a eukaryote, e.g., humans (i.e. being optimized for expression in humans), or for another eukaryote, animal or mammal as herein discussed; see, e.g., SaCas9 human codon optimized sequence in WO 2014/093622 ( PCT/US2013/074667 ) as an example of a codon optimized sequence (from knowledge in the art and this disclosure, codon optimizing coding nucleic acid molecule(s), especially as to effector protein (e.g., Cas13b) is within the ambit of the skilled artisan).
- an enzyme coding sequence encoding a RNA-targeting Cas13b protein is codon optimized for expression in particular cells, such as eukaryotic cells.
- the eukaryotic cells may be those of or derived from a particular organism, such as a mammal, including but not limited to human, or non-human eukaryote or animal or mammal as herein discussed, e.g., mouse, rat, rabbit, dog, livestock, or non-human mammal or primate.
- codon optimization refers to a process of modifying a nucleic acid sequence for enhanced expression in the host cells of interest by replacing at least one codon (e.g., about or more than about 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more codons) of the native sequence with codons that are more frequently or most frequently used in the genes of that host cell while maintaining the native amino acid sequence.
- codons e.g., about or more than about 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more codons
- Codon bias (differences in codon usage between organisms) often correlates with the efficiency of translation of messenger RNA (mRNA), which is in turn believed to be dependent on, among other things, the properties of the codons being translated and the availability of particular transfer RNA (tRNA) molecules.
- mRNA messenger RNA
- tRNA transfer RNA
- the predominance of selected tRNAs in a cell is generally a reflection of the codons used most frequently in peptide synthesis. Accordingly, genes can be tailored for optimal gene expression in a given organism based on codon optimization. Codon usage tables are readily available, for example, at the "Codon Usage Database" available at www.kazusa.orjp/codon/ and these tables can be adapted in a number of ways. See Nakamura, Y., et al.
- Codon usage tabulated from the international DNA sequence databases status for the year 2000
- Nucl. Acids Res. 28:292 2000
- Computer algorithms for codon optimizing a particular sequence for expression in a particular host cell are also available, such as Gene Forge (Aptagen; Jacobus, PA), are also available.
- one or more codons e.g., 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more, or all codons
- one or more codons e.g., 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more, or all codons
- the (i) Cas13b or nucleic acid molecule(s) encoding it or (ii) crRNA can be delivered separately; and advantageously at least one or both of one of (i) and (ii), e.g., an assembled complex is delivered via a particle or nanoparticle complex.
- RNA-targeting effector protein mRNA can be delivered prior to the RNA-targeting guide RNA or crRNA to give time for nucleic acid-targeting effector protein to be expressed.
- RNA-targeting effector protein (Cas13b) mRNA might be administered 1-12 hours (preferably around 2-6 hours) prior to the administration of RNA-targeting guide RNA or crRNA.
- RNA-targeting effector protein mRNA and RNA-targeting guide RNA or crRNA can be administered together.
- a second booster dose of guide RNA or crRNA can be administered 1-12 hours (preferably around 2-6 hours) after the initial administration of RNA-targeting effector (Cas13b) protein mRNA + guide RNA. Additional administrations of RNA-targeting effector protein mRNA and/or guide RNA or crRNA might be useful to achieve the most efficient levels of genome modification.
- the invention provides methods for using one or more elements of a RNA-targeting system.
- the RNA-targeting complex of the invention provides an effective means for modifying a target RNA single or double stranded, linear or super-coiled.
- the RNA-targeting complex of the invention has a wide variety of utility including modifying (e.g., deleting, inserting, translocating, inactivating, activating) a target RNA in a multiplicity of cell types.
- the RNA-targeting complex of the invention has a broad spectrum of applications in, e.g., gene therapy, drug screening, disease diagnosis, and prognosis.
- An exemplary RNA-targeting complex comprises a RNA-targeting effector protein complexed with a guide RNA or crRNA hybridized to a target sequence within the target locus of interest.
- this invention provides a method of cleaving a target RNA.
- the method may comprise modifying a target RNA using a RNA-targeting complex that binds to the target RNA and effect cleavage of said target RNA.
- the RNA-targeting complex of the invention when introduced into a cell, may create a break (e.g., a single or a double strand break) in the RNA sequence.
- the method can be used to cleave a disease RNA in a cell.
- an exogenous RNA template comprising a sequence to be integrated flanked by an upstream sequence and a downstream sequence may be introduced into a cell.
- RNA can be mRNA.
- the exogenous RNA template comprises a sequence to be integrated (e.g., a mutated RNA).
- the sequence for integration may be a sequence endogenous or exogenous to the cell. Examples of a sequence to be integrated include RNA encoding a protein or a non-coding RNA (e.g., a microRNA).
- the sequence for integration may be operably linked to an appropriate control sequence or sequences.
- the sequence to be integrated may provide a regulatory function.
- the upstream and downstream sequences in the exogenous RNA template are selected to promote recombination between the RNA sequence of interest and the donor RNA.
- the upstream sequence is a RNA sequence that shares sequence similarity with the RNA sequence upstream of the targeted site for integration.
- the downstream sequence is a RNA sequence that shares sequence similarity with the RNA sequence downstream of the targeted site of integration.
- the upstream and downstream sequences in the exogenous RNA template can have 75%, 80%, 85%, 90%, 95%, or 100% sequence identity with the targeted RNA sequence.
- the upstream and downstream sequences in the exogenous RNA template have about 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the targeted RNA sequence.
- the upstream and downstream sequences in the exogenous RNA template have about 99% or 100% sequence identity with the targeted RNA sequence.
- An upstream or downstream sequence may comprise from about 20 bp to about 2500 bp, for example, about 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, or 2500 bp.
- the exemplary upstream or downstream sequence have about 200 bp to about 2000 bp, about 600 bp to about 1000 bp, or more particularly about 700 bp to about 1000 bp.
- the exogenous RNA template may further comprise a marker.
- a marker may make it easy to screen for targeted integrations. Examples of suitable markers include restriction sites, fluorescent proteins, or selectable markers.
- the exogenous RNA template of the invention can be constructed using recombinant techniques (see, for example, Sambrook et al., 2001 and Ausubel et al., 1996).
- a break e.g., double or single stranded break in double or single stranded RNA
- the break is repaired via homologous recombination with an exogenous RNA template such that the template is integrated into the RNA target.
- the presence of a double-stranded break facilitates integration of the template.
- this invention provides a method of modifying expression of a RNA in a eukaryotic cell.
- the method comprises increasing or decreasing expression of a target polynucleotide by using a nucleic acid-targeting complex that binds to the DNA or RNA (e.g., mRNA or pre-mRNA).
- a target RNA can be inactivated to effect the modification of the expression in a cell. For example, upon the binding of a RNA-targeting complex to a target sequence in a cell, the target RNA is inactivated such that the sequence is not translated, the coded protein is not produced, or the sequence does not function as the wild-type sequence does.
- a protein or microRNA coding sequence may be inactivated such that the protein or microRNA or pre-microRNA transcript is not produced.
- the target RNA of a RNA-targeting complex can be any RNA endogenous or exogenous to the eukaryotic cell.
- the target RNA can be a RNA residing in the nucleus of the eukaryotic cell.
- the target RNA can be a sequence (e.g., mRNA or pre-mRNA) coding a gene product (e.g., a protein) or a non-coding sequence (e.g., ncRNA, lncRNA, tRNA, or rRNA).
- Examples of target RNA include a sequence associated with a signaling biochemical pathway, e.g., a signaling biochemical pathway-associated RNA.
- Examples of target RNA include a disease associated RNA.
- a “disease-associated” RNA refers to any RNA which is yielding translation products at an abnormal level or in an abnormal form in cells derived from a disease-affected tissues compared with tissues or cells of a non disease control. It may be a RNA transcribed from a gene that becomes expressed at an abnormally high level; it may be a RNA transcribed from a gene that becomes expressed at an abnormally low level, where the altered expression correlates with the occurrence and/or progression of the disease.
- a disease-associated RNA also refers to a RNA transcribed from a gene possessing mutation(s) or genetic variation that is directly responsible or is in linkage disequilibrium with a gene(s) that is responsible for the etiology of a disease.
- the translated products may be known or unknown, and may be at a normal or abnormal level.
- the target RNA of a RNA-targeting complex can be any RNA endogenous or exogenous to the eukaryotic cell.
- the target RNA can be a RNA residing in the nucleus of the eukaryotic cell.
- the target RNA can be a sequence (e.g., mRNA or pre-mRNA) coding a gene product (e.g., a protein) or a non-coding sequence (e.g., ncRNA, lncRNA, tRNA, or rRNA).
- the method may comprise allowing a RNA-targeting complex to bind to the target RNA to effect cleavage of said target RNA thereby modifying the target RNA, wherein the RNA-targeting complex comprises a nucleic acid-targeting effector (Cas13b) protein complexed with a guide RNA or crRNA hybridized to a target sequence within said target RNA.
- the invention provides a method of modifying expression of RNA in a eukaryotic cell.
- the method comprises allowing a RNA-targeting complex to bind to the RNA such that said binding results in increased or decreased expression of said RNA; wherein the RNA-targeting complex comprises a nucleic acid-targeting effector (Cas13b) protein complexed with a guide RNA.
- Methods of modifying a target RNA can be in a eukaryotic cell, which may be in vivo, ex vivo or in vitro.
- the method comprises sampling a cell or population of cells from a human or non-human animal, and modifying the cell or cells. Culturing may occur at any stage ex vivo. The cell or cells may even be re-introduced into the non-human animal or plant. For re-introduced cells it is particularly preferred that the cells are stem cells.
- RNA-targeting guide RNAs each associated with a distinct RNA-targeting guide RNAs
- an activator-adaptor protein fusion and a repressor-adaptor protein fusion to be used, with different RNA-targeting guide RNAs or crRNAs, to activate expression of RNA, whilst repressing another.
- They, along with their different guide RNAs or crRNAs can be administered together, or substantially together, in a multiplexed approach.
- RNA-targeting guide RNAs or crRNAs can be used all at the same time, for example 10 or 20 or 30 and so forth, whilst only one (or at least a minimal number) of effector protein (Cas13b) molecules need to be delivered, as a comparatively small number of effector protein molecules can be used with a large number modified guides.
- the adaptor protein may be associated (preferably linked or fused to) one or more activators or one or more repressors.
- the adaptor protein may be associated with a first activator and a second activator.
- the first and second activators may be the same, but they are preferably different activators.
- Linkers are preferably used, over a direct fusion to the adaptor protein, where two or more functional domains are associated with the adaptor protein. Suitable linkers might include the GlySer linker.
- the RNA-targeting effector protein-guide RNA complex as a whole may be associated with two or more functional domains.
- there may be two or more functional domains associated with the RNA-targeting effector protein or there may be two or more functional domains associated with the guide RNA or crRNA (via one or more adaptor proteins), or there may be one or more functional domains associated with the RNA-targeting effector protein and one or more functional domains associated with the guide RNA or crRNA (via one or more adaptor proteins).
- the fusion between the adaptor protein and the activator or repressor may include a linker.
- a linker For example, GlySer linkers GGGS can be used. They can be used in repeats of 3 ((GGGGS) 3 ) or 6, 9 or even 12 or more, to provide suitable lengths, as required.
- Linkers can be used between the guide RNAs and the functional domain (activator or repressor), or between the nucleic acid-targeting effector protein and the functional domain (activator or repressor). The linkers the user to engineer appropriate amounts of "mechanical flexibility".
- CRISPR-Cas13b knockdown allows for temporary reduction of gene expression through the use of artificial transcription factors, e.g., via mutating residues in cleavage domain(s) of the Cas13b protein results in the generation of a catalytically inactive Cas13b protein.
- a catalytically inactive Cas13b complexes with a guide RNA or crRNA and localizes to the RNA sequence specified by that guide RNA's or crRNA's targeting domain, however, it does not cleave the target. Fusion of the inactive Cas13b protein to an effector domain, e.g., a transcription repression domain, enables recruitment of the effector to any site specified by the guide RNA.
- the invention thus provides a system for specific delivery of functional components to the RNA environment.
- This can be ensured using the CRISPR systems comprising the RNA targeting effector proteins of the present invention (Table 1 Cas13b) which allow specific targeting of different components to RNA.
- More particularly such components include activators or repressors, such as activators or repressors of RNA translation, degradation, etc.
- the invention provides non-naturally occurring or engineered composition
- a guide RNA or crRNA comprising a guide sequence capable of hybridizing to a target sequence of interest in a cell, wherein the guide RNA or crRNA is modified by the insertion of one or more distinct RNA sequence(s) that bind an adaptor protein.
- the RNA sequences may bind to two or more adaptor proteins (e.g. aptamers), and wherein each adaptor protein is associated with one or more functional domains.
- the functional domains can be same or different, e.g., two of the same or two different activators or repressors.
- the invention provides a herein-discussed composition, wherein the one or more functional domains are attached to the RNA targeting enzyme so that upon binding to the target RNA the functional domain is in a spatial orientation allowing for the functional domain to function in its attributed function;
- the invention provides a herein-discussed composition, wherein the composition comprises a CRISPR-Cas13b complex having at least three functional domains, at least one of which is associated with the RNA targeting enzyme and at least two of which are associated with the gRNA or crRNA.
- TALEs, CRISPR-Cas systems, or components thereof or nucleic acid molecules thereof (including, for instance HDR template) or nucleic acid molecules encoding or providing components thereof may be delivered by a delivery system herein described both generally and in detail.
- Vector delivery e.g., plasmid, viral delivery:
- the CRISPR enzyme , and/or any of the present RNAs, for instance a guide RNA can be delivered using any suitable vector, e.g., plasmid or viral vectors, such as adeno associated virus (AAV), lentivirus, adenovirus or other viral vector types, or combinations thereof.
- Effector proteins and one or more guide RNAs can be packaged into one or more vectors, e.g., plasmid or viral vectors.
- the vector e.g., plasmid or viral vector is delivered to the tissue of interest by, for example, an intramuscular injection, while other times the delivery is via intravenous, transdermal, intranasal, oral, mucosal, or other delivery methods. Such delivery may be either via a single dose, or multiple doses.
- the actual dosage to be delivered herein may vary greatly depending upon a variety of factors, such as the vector choice, the target cell, organism, or tissue, the general condition of the subject to be treated, the degree of transformation/modification sought, the administration route, the administration mode, the type of transformation/modification sought, etc.
- Such a dosage may further contain, for example, a carrier (water, saline, ethanol, glycerol, lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin, peanut oil, sesame oil, etc.), a diluent, a pharmaceutically-acceptable carrier (e.g., phosphate-buffered saline), a pharmaceutically-acceptable excipient, and/or other compounds known in the art.
- a carrier water, saline, ethanol, glycerol, lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin, peanut oil, sesame oil, etc.
- a pharmaceutically-acceptable carrier e.g., phosphate-buffered saline
- a pharmaceutically-acceptable excipient e.g., phosphate-buffered saline
- the dosage may further contain one or more pharmaceutically acceptable salts such as, for example, a mineral acid salt such as a hydrochloride, a hydrobromide, a phosphate, a sulfate, etc.; and the salts of organic acids such as acetates, propionates, malonates, benzoates, etc.
- auxiliary substances such as wetting or emulsifying agents, pH buffering substances, gels or gelling materials, flavorings, colorants, microspheres, polymers, suspension agents, etc. may also be present herein.
- Suitable exemplary ingredients include microcrystalline cellulose, carboxymethylcellulose sodium, polysorbate 80, phenylethyl alcohol, chlorobutanol, potassium sorbate, sorbic acid, sulfur dioxide, propyl gallate, the parabens, ethyl vanillin, glycerin, phenol, parachlorophenol, gelatin, albumin and a combination thereof.
- the delivery is via an adenovirus, which may be at a single booster dose containing at least 1 ⁇ 10 5 particles (also referred to as particle units, pu) of adenoviral vector.
- the dose preferably is at least about 1 ⁇ 10 6 particles (for example, about 1 ⁇ 10 6 -1 ⁇ 10 12 particles), more preferably at least about 1 ⁇ 10 7 particles, more preferably at least about 1 ⁇ 10 8 particles (e.g., about 1 ⁇ 10 8 -1 ⁇ 10 11 particles or about 1 ⁇ 10 8 -1 ⁇ 10 12 particles), and most preferably at least about 1 ⁇ 10 0 particles (e.g., about 1 ⁇ 10 9 -1 ⁇ 10 10 particles or about 1 ⁇ 10 9 -1 ⁇ 10 12 particles), or even at least about 1 ⁇ 10 10 particles (e.g., about 1 ⁇ 10 10 -1 ⁇ 10 12 particles) of the adenoviral vector.
- the dose comprises no more than about 1 ⁇ 10 14 particles, preferably no more than about 1 ⁇ 10 13 particles, even more preferably no more than about 1 ⁇ 10 12 particles, even more preferably no more than about 1 ⁇ 10 11 particles, and most preferably no more than about 1 ⁇ 10 10 particles (e.g., no more than about 1 ⁇ 10 9 articles).
- the dose may contain a single dose of adenoviral vector with, for example, about 1 ⁇ 10 6 particle units (pu), about 2 ⁇ 10 6 pu, about 4 ⁇ 10 6 pu, about 1 ⁇ 10 7 pu, about 2 ⁇ 10 7 pu, about 4 ⁇ 10 7 pu, about 1 ⁇ 10 8 pu, about 2 ⁇ 10 8 pu, about 4 ⁇ 10 8 pu, about 1 ⁇ 10 9 pu, about 2 ⁇ 10 9 pu, about 4 ⁇ 10 9 pu, about 1 ⁇ 10 10 pu, about 2 ⁇ 10 10 pu, about 4 ⁇ 10 10 pu, about 1 ⁇ 10 11 pu, about 2 ⁇ 10 11 pu, about 4 ⁇ 10 11 pu, about 1 ⁇ 10 12 pu, about 2 ⁇ 10 12 pu, or about 4 ⁇ 10 12 pu of adenoviral vector.
- adenoviral vector with, for example, about 1 ⁇ 10 6 particle units (pu), about 2 ⁇ 10 6 pu, about 4 ⁇ 10 6 pu, about 1 ⁇ 10 7 pu, about 2 ⁇ 10 7 pu
- the adenoviral vectors in U.S. Patent No. 8,454,972 B2 to Nabel, et. al., granted on June 4, 2013 , and the dosages at col 29, lines 36-58 thereof.
- the adenovirus is delivered via multiple doses.
- the delivery is via an AAV.
- a therapeutically effective dosage for in vivo delivery of the AAV to a human is believed to be in the range of from about 20 to about 50 ml of saline solution containing from about 1 ⁇ 10 10 to about 1 ⁇ 10 10 functional AAV/ml solution. The dosage may be adjusted to balance the therapeutic benefit against any side effects.
- the AAV dose is generally in the range of concentrations of from about 1 ⁇ 10 5 to 1 ⁇ 10 50 genomes AAV, from about 1 ⁇ 10 8 to 1 ⁇ 10 20 genomes AAV, from about 1 ⁇ 10 10 to about 1 ⁇ 10 16 genomes, or about 1 ⁇ 10 11 to about 1 ⁇ 10 16 genomes AAV.
- a human dosage may be about 1 ⁇ 10 13 genomes AAV. Such concentrations may be delivered in from about 0.001 ml to about 100 ml, about 0.05 to about 50 ml, or about 10 to about 25 ml of a carrier solution. Other effective dosages can be readily established by one of ordinary skill in the art through routine trials establishing dose response curves. See, for example, U.S. Patent No. 8,404,658 B2 to Hajjar, et al., granted on March 26, 2013 , at col. 27, lines 45-60.
- the delivery is via a plasmid.
- the dosage should be a sufficient amount of plasmid to elicit a response.
- suitable quantities of plasmid DNA in plasmid compositions can be from about 0.1 to about 2 mg, or from about 1 ⁇ g to about 10 ⁇ g per 70 kg individual.
- Plasmids of the invention will generally comprise (i) a promoter; (ii) a sequence encoding an nucleic acid-targeting CRISPR enzyme, operably linked to said promoter; (iii) a selectable marker; (iv) an origin of replication; and (v) a transcription terminator downstream of and operably linked to (ii).
- the plasmid can also encode the RNA components of a CRISPR complex, but one or more of these may instead be encoded on a different vector.
- mice used in experiments are typically about 20g and from mice experiments one can scale up to a 70 kg individual.
- RNA molecules of the invention are delivered in liposome or lipofectin formulations and the like and can be prepared by methods well known to those skilled in the art. Such methods are described, for example, in U.S. Pat. Nos. 5,593,972 , 5,589,466 , and 5,580,859 . Delivery systems aimed specifically at the enhanced and improved delivery of siRNA into mammalian cells have been developed, (see, for example, Shen etalFEBS Let. 2003, 539:111-114 ; Xia et al., Nat. Biotech. 2002, 20:1006-1010 ; Reich et al., Mol. Vision. 2003, 9: 210-216 ; Sorensen et al., J.
- siRNA has recently been successfully used for inhibition of gene expression in primates (see for example. Tolentino et al., Retina 24(4):660 which may also be applied to the present invention.
- RNA delivery is a useful method of in vivo delivery. It is possible to deliver nucleic acid-targeting Cas protein and guide RNA (and, for instance, HR repair template) into cells using liposomes or particles.
- delivery of the nucleic acid-targeting Cas13b protein and/or delivery of the guide RNAs or crRNAs of the invention may be in RNA form and via microvesicles, liposomes or particles.
- Cas13b mRNA and guide RNA or crRNA can be packaged into liposomal particles for delivery in vivo.
- Liposomal transfection reagents such as lipofectamine from Life Technologies and other reagents on the market can effectively deliver RNA molecules into the liver.
- Means of delivery of RNA also preferred include delivery of RNA via nanoparticles ( Cho, S., Goldberg, M., Son, S., Xu, Q., Yang, F., Mei, Y., Bogatyrev, S., Langer, R. and Anderson, D., Lipid-like nanoparticles for small interfering RNA delivery to endothelial cells, Advanced Functional Materials, 19: 3112-3118, 2010 ) or exosomes ( Schroeder, A., Levins, C., Cortez, C., Langer, R., and Anderson, D., Lipid-based nanotherapeutics for siRNA delivery, Journal of Internal Medicine, 267: 9-21, 2010, PMID: 20059641 ).
- exosomes have been shown to be particularly useful in delivery siRNA, a system with some parallels to the RNA-targeting system.
- El-Andaloussi S, et al. (“Exosome-mediated delivery of siRNA in vitro and in vivo.” Nat Protoc. 2012 Dec;7(12):2112-26. doi: 10.1038/nprot.2012.131. Epub 2012 Nov 15 .) describe how exosomes are promising tools for drug delivery across different biological barriers and can be harnessed for delivery of siRNA in vitro and in vivo.
- Their approach is to generate targeted exosomes through transfection of an expression vector, comprising an exosomal protein fused with a peptide ligand.
- RNA is loaded into the exosomes.
- Delivery or administration according to the invention can be performed with exosomes, in particular but not limited to the brain.
- Vitamin E ⁇ -tocopherol
- HDL high density lipoprotein
- siRNA short-interfering RNA
- Mice were infused via Osmotic minipumps (model 1007D; Alzet, Cupertino, CA) filled with phosphate-buffered saline (PBS) or free TocsiBACE or Toc-siBACE/HDL and connected with Brain Infusion Kit 3 (Alzet).
- PBS phosphate-buffered saline
- a braininfusion cannula was placed about 0.5mm posterior to the bregma at midline for infusion into the dorsal third ventricle.
- Uno et al. found that as little as 3 nmol of Toc-siRNA with HDL could induce a target reduction in comparable degree by the same ICV infusion method.
- nucleic acid-targeting effector protein conjugated to ⁇ -tocopherol and co-administered with HDL targeted to the brain may be contemplated for humans in the present invention, for example, about 3 nmol to about 3 ⁇ mol of nucleic acid-targeting effector protein targeted to the brain may be contemplated.
- Zou et al. (HUMAN GENE THERAPY 22:465-475 (April 2011 )) describes a method of lentiviral-mediated delivery of short-hairpin RNAs targeting PKC ⁇ for in vivo gene silencing in the spinal cord of rats. Zou et al.
- nucleic acid-targeting effector protein expressed in a lentiviral vector targeted to the brain may be contemplated for humans in the present invention, for example, about 10-50 ml of nucleic acid-targeting effector protein targeted to the brain in a lentivirus having a titer of 1 ⁇ 10 9 transducing units (TU)/ml may be contemplated.
- material can be delivered intrastriatally e.g., by injection. Injection can be performed stereotactically via a craniotomy.
- RNA-targeting effector protein coding nucleic acid molecules, e.g., DNA
- vectors e.g., viral vectors
- the promoter used to drive RNA-targeting effector protein coding nucleic acid molecule expression can include AAV ITR can serve as a promoter: this is advantageous for eliminating the need for an additional promoter element (which can take up space in the vector). The additional space freed up can be used to drive the expression of additional elements (gRNA, etc.). Also, ITR activity is relatively weaker, so can be used to reduce potential toxicity due to over expression of nucleic acid-targeting effector protein. For ubiquitous expression, can use promoters: CMV, CAG, CBh, PGK, SV40, Ferritin heavy or light chains, etc.
- promoters For brain or other CNS expression, can use promoters: SynapsinI for all neurons, CaMKIIalpha for excitatory neurons, GAD67 or GAD65 or VGAT for GABAergic neurons, etc.
- liver expression can use Albumin promoter.
- lung expression can use SP-B.
- endothelial cells can use ICAM.
- hematopoietic cells can use IFNbeta or CD45.
- Osteoblasts can use OG-2.
- the promoter used to drive guide RNA can include: Pol III promoters such as U6 or H1; Pol II promoter and intronic cassettes to express guide RNA or crRNA.
- AAV Adeno associated virus
- Cas13b and one or more guide RNA or crRNA can be delivered using adeno associated virus (AAV), lentivirus, adenovirus or other plasmid or viral vector types, in particular, using formulations and doses from, for example, US Patents Nos. 8,454,972 (formulations, doses for adenovirus), 8,404,658 (formulations, doses for AAV) and 5,846,946 (formulations, doses for DNA plasmids) and from clinical trials and publications regarding the clinical trials involving lentivirus, AAV and adenovirus.
- AAV the route of administration, formulation and dose can be as in US Patent No. 8,454,972 and as in clinical trials involving AAV.
- the route of administration, formulation and dose can be as in US Patent No. 8,404,658 and as in clinical trials involving adenovirus.
- the route of administration, formulation and dose can be as in US Patent No 5,846,946 and as in clinical studies involving plasmids.
- Doses may be based on or extrapolated to an average 70 kg individual (e.g., a male adult human), and can be adjusted for patients, subjects, mammals of different weight and species. Frequency of administration is within the ambit of the medical or veterinary practitioner (e.g., physician, veterinarian), depending on usual factors including the age, sex, general health, other conditions of the patient or subject and the particular condition or symptoms being addressed.
- the viral vectors can be injected into the tissue of interest.
- the expression of RNA-targeting effector protein can be driven by a cell-type specific promoter.
- liver-specific expression might use the Albumin promoter and neuron-specific expression (e.g., for targeting CNS disorders) might use the Synapsin I promoter.
- AAV is advantageous over other viral vectors for a couple of reasons: Low toxicity (this may be due to the purification method not requiring ultra centrifugation of cell particles that can activate the immune response) and Low probability of causing insertional mutagenesis because it doesn't integrate into the host genome.
- AAV has a packaging limit of 4.5 or 4.75 Kb. This means that the RNA-targeting effector protein (Cas13b effector protein) coding sequence as well as a promoter and transcription terminator have to be all fit into the same viral vector.
- the AAV can be AAV1, AAV2, AAV5 or any combination thereof.
- AAV8 is useful for delivery to the liver. The herein promoters and vectors are preferred individually.
- a tabulation of certain AAV serotypes as to these cells is as follows: Cell Line AAV-1 AAV-2 AAV-3 AAV-4 AAV-5 AAV-6 AAV-8 AAV-9 Huh-7 13 100 2.5 0.0 0.1 10 0.7 0.0 HEK293 25 100 2.5 0.1 0.1 5 0.7 0.1 HeLa 3 100 2.0 0.1 6.7 1 0.2 0.1 HepG2 3 100 16.7 0.3 1.7 5 0.3 ND Hep1A 20 100 0.2 1.0 0.1 1 0.2 0.0 911 17 100 11 0.2 0.1 17 0.1 ND CHO 100 100 14 1.4 333 50 10 1.0 COS 33 100 33 3.3 5.0 14 2.0 0.5 MeWo 10 100 20 0.3 6.7 10 1.0 0.2 NIH3T3 10 100 2.9 2.9 0.3 10 0.3 ND A549 14 100 20 ND 0.5 10 0.5 0.1 HT1180 20 100 10 0.1 0.3 0.3 ND A549 14 100 20 ND 0.5 10 0.5 0.1 HT1180 20 100 10 0.1 0.3
- Lentiviruses are complex retroviruses that have the ability to infect and express their genes in both mitotic and post-mitotic cells.
- the most commonly known lentivirus is the human immunodeficiency virus (HIV), which uses the envelope glycoproteins of other viruses to target a broad range of cell types.
- OptiMEM serum-free media and transfection was done 4 hours later.
- Cells were transfected with 10 ⁇ g of lentiviral transfer plasmid (pCasES10) and the following packaging plasmids: 5 ⁇ g of pMD2.G (VSV-g pseudotype), and 7.5ug of psPAX2 (gag/pol/rev/tat).
- Transfection was done in 4mL OptiMEM with a cationic lipid delivery agent (50uL Lipofectamine 2000 and 100ul Plus reagent).
- the media was changed to antibiotic-free DMEM with 10% fetal bovine serum. These methods use serum during cell culture, but serum-free methods are preferred.
- Lentivirus may be purified as follows. Viral supernatants were harvested after 48 hours. Supernatants were first cleared of debris and filtered through a 0.45um low protein binding (PVDF) filter. They were then spun in a ultracentrifuge for 2 hours at 24,000 rpm. Viral pellets were resuspended in 50ul of DMEM overnight at 4C. They were then aliquotted and immediately frozen at -80°C.
- PVDF 0.45um low protein binding
- minimal non-primate lentiviral vectors based on the equine infectious anemia virus are also contemplated, especially for ocular gene therapy (see, e.g., Balagaan, J Gene Med 2006; 8: 275 - 285 ).
- RetinoStat ® an equine inffctious anemia virus-based lentiviral gene therapy vector that expresses angiostatic proteins endostatin and angiostatin that is delivered via a subretinal injection for the treatment of the web form of age-related macular degeneration is also contemplated (see, e.g., Binley et al., HUMAN GENE THERAPY 23:980-991 (September 2012 )) and this vector may be modified for the nucleic acid-targeting system of the present invention.
- self-inactivating lentiviral vectors with an siRNA targeting a common exon shared by HIV tat/rev, a nucleolar-localizing TAR decoy, and an anti-CCR5-specific hammerhead ribozyme may be used/and or adapted to the nucleic acid-targeting system of the present invention.
- a minimum of 2.5 ⁇ 10 6 CD34+ cells per kilogram patient weight may be collected and prestimulated for 16 to 20 hours in X-VIVO 15 medium (Lonza) containing 2 ⁇ mol/L-glutamine, stem cell factor (100 ng/ml), Flt-3 ligand (Flt-3L) (100 ng/ml), and thrombopoietin (10 ng/ml) (CellGenix) at a density of 2 ⁇ 10 6 cells/ml.
- Prestimulated cells may be transduced with lentiviral at a multiplicity of infection of 5 for 16 to 24 hours in 75-cm 2 tissue culture flasks coated with fibronectin (25 mg/cm 2 ) (RetroNectin,Takara Bio Inc.).
- Lentiviral vectors have been disclosed as in the treatment for Parkinson's Disease, see, e.g., US Patent Publication No. 20120295960 and US Patent Nos. 7303910 and 7351585 .
- Lentiviral vectors have also been disclosed for the treatment of ocular diseases, see e.g., US Patent Publication Nos. 20060281180 , 20090007284 , US20110117189 ; US20090017543 ; US20070054961 , US20100317109 .
- Lentiviral vectors have also been disclosed for delivery to the brain, see, e.g., US Patent Publication Nos. US20110293571 ; US20110293571 , US20040013648 , US20070025970 , US20090111106 and US Patent No. US7259015 .
- RNA delivery The nucleic acid-targeting Cas13b protein, and/or guide RNA, can also be delivered in the form of RNA.
- mRNA can be synthesized using a PCR cassette containing the following elements: T7_promoter-kozak sequence (GCCACC)-effector protrein-3' UTR from beta globin-polyA tail (a string of 120 or more adenines).
- GCCACC T7_promoter-kozak sequence
- the cassette can be used for transcription by T7 polymerase.
- Guide RNAs or crRNAs can also be transcribed using in vitro transcription from a cassette containing T7_promoter-GG- guide RNA or crRNA sequence.
- Particle delivery systems and/or formulations are Particle delivery systems and/or formulations:
- a particle is defined as a small object that behaves as a whole unit with respect to its transport and properties. Particles are further classified according to diameter. Coarse particles cover a range between 2,500 and 10,000 nanometers. Fine particles are sized between 100 and 2,500 nanometers. Ultrafine particles, or nanoparticles, are generally between 1 and 100 nanometers in size. The basis of the 100-nm limit is the fact that novel properties that differentiate particles from the bulk material typically develop at a critical length scale of under 100 nm.
- a particle delivery system/formulation is defined as any biological delivery system/formulation which includes a particle in accordance with the present invention.
- a particle in accordance with the present invention is any entity having a greatest dimension (e.g. diameter) of less than 100 microns ( ⁇ m). In some embodiments, inventive particles have a greatest dimension of less than 10 ⁇ m. In some embodiments, inventive particles have a greatest dimension of less than 2000 nanometers (nm). In some embodiments, inventive particles have a greatest dimension of less than 1000 nanometers (nm).
- inventive particles have a greatest dimension of less than 900 nm, 800 nm, 700 nm, 600 nm, 500 nm, 400 nm, 300 nm, 200 nm, or 100 nm.
- inventive particles have a greatest dimension (e.g., diameter) of 500 nm or less.
- inventive particles have a greatest dimension (e.g., diameter) of 250 nm or less.
- inventive particles have a greatest dimension (e.g., diameter) of 200 nm or less.
- inventive particles have a greatest dimension (e.g., diameter) of 150 nm or less.
- inventive particles have a greatest dimension (e.g., diameter) of 100 nm or less. Smaller particles, e.g., having a greatest dimension of 50 nm or less are used in some embodiments of the invention. In some embodiments, inventive particles have a greatest dimension ranging between 25 nm and 200 nm.
- Particle characterization is done using a variety of different techniques.
- Common techniques are electron microscopy (TEM, SEM), atomic force microscopy (AFM), dynamic light scattering (DLS), X-ray photoelectron spectroscopy (XPS), powder X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FTIR), matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF), ultraviolet-visible spectroscopy, dual polarisation interferometry and nuclear magnetic resonance (NMR).
- TEM electron microscopy
- AFM atomic force microscopy
- DLS dynamic light scattering
- XPS X-ray photoelectron spectroscopy
- XRD powder X-ray diffraction
- FTIR Fourier transform infrared spectroscopy
- MALDI-TOF matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
- Characterization may be made as to native particles (i.e., preloading) or after loading of the cargo (herein cargo refers to e.g., one or more components of CRISPR-Cas13b system e.g., Cas13b enzyme or mRNA or guide RNA, or any combination thereof, and may include additional carriers and/or excipients) to provide particles of an optimal size for delivery for any in vitro, ex vivo and/or in vivo application of the present invention.
- particle dimension (e.g., diameter) characterization is based on measurements using dynamic laser scattering (DLS). Mention is made of US Patent No. 8,709,843 ; US Patent No. 6,007,845 ; US Patent No.
- Particles delivery systems within the scope of the present invention may be provided in any form, including but not limited to solid, semi-solid, emulsion, or colloidal particles.
- any of the delivery systems described herein including but not limited to, e.g., lipid-based systems, liposomes, micelles, microvesicles, exosomes, or gene gun may be provided as particle delivery systems within the scope of the present invention.
- Cas13b mRNA and guide RNA or crRNA may be delivered simultaneously using particles or lipid envelopes; for instance, CRISPR enzyme and RNA of the invention, e.g., as a complex, can be delivered via a particle as in Dahlman et al., WO2015089419 A2 and documents cited therein, such as 7C1 (see, e.g., James E. Dahlman and Carmen Barnes et al.
- DOTAP 1,2-dioleoyl-3-trimethylammonium-propane
- DMPC 1,
- Cas13b effector protein mRNA and guide RNA may be delivered simultaneously using particles or lipid envelopes.
- This Dahlman et al technology can be applied in the instant invention.
- An epoxide-modified lipidpolymer may be utilized to deliver the nucleic acid-targeting system of the present invention to pulmonary, cardiovascular or renal cells, however, one of skill in the art may adapt the system to deliver to other target organs. Dosage ranging from about 0.05 to about 0.6 mg/kg are envisioned. Dosages over several days or weeks are also envisioned, with a total dosage of about 2 mg/kg.
- particles based on self-assembling bioadhesive polymers are contemplated, which may be applied to oral delivery of peptides, intravenous delivery of peptides and nasal delivery of peptides, all to the brain.
- Other embodiments, such as oral absorption and ocular delivery of hydrophobic drugs are also contemplated.
- the molecular envelope technology involves an engineered polymer envelope which is protected and delivered to the site of the disease (see, e.g., Mazza, M. et al. ACSNano, 2013. 7(2): 1016-1026 ; Siew, A., et al. Mol Pharm, 2012. 9(1):14-28 ; Lalatsa, A., et al. J Contr Rel, 2012.
- US patent application 20110293703 relates to lipidoid compounds are also particularly useful in the administration of polynucleotides, which may be applied to deliver the nucleic acid-targeting system of the present invention.
- the aminoalcohol lipidoid compounds are combined with an agent to be delivered to a cell or a subject to form microparticles, nanoparticles, liposomes, or micelles.
- the agent to be delivered by the particles, liposomes, or micelles may be in the form of a gas, liquid, or solid, and the agent may be a polynucleotide, protein, peptide, or small molecule.
- the minoalcohol lipidoid compounds may be combined with other aminoalcohol lipidoid compounds, polymers (synthetic or natural), surfactants, cholesterol, carbohydrates, proteins, lipids, etc. to form the particles. These particles may then optionally be combined with a pharmaceutical excipient to form a pharmaceutical composition.
- US Patent Publication No. 20110293703 also provides methods of preparing the aminoalcohol lipidoid compounds. One or more equivalents of an amine are allowed to react with one or more equivalents of an epoxide-terminated compound under suitable conditions to form an aminoalcohol lipidoid compound of the present invention.
- all the amino groups of the amine are fully reacted with the epoxide-terminated compound to form tertiary amines. In other embodiments, all the amino groups of the amine are not fully reacted with the epoxide-terminated compound to form tertiary amines thereby resulting in primary or secondary amines in the aminoalcohol lipidoid compound. These primary or secondary amines are left as is or may be reacted with another electrophile such as a different epoxide-terminated compound.
- amines may be fully functionalized with two epoxide-derived compound tails while other molecules will not be completely functionalized with epoxide-derived compound tails.
- a diamine or polyamine may include one, two, three, or four epoxide-derived compound tails off the various amino moieties of the molecule resulting in primary, secondary, and tertiary amines. In certain embodiments, all the amino groups are not fully functionalized.
- two of the same types of epoxide-terminated compounds are used. In other embodiments, two or more different epoxide-terminated compounds are used.
- the synthesis of the aminoalcohol lipidoid compounds is performed with or without solvent, and the synthesis may be performed at higher temperatures ranging from 30-100 °C., preferably at approximately 50-90 °C.
- the prepared aminoalcohol lipidoid compounds may be optionally purified.
- the mixture of aminoalcohol lipidoid compounds may be purified to yield an aminoalcohol lipidoid compound with a particular number of epoxide-derived compound tails. Or the mixture may be purified to yield a particular stereo- or regioisomer.
- the aminoalcohol lipidoid compounds may also be alkylated using an alkyl halide (e.g., methyl iodide) or other alkylating agent, and/or they may be acylated.
- US Patent Publication No. 20110293703 also provides libraries of aminoalcohol lipidoid compounds prepared by the inventive methods. These aminoalcohol lipidoid compounds may be prepared and/or screened using high-throughput techniques involving liquid handlers, robots, microtiter plates, computers, etc. In certain embodiments, the aminoalcohol lipidoid compounds are screened for their ability to transfect polynucleotides or other agents (e.g., proteins, peptides, small molecules) into the cell.
- US Patent Publication No. 20130302401 relates to a class of poly(beta-amino alcohols) (PBAAs) has been prepared using combinatorial polymerization.
- PBAAs poly(beta-amino alcohols)
- the inventive PBAAs may be used in biotechnology and biomedical applications as coatings (such as coatings of films or multilayer films for medical devices or implants), additives, materials, excipients, non-biofouling agents, micropatterning agents, and cellular encapsulation agents.
- coatings such as coatings of films or multilayer films for medical devices or implants
- additives materials, excipients, non-biofouling agents, micropatterning agents, and cellular encapsulation agents.
- these PBAAs When used as surface coatings, these elicited different levels of inflammation, both in vitro and in vivo, depending on their chemical structures.
- the large chemical diversity of this class of materials allowed us to identify polymer coatings that inhibit macrophage activation in vitro.
- these coatings reduce the recruitment of inflammatory cells, and reduce fibrosis, following the subcutaneous implantation of carboxylated polystyrene microparticles.
- polymers may be used to form polyelectrolyte complex capsules for cell encapsulation.
- the invention may also have many other biological applications such as antimicrobial coatings, DNA or siRNA delivery, and stem cell tissue engineering.
- the teachings of US Patent Publication No. 20130302401 may be applied to the nucleic acid-targeting system of the present invention.
- lipid nanoparticles are contemplated.
- An antitransthyretin small interfering RNA has been encapsulated in lipid nanoparticles and delivered to humans (see, e.g., Coelho et al., N Engl J Med 2013;369:819-29 ), and such a system may be adapted and applied to the nucleic acid-targeting system of the present invention.
- Doses of about 0.01 to about 1 mg per kg of body weight administered intravenously are contemplated.
- Medications to reduce the risk of infusion-related reactions are contemplated, such as dexamethasone, acetampinophen, diphenhydramine or cetirizine, and ranitidine are contemplated.
- LNPs have been shown to be highly effective in delivering siRNAs to the liver (see, e.g., Tabernero et al., Cancer Discovery, April 2013, Vol. 3, No. 4, pages 363-470 ) and are therefore contemplated for delivering RNA encoding nucleic acid-targeting effector protein to the liver.
- a dosage of about four doses of 6 mg/kg of the LNP every two weeks may be contemplated.
- ionizable cationic lipids with pKa values below 7 were developed (see, e.g., Rosin et al, Molecular Therapy, vol. 19, no. 12, pages 1286-2200, Dec. 2011 ).
- Negatively charged polymers such as RNA may be loaded into LNPs at low pH values (e.g., pH 4) where the ionizable lipids display a positive charge.
- pH values e.g., pH 4
- the LNPs exhibit a low surface charge compatible with longer circulation times.
- ionizable cationic lipids Four species of ionizable cationic lipids have been focused upon, namely 1,2-dilineoyl-3-dimethylammonium-propane (DLinDAP), 1,2-dilinoleyloxy-3-N,N-dimethylaminopropane (DLinDMA), 1,2-dilinoleyloxy-keto-N,N-dimethyl-3-aminopropane (DLinKDMA), and 1,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLinKC2-DMA).
- DLinDAP 1,2-dilineoyl-3-dimethylammonium-propane
- DLinDMA 1,2-dilinoleyloxy-3-N,N-dimethylaminopropane
- DLinKDMA 1,2-dilinoleyloxy-keto-N,N-dimethyl-3
- LNP siRNA systems containing these lipids exhibit remarkably different gene silencing properties in hepatocytes in vivo, with potencies varying according to the series DLinKC2-DMA>DLinKDMA>DLinDMA>>DLinDAP employing a Factor VII gene silencing model (see, e.g., Rosin et al, Molecular Therapy, vol. 19, no. 12, pages 1286-2200, Dec. 2011 ).
- a dosage of 1 ⁇ g/ml of LNP or CRISPR-Cas RNA in or associated with the LNP may be contemplated, especially for a formulation containing DLinKC2-DMA.
- Preparation of LNPs and CRISPR-Cas13b encapsulation may be used/and or adapted from Rosin et al, Molecular Therapy, vol. 19, no. 12, pages 1286-2200, Dec. 2011 ).
- the cationic lipids 1,2-dilineoyl-3-dimethylammonium-propane (DLinDAP), 1,2-dilinoleyloxy-3-N,N-dimethylaminopropane (DLinDMA), 1,2-dilinoleyloxyketo-N,N-dimethyl-3-aminopropane (DLinK-DMA), 1,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLinKC2-DMA), (3-o-[2"-(methoxypolyethyleneglycol 2000) succinoyl]-1,2-dimyristoyl-sn-glycol (PEG-S-DMG), and R-3
- Cholesterol may be purchased from Sigma (St Louis, MO).
- the specific nucleic acid-targeting complex (CRISPR-Cas) RNA may be encapsulated in LNPs containing DLinDAP, DLinDMA, DLinK-DMA, and DLinKC2-DMA (cationic lipid:DSPC:CHOL: PEGS-DMG or PEG-C-DOMG at 40:10:40:10 molar ratios).
- 0.2% SP-DiOC18 Invitrogen, Burlington, Canada
- Encapsulation may be performed by dissolving lipid mixtures comprised of cationic lipid:DSPC:cholesterol:PEG-c-DOMG (40:10:40:10 molar ratio) in ethanol to a final lipid concentration of 10 mmol/l.
- This ethanol solution of lipid may be added drop-wise to 50 mmol/l citrate, pH 4.0 to form multilamellar vesicles to produce a final concentration of 30% ethanol vol/vol.
- Large unilamellar vesicles may be formed following extrusion of multilamellar vesicles through two stacked 80 nm Nuclepore polycarbonate filters using the Extruder (Northern Lipids, Vancouver, Canada).
- Encapsulation may be achieved by adding RNA dissolved at 2 mg/ml in 50 mmol/l citrate, pH 4.0 containing 30% ethanol vol/vol drop-wise to extruded preformed large unilamellar vesicles and incubation at 31 °C for 30 minutes with constant mixing to a final RNA/lipid weight ratio of 0.06/1 wt/wt. Removal of ethanol and neutralization of formulation buffer were performed by dialysis against phosphate-buffered saline (PBS), pH 7.4 for 16 hours using Spectra/Por 2 regenerated cellulose dialysis membranes.
- PBS phosphate-buffered saline
- RNA encapsulation efficiency may be determined by removal of free RNA using VivaPureD MiniH columns (Sartorius Stedim Biotech) from samples collected before and after dialysis. The encapsulated RNA may be extracted from the eluted particles and quantified at 260 nm.
- RNA to lipid ratio was determined by measurement of cholesterol content in vesicles using the Cholesterol E enzymatic assay from Wako Chemicals USA (Richmond, VA).
- PEGylated liposomes or LNPs are likewise suitable for delivery of a nucleic acid-targeting system or components thereof. Preparation of large LNPs may be used/and or adapted from Rosin et al, Molecular Therapy, vol. 19, no. 12, pages 1286-2200, Dec. 2011 .
- a lipid premix solution (20.4 mg/ml total lipid concentration) may be prepared in ethanol containing DLinKC2-DMA, DSPC, and cholesterol at 50:10:38.5 molar ratios.
- Sodium acetate may be added to the lipid premix at a molar ratio of 0.75:1 (sodium acetate:DLinKC2-DMA).
- the lipids may be subsequently hydrated by combining the mixture with 1.85 volumes of citrate buffer (10 mmol/l, pH 3.0) with vigorous stirring, resulting in spontaneous liposome formation in aqueous buffer containing 35% ethanol.
- the liposome solution may be incubated at 37 °C to allow for time-dependent increase in particle size.
- Aliquots may be removed at various times during incubation to investigate changes in liposome size by dynamic light scattering (Zetasizer Nano ZS, Malvern Instruments, Worcestershire, UK).
- stock 10 mg/ml PEG-DMG in 35% (vol/vol) ethanol
- the liposomes should their size, effectively quenching further growth.
- RNA may then be added to the empty liposomes at a RNA to total lipid ratio of approximately 1:10 (wt:wt), followed by incubation for 30 minutes at 37 °C to form loaded LNPs.
- the mixture may be subsequently dialyzed overnight in PBS and filtered with a 0.45- ⁇ m syringe filter.
- Spherical Nucleic Acid (SNA TM ) constructs and other particles (particularly gold particles) are also contemplated as a means to delivery nucleic acid-targeting system to intended targets.
- Significant data show that AuraSense Therapeutics' Spherical Nucleic Acid (SNA TM ) constructs, based upon nucleic acid-functionalized gold particles, are useful.
- Literature that may be employed in conjunction with herein teachings include: Cutler et al., J. Am. Chem. Soc. 2011 133:9254-9257 , Hao et al., Small. 2011 7:3158-3162 , Zhang et al., ACS Nano. 2011 5:6962-6970 , Cutler et al., J. Am. Chem. Soc. 2012 134:1376-1391 , Young et al., Nano Lett. 2012 12:3867-71 , Zheng et al., Proc. Natl. Acad. Sci. USA. 2012 109:11975-80 , Mirkin, Nanomedicine 2012 7:635-638 Zhang et al., J. Am. Chem.
- Self-assembling particles with RNA may be constructed with polyethyleneimine (PEI) that is PEGylated with an Arg-Gly-Asp (RGD) peptide ligand attached at the distal end of the polyethylene glycol (PEG).
- PEI polyethyleneimine
- RGD Arg-Gly-Asp
- This system has been used, for example, as a means to target tumor neovasculature expressing integrins and deliver siRNA inhibiting vascular endothelial growth factor receptor-2 (VEGF R2) expression and thereby achieve tumor angiogenesis (see, e.g., Schiffelers et al., Nucleic Acids Research, 2004, Vol. 32, No. 19 ).
- VEGF R2 vascular endothelial growth factor receptor-2
- Nanoplexes may be prepared by mixing equal volumes of aqueous solutions of cationic polymer and nucleic acid to give a net molar excess of ionizable nitrogen (polymer) to phosphate (nucleic acid) over the range of 2 to 6.
- the electrostatic interactions between cationic polymers and nucleic acid resulted in the formation of polyplexes with average particle size distribution of about 100 nm, hence referred to here as nanoplexes.
- a dosage of about 100 to 200 mg of nucleic acid-targeting complex RNA is envisioned for delivery in the self-assembling particles of Schiffelers et al.
- the nanoplexes of Bartlett et al. may also be applied to the present invention.
- the nanoplexes of Bartlett et al. are prepared by mixing equal volumes of aqueous solutions of cationic polymer and nucleic acid to give a net molar excess of ionizable nitrogen (polymer) to phosphate (nucleic acid) over the range of 2 to 6.
- the electrostatic interactions between cationic polymers and nucleic acid resulted in the formation of polyplexes with average particle size distribution of about 100 nm, hence referred to here as nanoplexes.
- DOTA-NHSester 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid mono(N-hydroxysuccinimide ester)
- DOTA-NHSester 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid mono(N-hydroxysuccinimide ester)
- the amine modified RNA sense strand with a 100-fold molar excess of DOTA-NHS-ester in carbonate buffer (pH 9) was added to a microcentrifuge tube. The contents were reacted by stirring for 4 h at room temperature.
- the DOTA-RNAsense conjugate was ethanol-precipitated, resuspended in water, and annealed to the unmodified antisense strand to yield DOTA-siRNA.
- Tf-targeted and nontargeted siRNA particles may be formed by using cyclodextrin-containing polycations. Typically, particles were formed in water at a charge ratio of 3 (+/-) and an siRNA concentration of 0.5 g/liter. One percent of the adamantane-PEG molecules on the surface of the targeted particles were modified with Tf (adamantane-PEG-Tf). The particles were suspended in a 5% (wt/vol) glucose carrier solution for injection.
- RNA clinical trial that uses a targeted particle-delivery system (clinical trial registration number NCT00689065).
- Patients with solid cancers refractory to standard-of-care therapies are administered doses of targeted particles on days 1, 3, 8 and 10 of a 21-day cycle by a 30-min intravenous infusion.
- the particles comprise, consist essentially of, or consist of a synthetic delivery system containing: (1) a linear, cyclodextrin-based polymer (CDP), (2) a human transferrin protein (TF) targeting ligand displayed on the exterior of the nanoparticle to engage TF receptors (TFR) on the surface of the cancer cells, (3) a hydrophilic polymer (polyethylene glycol (PEG) used to promote nanoparticle stability in biological fluids), and (4) siRNA designed to reduce the expression of the RRM2 (sequence used in the clinic was previously denoted siR2B+5).
- CDP linear, cyclodextrin-based polymer
- TF human transferrin protein
- TFR TF receptors
- siRNA designed to reduce the expression of the RRM2 (sequence used in the clinic was previously denoted siR2B+5).
- the TFR has long been known to be upregulated in malignant cells, and RRM2 is an established anti-cancer target.
- nucleic acid-targeting system of the present invention Similar doses may also be contemplated for the nucleic acid-targeting system of the present invention.
- the delivery of the invention may be achieved with particles containing a linear, cyclodextrin-based polymer (CDP), a human transferrin protein (TF) targeting ligand displayed on the exterior of the particle to engage TF receptors (TFR) on the surface of the cancer cells and/or a hydrophilic polymer (for example, polyethylene glycol (PEG) used to promote particle stability in biological fluids).
- CDP linear, cyclodextrin-based polymer
- TF human transferrin protein
- TFR TF receptors
- hydrophilic polymer for example, polyethylene glycol (PEG) used to promote particle stability in biological fluids
- RNA-targeting complex e.g., nucleic acid-targeting effector (Cas13b) protein or mRNA therefor, or guide RNA or crRNA delivered using particles or lipid envelopes.
- Other delivery systems or vectors are may be used in conjunction with the particle aspects of the invention.
- Particles encompassed in the present invention may be provided in different forms, e.g., as solid particles (e.g., metal such as silver, gold, iron, titanium), non-metal, lipid-based solids, polymers), suspensions of particles, or combinations thereof.
- Metal, dielectric, and semiconductor particles may be prepared, as well as hybrid structures (e.g., core-shell particles).
- Particles made of semiconducting material may also be labeled quantum dots if they are small enough (typically sub 10 nm) that quantization of electronic energy levels occurs. Such nanoscale particles are used in biomedical applications as drug carriers or imaging agents and may be adapted for similar purposes in the present invention.
- a prototype particle of semi-solid nature is the liposome.
- Various types of liposome particles are currently used clinically as delivery systems for anticancer drugs and vaccines.
- Particles with one half hydrophilic and the other half hydrophobic are termed Janus particles and are particularly effective for stabilizing emulsions. They can self-assemble at water/oil interfaces and act as solid surfactants.
- US Patent No. 8,709,843 provides a drug delivery system for targeted delivery of therapeutic agent-containing particles to tissues, cells, and intracellular compartments.
- the invention provides targeted particles comprising polymer conjugated to a surfactant, hydrophilic polymer or lipid.
- US Patent No. 6,007,845 provides particles which have a core of a multiblock copolymer formed by covalently linking a multifunctional compound with one or more hydrophobic polymers and one or more hydrophilic polymers, and contain a biologically active material.
- 5,855,913 provides a particulate composition having aerodynamically light particles having a tap density of less than 0.4 g/cm3 with a mean diameter of between 5 ⁇ m and 30 ⁇ m, incorporating a surfactant on the surface thereof for drug delivery to the pulmonary system.
- US Patent No. 5,985,309 provides particles incorporating a surfactant and/or a hydrophilic or hydrophobic complex of a positively or negatively charged therapeutic or diagnostic agent and a charged molecule of opposite charge for delivery to the pulmonary system.
- US. Patent No. 5,543,158 provides biodegradable injectable particles having a biodegradable solid core containing a biologically active material and poly(alkylene glycol) moieties on the surface.
- conjugated polyethyleneimine (PEI) polymers and conjugated aza-macrocycles (collectively referred to as “conjugated lipomer” or “lipomers”).
- conjugated lipomers can be used in the context of the nucleic acid-targeting system to achieve in vitro, ex vivo and in vivo genomic perturbations to modify gene expression, including modulation of protein expression.
- Exosomes are endogenous nano-vesicles that transport RNAs and proteins, and which can deliver RNA to the brain and other target organs.
- Alvarez-Erviti et al. 2011, Nat Biotechnol 29: 341 ) used self-derived dendritic cells for exosome production.
- Targeting to the brain was achieved by engineering the dendritic cells to express Lamp2b, an exosomal membrane protein, fused to the neuron-specific RVG peptide. Purified exosomes were loaded with exogenous RNA by electroporation.
- RVG-targeted exosomes delivered GAPDH siRNA specifically to neurons, microglia, oligodendrocytes in the brain, resulting in a specific gene knockdown. Pre-exposure to RVG exosomes did not attenuate knockdown, and non-specific uptake in other tissues was not observed. The therapeutic potential of exosome-mediated siRNA delivery was demonstrated by the strong mRNA (60%) and protein (62%) knockdown of BACE1, a therapeutic target in Alzheimer's disease.
- Alvarez-Erviti et al. harvested bone marrow from inbred C57BL/6 mice with a homogenous major histocompatibility complex (MHC) haplotype.
- MHC major histocompatibility complex
- GM-CSF granulocyte/macrophage-colony stimulating factor
- the exosomes produced were physically homogenous, with a size distribution peaking at 80 nm in diameter as determined by particle tracking analysis (NTA) and electron microscopy.
- NTA particle tracking analysis
- Alvarez-Erviti et al. obtained 6-12 ⁇ g of exosomes (measured based on protein concentration) per 10 6 cells.
- Alvarez-Erviti et al. investigated the possibility of loading modified exosomes with exogenous cargoes using electroporation protocols adapted for nanoscale applications. As electroporation for membrane particles at the nanometer scale is not well-characterized, nonspecific Cy5-labeled RNA was used for the empirical optimization of the electroporation protocol.
- RNA The amount of encapsulated RNA was assayed after ultracentrifugation and lysis of exosomes. Electroporation at 400 V and 125 ⁇ F resulted in the greatest retention of RNA and was used for all subsequent experiments. Alvarez-Erviti et al.
- each BACE1 siRNA encapsulated in 150 ⁇ g of RVG exosomes administered 150 ⁇ g of each BACE1 siRNA encapsulated in 150 ⁇ g of RVG exosomes to normal C57BL/6 mice and compared the knockdown efficiency to four controls: untreated mice, mice injected with RVG exosomes only, mice injected with BACE1 siRNA complexed to an in vivo cationic liposome reagent and mice injected with BACE1 siRNA complexed to RVG-9R, the RVG peptide conjugated to 9 D-arginines that electrostatically binds to the siRNA.
- nucleic acid-targeting system of the present invention may be applied to deliver the nucleic acid-targeting system of the present invention to therapeutic targets, especially neurodegenerative diseases.
- a dosage of about 100 to 1000 mg of nucleic acid-targeting system encapsulated in about 100 to 1000 mg of RVG exosomes may be contemplated for the present invention.
- El-Andaloussi et al. provides exosomes derived from cultured cells harnessed for delivery of RNA in vitro and in vivo. This protocol first describes the generation of targeted exosomes through transfection of an expression vector, comprising an exosomal protein fused with a peptide ligand. Next, El-Andaloussi et al. explain how to purify and characterize exosomes from transfected cell supernatant. Next, E1-Andaloussi et al. detail crucial steps for loading RNA into exosomes. Finally, El-Andaloussi et al.
- Exosomes are nano-sized vesicles (30-90nm in size) produced by many cell types, including dendritic cells (DC), B cells, T cells, mast cells, epithelial cells and tumor cells. These vesicles are formed by inward budding of late endosomes and are then released to the extracellular environment upon fusion with the plasma membrane. Because exosomes naturally carry RNA between cells, this property may be useful in gene therapy, and from this disclosure can be employed in the practice of the instant invention.
- DC dendritic cells
- B cells B cells
- T cells T cells
- mast cells epithelial cells
- tumor cells epithelial cells
- Exosomes from plasma can be prepared by centrifugation of buffy coat at 900g for 20 min to isolate the plasma followed by harvesting cell supernatants, centrifuging at 300g for 10 min to eliminate cells and at 16 500g for 30 min followed by filtration through a 0.22 mm filter. Exosomes are pelleted by ultracentrifugation at 120 000g for70 min. Chemical transfection of siRNA into exosomes is carried out according to the manufacturer's instructions in RNAi Human/Mouse Starter Kit (Quiagen, Hilden, Germany). siRNA is added to 100 ml PBS at a final concentration of 2 mmol/ml. After adding HiPerFect transfection reagent, the mixture is incubated for 10 min at RT.
- exosomes are re-isolated using aldehyde/sulfate latex beads.
- the chemical transfection of nucleic acid-targeting system into exosomes may be conducted similarly to siRNA.
- the exosomes may be co-cultured with monocytes and lymphocytes isolated from the peripheral blood of healthy donors. Therefore, it may be contemplated that exosomes containing nucleic acid-targeting system may be introduced to monocytes and lymphocytes of and autologously reintroduced into a human. Accordingly, delivery or administration according to the invention may be performed using plasma exosomes.
- Liposomes are spherical vesicle structures composed of a uni- or multilamellar lipid bilayer surrounding internal aqueous compartments and a relatively impermeable outer lipophilic phospholipid bilayer. Liposomes have gained considerable attention as drug delivery carriers because they are biocompatible, nontoxic, can deliver both hydrophilic and lipophilic drug molecules, protect their cargo from degradation by plasma enzymes, and transport their load across biological membranes and the blood brain barrier (BBB) (see, e.g., Spuch and Navarro, Journal of Drug Delivery, vol. 2011, Article ID 469679, 12 pages, 2011. doi: 1 0.1155/2011/469679 for review).
- BBB blood brain barrier
- Liposomes can be made from several different types of lipids; however, phospholipids are most commonly used to generate liposomes as drug carriers. Although liposome formation is spontaneous when a lipid film is mixed with an aqueous solution, it can also be expedited by applying force in the form of shaking by using a homogenizer, sonicator, or an extrusion apparatus (see, e.g., Spuch and Navarro, Journal of Drug Delivery, vol. 2011, Article ID 469679, 12 pages, 2011. doi: 10.1155/2011/469679 for review).
- liposomes may be added to liposomes in order to modify their structure and properties.
- either cholesterol or sphingomyelin may be added to the liposomal mixture in order to help stabilize the liposomal structure and to prevent the leakage of the liposomal inner cargo.
- liposomes are prepared from hydrogenated egg phosphatidylcholine or egg phosphatidylcholine, cholesterol, and dicetyl phosphate, and their mean vesicle sizes were adjusted to about 50 and 100 nm. (see, e.g., Spuch and Navarro, Journal of Drug Delivery, vol. 2011, Article ID 469679, 12 pages, 2011. doi: 10.1155/2011/469679 for review).
- a liposome formulation may be mainly comprised of natural phospholipids and lipids such as 1,2-distearoryl-sn-glycero-3-phosphatidyl choline (DSPC), sphingomyelin, egg phosphatidylcholines and monosialoganglioside. Since this formulation is made up of phospholipids only, liposomal formulations have encountered many challenges, one of the ones being the instability in plasma. Several attempts to overcome these challenges have been made, specifically in the manipulation of the lipid membrane. One of these attempts focused on the manipulation of cholesterol.
- DSPC 1,2-distearoryl-sn-glycero-3-phosphatidyl choline
- the nucleic acid-targeting system or conmponents thereof may be administered in liposomes, such as a stable nucleic-acid-lipid particle (SNALP) (see, e.g., Morrissey et al., Nature Biotechnology, Vol. 23, No. 8, August 2005 ).
- SNALP stable nucleic-acid-lipid particle
- Daily intravenous injections of about 1, 3 or 5 mg/kg/day of a specific nucleic acid-targeting system targeted in a SNALP are contemplated.
- the daily treatment may be over about three days and then weekly for about five weeks.
- a specific nucleic acid-targeting system encapsulated SNALP administered by intravenous injection to at doses of about 1 or 2.5 mg/kg are also contemplated (see, e.g., Zimmerman et al., Nature Letters, Vol. 441, 4 May 2006 ).
- the SNALP formulation may contain the lipids 3-N-[(wmethoxypoly(ethylene glycol) 2000) carbamoyl] -1,2-dimyristyloxypropylamine (PEG-C-DMA), 1,2-dilinoleyloxy-N,N-dimethyl-3-aminopropane (DLinDMA), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and cholesterol, in a 2:40:10:48 molar per cent ratio (see, e.g., Zimmerman et al., Nature Letters, Vol. 441, 4 May 2006 ).
- SNALPs stable nucleic-acid-lipid particles
- the SNALP liposomes may be prepared by formulating D-Lin-DMA and PEG-C-DMA with distearoylphosphatidylcholine (DSPC), Cholesterol and siRNA using a 25:1 lipid/siRNA ratio and a 48/40/10/2 molar ratio of Cholesterol/D-Lin-DMA/DSPC/PEG-C-DMA.
- a SNALP may comprise synthetic cholesterol (Sigma-Aldrich, St Louis, MO, USA), dipalmitoylphosphatidylcholine (Avanti Polar Lipids, Alabaster, AL, USA), 3-N-[(w-methoxy poly(ethylene glycol)2000)carbamoyl]-1,2-dimyrestyloxypropylamine, and cationic 1,2-dilinoleyloxy-3-N,Ndimethylaminopropane (see, e.g., Geisbert et al., Lancet 2010; 375: 1896-905 ).
- a SNALP may comprise synthetic cholesterol (Sigma-Aldrich), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC; Avanti Polar Lipids Inc.), PEG-cDMA, and 1,2-dilinoleyloxy-3-(N;N-dimethyl)aminopropane (DLinDMA) (see, e.g., Judge, J. Clin. Invest. 119:661-673 (2009 )).
- Formulations used for in vivo studies may comprise a final lipid/RNA mass ratio of about 9:1.
- the stability profile of RNAi nanomedicines has been reviewed by Barros and Gollob of Alnylam Pharmaceuticals (see, e.g., Advanced Drug Delivery Reviews 64 (2012) 1730-1737 ).
- the stable nucleic acid lipid particle is comprised of four different lipids - an ionizable lipid (DLinDMA) that is cationic at low pH, a neutral helper lipid, cholesterol, and a diffusible polyethylene glycol (PEG)-lipid.
- the particle is approximately 80 nm in diameter and is chargeneutral at physiologic pH.
- the ionizable lipid serves to condense lipid with the anionic RNA during particle formation.
- the ionizable lipid When positively charged under increasingly acidic endosomal conditions, the ionizable lipid also mediates the fusion of SNALP with the endosomal membrane enabling release of RNA into the cytoplasm.
- the PEG-lipid stabilizes the particle and reduces aggregation during formulation, and subsequently provides a neutral hydrophilic exterior that improves pharmacokinetic properties.
- Tekmira Pharmaceuticals recently completed a phase I single-dose study of SNALP-ApoB in adult volunteers with elevated LDL cholesterol. ApoB is predominantly expressed in the liver and jejunum and is essential for the assembly and secretion of VLDL and LDL.
- FAP familial amyloidotic polyneuropathy
- FAC familial amyloidotic cardiomyopathy
- SSA senile systemic amyloidosis
- a SNALP may be made by solubilizing a cationic lipid, DSPC, cholesterol and PEG-lipid e.g., in ethanol, e.g., at a molar ratio of 40:10:40:10, respectively (see, Semple et al., Nature Niotechnology, Volume 28 Number 2 February 2010, pp. 172-177 ).
- the lipid mixture was added to an aqueous buffer (50 mM citrate, pH 4) with mixing to a final ethanol and lipid concentration of 30% (vol/vol) and 6.1 mg/ml, respectively, and allowed to equilibrate at 22 °C for 2 min before extrusion.
- the hydrated lipids were extruded through two stacked 80 nm pore-sized filters (Nuclepore) at 22 °C using a Lipex Extruder (Northern Lipids) until a vesicle diameter of 70-90 nm, as determined by dynamic light scattering analysis, was obtained. This generally required 1-3 passes.
- the siRNA (solubilized in a 50 mM citrate, pH 4 aqueous solution containing 30% ethanol) was added to the pre-equilibrated (35 °C) vesicles at a rate of ⁇ 5 ml/min with mixing.
- siRNA/lipid ratio 0.06 (wt/wt) was reached, the mixture was incubated for a further 30 min at 35 °C to allow vesicle reorganization and encapsulation of the siRNA.
- the ethanol was then removed and the external buffer replaced with PBS (155 mM NaCl, 3 mM Na 2 HPO 4 , 1 mM KH 2 PO 4 , pH 7.5) by either dialysis or tangential flow diafiltration.
- siRNA were encapsulated in SNALP using a controlled step-wise dilution method process.
- the lipid constituents of KC2-SNALP were DLin-KC2-DMA (cationic lipid), dipalmitoylphosphatidylcholine (DPPC; Avanti Polar Lipids), synthetic cholesterol (Sigma) and PEG-C-DMA used at a molar ratio of 57.1:7.1:34.3:1.4.
- SNALP were dialyzed against PBS and filter sterilized through a 0.2 ⁇ m filter before use.
- Mean particle sizes were 75-85 nm and 90-95% of the siRNA was encapsulated within the lipid particles.
- the final siRNA/lipid ratio in formulations used for in vivo testing was -0.15 (wt/wt).
- LNP-siRNA systems containing Factor VII siRNA were diluted to the appropriate concentrations in sterile PBS immediately before use and the formulations were administered intravenously through the lateral tail vein in a total volume of 10 ml/kg. This method and these delivery systems may be extrapolated to the nucleic acid-targeting system of the present invention.
- cationic lipids such as amino lipid 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA) may be utilized to encapsulate nucleic acid-targeting system or components thereof or nucleic acid molecule(s) coding therefor e.g., similar to SiRNA (see, e.g., Jayaraman, Angew. Chem. Int. Ed. 2012, 51, 8529 -8533 ), and hence may be employed in the practice of the invention.
- DLin-KC2-DMA amino lipid 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane
- a preformed vesicle with the following lipid composition may be contemplated: amino lipid, distearoylphosphatidylcholine (DSPC), cholesterol and (R)-2,3-bis(octadecyloxy) propyl-1-(methoxy poly(ethylene glycol)2000)propylcarbamate (PEG-lipid) in the molar ratio 40/10/40/10, respectively, and a FVII siRNA/total lipid ratio of approximately 0.05 (w/w).
- the particles may be extruded up to three times through 80 nm membranes prior to adding the guide RNA.
- Particles containing the highly potent amino lipid 16 may be used, in which the molar ratio of the four lipid components 16, DSPC, cholesterol and PEG-lipid (50/10/38.5/1.5) which may be further optimized to enhance in vivo activity.
- lipids may be formulated with the RNA-targeting system (CRISPR-Cas13b complex, i.e., the Cas13b complexed with crRNA) of the present invention or component(s) thereof or nucleic acid molecule(s) coding therefor to form lipid nanoparticles (LNPs).
- CRISPR-Cas13b complex i.e., the Cas13b complexed with crRNA
- LNPs lipid nanoparticles
- Lipids include, but are not limited to, DLin-KC2-DMA4, C12-200 and colipids disteroylphosphatidyl choline, cholesterol, and PEG-DMG may be formulated with RNA-targeting system instead of siRNA (see, e.g., Novobrantseva, Molecular Therapy-Nucleic Acids (2012) 1, e4; doi:10.1038/mtna.2011.3 ) using a spontaneous vesicle formation procedure.
- the component molar ratio may be about 50/10/38.5/1.5 (DLin-KC2-DMA or C12-200/disteroylphosphatidyl choline/cholesterol/PEG-DMG).
- the final lipid:siRNA weight ratio may be ⁇ 12:1 and 9:1 in the case of DLin-KC2-DMA and C12-200 lipid particles (LNPs), respectively.
- the formulations may have mean particle diameters of ⁇ 80 nm with >90% entrapment efficiency. A 3 mg/kg dose may be contemplated.
- Tekmira has a portfolio of approximately 95 patent families, in the U.S. and abroad, that are directed to various aspects of LNPs and LNP formulations (see, e.g., U.S. Pat. Nos.
- RNA-targeting system or components thereof or nucleic acid molecule(s) coding therefor may be delivered encapsulated in PLGA Microspheres such as that further described in US published applications 20130252281 and 20130245107 and 20130244279 (assigned to Moderna Therapeutics) which relate to aspects of formulation of compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor.
- the formulation may have a molar ratio 50:10:38.5:1.5-3.0 (cationic lipid:fusogenic lipid:cholesterol:PEG lipid).
- the PEG lipid may be selected from, but is not limited to PEG-c-DOMG, PEG-DMG.
- the fusogenic lipid may be DSPC. See also, Schrum et al., Delivery and Formulation of Engineered Nucleic Acids, US published application 20120251618 .
- Nanomerics' technology addresses bioavailability challenges for a broad range of therapeutics, including low molecular weight hydrophobic drugs, peptides, and nucleic acid based therapeutics (plasmid, siRNA, miRNA).
- Specific administration routes for which the technology has demonstrated clear advantages include the oral route, transport across the blood-brain-barrier, delivery to solid tumours, as well as to the eye. See, e.g., Mazza et al., 2013, ACS Nano. 2013 Feb 26;7(2): 1016-26 ; Uchegbu and Siew, 2013, J Pharm Sci. 102(2):305-10 and Lalatsa et al., 2012, J Control Release. 2012 Jul 20; 161(2):523-36 .
- US Patent Publication No. 20050019923 describes cationic dendrimers for delivering bioactive molecules, such as polynucleotide molecules, peptides and polypeptides and/or pharmaceutical agents, to a mammalian body.
- the dendrimers are suitable for targeting the delivery of the bioactive molecules to, for example, the liver, spleen, lung, kidney or heart (or even the brain).
- Dendrimers are synthetic 3-dimensional macromolecules that are prepared in a step-wise fashion from simple branched monomer units, the nature and functionality of which can be easily controlled and varied.
- Dendrimers are synthesized from the repeated addition of building blocks to a multifunctional core (divergent approach to synthesis), or towards a multifunctional core (convergent approach to synthesis) and each addition of a 3-dimensional shell of building blocks leads to the formation of a higher generation of the dendrimers.
- Polypropylenimine dendrimers start from a diaminobutane core to which is added twice the number of amino groups by a double Michael addition of acrylonitrile to the primary amines followed by the hydrogenation of the nitriles. This results in a doubling of the amino groups.
- Polypropylenimine dendrimers contain 100% protonable nitrogens and up to 64 terminal amino groups (generation 5, DAB 64).
- Protonable groups are usually amine groups which are able to accept protons at neutral pH.
- the use of dendrimers as gene delivery agents has largely focused on the use of the polyamidoamine. and phosphorous containing compounds with a mixture of amine/amide or N--P(O 2 )S as the conjugating units respectively with no work being reported on the use of the lower generation polypropylenimine dendrimers for gene delivery.
- Polypropylenimine dendrimers have also been studied as pH sensitive controlled release systems for drug delivery and for their encapsulation of guest molecules when chemically modified by peripheral amino acid groups. The cytotoxicity and interaction of polypropylenimine dendrimers with DNA as well as the transfection efficacy of DAB 64 has also been studied.
- cationic dendrimers such as polypropylenimine dendrimers
- display suitable properties such as specific targeting and low toxicity, for use in the targeted delivery of bioactive molecules, such as genetic material.
- derivatives of the cationic dendrimer also display suitable properties for the targeted delivery of bioactive molecules.
- Bioactive Polymers US published application 20080267903 , which discloses "Various polymers, including cationic polyamine polymers and dendrimeric polymers, are shown to possess anti-proliferative activity, and may therefore be useful for treatment of disorders characterised by undesirable cellular proliferation such as neoplasms and tumours, inflammatory disorders (including autoimmune disorders), psoriasis and atherosclerosis.
- the polymers may be used alone as active agents, or as delivery vehicles for other therapeutic agents, such as drug molecules or nucleic acids for gene therapy.
- the polymers' own intrinsic anti-tumour activity may complement the activity of the agent to be delivered."
- the disclosures of these patent publications may be employed in conjunction with herein teachings for delivery of nucleic acidtargetingsystem(s) or component(s) thereof or nucleic acid molecule(s) coding therefor.
- Supercharged proteins are a class of engineered or naturally occurring proteins with unusually high positive or negative net theoretical charge and may be employed in delivery of nucleic acid-targetingsystem(s) or component(s) thereof or nucleic acid molecule(s) coding therefor. Both supernegatively and superpositively charged proteins exhibit a remarkable ability to withstand thermally or chemically induced aggregation. Superpositively charged proteins are also able to penetrate mammalian cells. Associating cargo with these proteins, such as plasmid DNA, RNA, or other proteins, can enable the functional delivery of these macromolecules into mammalian cells both in vitro and in vivo. David Liu's lab reported the creation and characterization of supercharged proteins in 2007 ( Lawrence et al., 2007, Journal of the American Chemical Society 129, 10110-10112 ).
- RNA and plasmid DNA into mammalian cells are valuable both for research and therapeutic applications ( Akinc et al., 2010, Nat. Biotech. 26, 561-569 ).
- Purified +36 GFP protein (or other superpositively charged protein) is mixed with RNAs in the appropriate serum-free media and allowed to complex prior addition to cells. Inclusion of serum at this stage inhibits formation of the supercharged protein-RNA complexes and reduces the effectiveness of the treatment.
- the following protocol has been found to be effective for a variety of cell lines ( McNaughton et al., 2009, Proc. Natl. Acad. Sci. USA 106, 6111-6116 ).
- +36 GFP was found to be an effective plasmid delivery reagent in a range of cells. See also, e.g., McNaughton et al., Proc. Natl. Acad. Sci. USA 106, 6111-6116 (2009 ); Cronican et al., ACS Chemical Biology 5, 747-752 (2010 ); Cronican et al., Chemistry & Biology 18, 833-838 (2011 ); Thompson et al., Methods in Enzymology 503, 293-319 (2012 ); Thompson, D.B., et al., Chemistry & Biology 19 (7), 831-843 (2012 ).
- the methods of the super charged proteins may be used and/or adapted for delivery of the RNA-targeting system(s) or component(s) thereof or nucleic acid molecule(s) coding therefor of the invention.
- CPPs cell penetrating peptides
- CPPs are short peptides that facilitate cellular uptake of various molecular cargo (from nanosize particles to small chemical molecules and large fragments of DNA).
- the term "cargo" as used herein includes but is not limited to the group consisting of therapeutic agents, diagnostic probes, peptides, nucleic acids, antisense oligonucleotides, plasmids, proteins, particles including nanoparticles, liposomes, chromophores, small molecules and radioactive materials.
- the cargo may also comprise any component of the CRISPR Cas system or the entire functional CRISPR Cas system.
- aspects of the present invention further provide methods for delivering a desired cargo into a subject comprising: (a) preparing a complex comprising the cell penetrating peptide of the present invention and a desired cargo, and (b) orally, intraarticularly, intraperitoneally, intrathecally, intrarterially, intranasally, intraparenchymally, subcutaneously, intramuscularly, intravenously, dermally, intrarectally, or topically administering the complex to a subject.
- the cargo is associated with the peptides either through chemical linkage via covalent bonds or through non-covalent interactions.
- CPPs The function of the CPPs are to deliver the cargo into cells, a process that commonly occurs through endocytosis with the cargo delivered to the endosomes of living mammalian cells.
- Cell-penetrating peptides are of different sizes, amino acid sequences, and charges but all CPPs have one distinct characteristic, which is the ability to translocate the plasma membrane and facilitate the delivery of various molecular cargoes to the cytoplasm or an organelle.
- CPP translocation may be classified into three main entry mechanisms: direct penetration in the membrane, endocytosis-mediated entry, and translocation through the formation of a transitory structure.
- CPPs have found numerous applications in medicine as drug delivery agents in the treatment of different diseases including cancer and virus inhibitors, as well as contrast agents for cell labeling.
- CPPs hold great potential as in vitro and in vivo delivery vectors for use in research and medicine.
- CPPs typically have an amino acid composition that either contains a high relative abundance of positively charged amino acids such as lysine or arginine or has sequences that contain an alternating pattern of polar/charged amino acids and non-polar, hydrophobic amino acids. These two types of structures are referred to as polycationic or amphipathic, respectively.
- a third class of CPPs are the hydrophobic peptides, containing only apolar residues, with low net charge or have hydrophobic amino acid groups that are crucial for cellular uptake.
- US Patent 8,372,951 provides a CPP derived from eosinophil cationic protein (ECP) which exhibits highly cell-penetrating efficiency and low toxicity. Aspects of delivering the CPP with its cargo into a vertebrate subject are also provided. Further aspects of CPPs and their delivery are described in U. S. patents 8,575,305 ; 8;614,194 and 8,044,019. CPPs can be used to deliver the CRISPR-Cas system or components thereof.
- ECP eosinophil cationic protein
- CPPs can be employed to deliver the CRISPR-Cas system or components thereof is also provided in the manuscript " Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA", by Suresh Ramakrishna, Abu-Bonsrah Kwaku Dad, Jagadish Beloor, et al. Genome Res. 2014 Apr 2. [Epub ahead of print ], wherein it is demonstrated that treatment with CPP-conjugated recombinant Cas9 protein and CPP-complexed guide RNAs lead to endogenous gene disruptions in human cell lines.
- the Cas9 protein was conjugated to CPP via a thioether bond
- the guide RNA was complexed with CPP, forming condensed, positively charged particles. It was shown that simultaneous and sequential treatment of human cells, including embryonic stem cells, dermal fibroblasts, HEK293T cells, HeLa cells, and embryonic carcinoma cells, with the modified Cas9 and guide RNA led to efficient gene disruptions with reduced off-target mutations relative to plasmid transfections. CPP delivery can be used in the practice of the invention.
- implantable devices are also contemplated for delivery of the RNA-targeting system or component(s) thereof or nucleic acid molecule(s) coding therefor.
- US Patent Publication 20110195123 discloses an implantable medical device which elutes a drug locally and in prolonged period is provided, including several types of such a device, the treatment modes of implementation and methods of implantation.
- the device comprising of polymeric substrate, such as a matrix for example, that is used as the device body, and drugs, and in some cases additional scaffolding materials, such as metals or additional polymers, and materials to enhance visibility and imaging.
- An implantable delivery device can be advantageous in providing release locally and over a prolonged period, where drug is released directly to the extracellular matrix (ECM) of the diseased area such as tumor, inflammation, degeneration or for symptomatic objectives, or to injured smooth muscle cells, or for prevention.
- ECM extracellular matrix
- One kind of drug is RNA, as disclosed above, and this system may be used/and or adapted to the nucleic acid-targeting system of the present invention.
- the modes of implantation in some embodiments are existing implantation procedures that are developed and used today for other treatments, including brachytherapy and needle biopsy. In such cases the dimensions of the new implant described in this invention are similar to the original implant. Typically a few devices are implanted during the same treatment procedure.
- US Patent Publication 20110195123 provides a drug delivery implantable or insertable system, including systems applicable to a cavity such as the abdominal cavity and/or any other type of administration in which the drug delivery system is not anchored or attached, comprising a biostable and/or degradable and/or bioabsorbable polymeric substrate, which may for example optionally be a matrix. It should be noted that the term "insertion” also includes implantation.
- the drug delivery system is preferably implemented as a "Loder” as described in US Patent Publication 20110195123 .
- the polymer or plurality of polymers are biocompatible, incorporating an agent and/or plurality of agents, enabling the release of agent at a controlled rate, wherein the total volume of the polymeric substrate, such as a matrix for example, in some embodiments is optionally and preferably no greater than a maximum volume that permits a therapeutic level of the agent to be reached. As a non-limiting example, such a volume is preferably within the range of 0.1 m 3 to 1000 mm 3 , as required by the volume for the agent load.
- the Loder may optionally be larger, for example when incorporated with a device whose size is determined by functionality, for example and without limitation, a knee joint, an intra-uterine or cervical ring and the like.
- the drug delivery system (for delivering the composition) is designed in some embodiments to preferably employ degradable polymers, wherein the main release mechanism is bulk erosion; or in some embodiments, non degradable, or slowly degraded polymers are used, wherein the main release mechanism is diffusion rather than bulk erosion, so that the outer part functions as membrane, and its internal part functions as a drug reservoir, which practically is not affected by the surroundings for an extended period (for example from about a week to about a few months). Combinations of different polymers with different release mechanisms may also optionally be used.
- the concentration gradient at the surface is preferably maintained effectively constant during a significant period of the total drug releasing period, and therefore the diffusion rate is effectively constant (termed "zero mode" diffusion).
- the term “constant” it is meant a diffusion rate that is preferably maintained above the lower threshold of therapeutic effectiveness, but which may still optionally feature an initial burst and/or may fluctuate, for example increasing and decreasing to a certain degree.
- the diffusion rate is preferably so maintained for a prolonged period, and it can be considered constant to a certain level to optimize the therapeutically effective period, for example the effective silencing period.
- the drug delivery system optionally and preferably is designed to shield the nucleotide based therapeutic agent from degradation, whether chemical in nature or due to attack from enzymes and other factors in the body of the subject.
- US Patent Publication 20110195123 is optionally associated with sensing and/or activation appliances that are operated at and/or after implantation of the device, by non and/or minimally invasive methods of activation and/or acceleration/deceleration, for example optionally including but not limited to thermal heating and cooling, laser beams, and ultrasonic, including focused ultrasound and/or RF (radiofrequency) methods or devices.
- sensing and/or activation appliances that are operated at and/or after implantation of the device, by non and/or minimally invasive methods of activation and/or acceleration/deceleration, for example optionally including but not limited to thermal heating and cooling, laser beams, and ultrasonic, including focused ultrasound and/or RF (radiofrequency) methods or devices.
- RF radiofrequency
- the site for local delivery may optionally include target sites characterized by high abnormal proliferation of cells, and suppressed apoptosis, including tumors, active and or chronic inflammation and infection including autoimmune diseases states, degenerating tissue including muscle and nervous tissue, chronic pain, degenerative sites, and location of bone fractures and other wound locations for enhancement of regeneration of tissue, and injured cardiac, smooth and striated muscle.
- the site for implantation of the composition, or target site preferably features a radius, area and/or volume that is sufficiently small for targeted local delivery.
- the target site optionally has a diameter in a range of from about 0.1 mm to about 5 cm.
- the location of the target site is preferably selected for maximum therapeutic efficacy.
- the composition of the drug delivery system (optionally with a device for implantation as described above) is optionally and preferably implanted within or in the proximity of a tumor environment, or the blood supply associated thereof.
- the composition (optionally with the device) is optionally implanted within or in the proximity to pancreas, prostate, breast, liver, via the nipple, within the vascular system and so forth.
- the target location is optionally selected from the group comprising, consisting essentially of, or consisting of (as non-limiting examples only, as optionally any site within the body may be suitable for implanting a Loder): 1. brain at degenerative sites like in Parkinson or Alzheimer disease at the basal ganglia, white and gray matter; 2.
- ALS amyotrophic lateral sclerosis
- ALS amyotrophic lateral sclerosis
- HPV amyotrophic lateral sclerosis
- active and chronic inflammatory joints 5. dermis as in the case of psoriasis; 6. sympathetic and sensoric nervous sites for analgesic effect; 7.
- Intra osseous implantation 8. acute and chronic infection sites; 9.
- Intra vaginal 10. Inner ear--auditory system, labyrinth of the inner ear, vestibular system; 11. Intra tracheal; 12. Intra-cardiac; coronary, epicardiac; 13. urinary bladder; 14. biliary system; 15. parenchymal tissue including and not limited to the kidney, liver, spleen; 16. lymph nodes; 17. salivary glands; 18.
- dental gums 19. Intra-articular (into joints); 20. Intra-ocular; 21. Brain tissue; 22. Brain ventricles; 23. Cavities, including abdominal cavity (for example but without limitation, for ovary cancer); 24. Intra esophageal and 25. Intra rectal.
- insertion of the system is associated with injection of material to the ECM at the target site and the vicinity of that site to affect local pH and/or temperature and/or other biological factors affecting the diffusion of the drug and/or drug kinetics in the ECM, of the target site and the vicinity of such a site.
- the release of said agent could be associated with sensing and/or activation appliances that are operated prior and/or at and/or after insertion, by non and/or minimally invasive and/or else methods of activation and/or acceleration/deceleration, including laser beam, radiation, thermal heating and cooling, and ultrasonic, including focused ultrasound and/or RF (radiofrequency) methods or devices, and chemical activators.
- the drug preferably comprises a RNA, for example for localized cancer cases in breast, pancreas, brain, kidney, bladder, lung, and prostate as described below.
- RNAi many drugs are applicable to be encapsulated in Loder, and can be used in association with this invention, as long as such drugs can be encapsulated with the Loder substrate, such as a matrix for example, and this system may be used and/or adapted to deliver the nucleic acid-targeting system of the present invention.
- the Loder substrate such as a matrix for example
- this system may be used and/or adapted to deliver the nucleic acid-targeting system of the present invention.
- neuro and muscular degenerative diseases develop due to abnormal gene expression.
- Local delivery of RNAs may have therapeutic properties for interfering with such abnormal gene expression.
- Local delivery of anti apoptotic, anti inflammatory and anti degenerative drugs including small drugs and macromolecules may also optionally be therapeutic.
- the Loder is applied for prolonged release at constant rate and/or through a dedicated device that
- Implantable device technology herein discussed can be employed with herein teachings and hence by this disclosure and the knowledge in the art, CRISPR-Cas13b system or complex or components thereof or nucleic acid molecules thereof or encoding or providing components may be delivered via an implantable device.
- a nucleic acid-targeting system that targets RNA can be used to screen patients or patient samples for the presence of particular RNA.
- CRISPR effector (Cas13b) protein or mRNA therefor (or more generally a nucleuic acid molecule therefor) and guide RNA or crRNA might also be delivered separately e.g., the former 1-12 hours (preferably around 2-6 hours) prior to the administration of guide RNA or crRNA, or together.
- a second booster dose of guide RNA or crRNA can be administered 1-12 hours (preferably around 2-6 hours) after the initial administration.
- the Cas13b effector protein is sometimes referred to herein as a CRISPR Enzyme. It will be appreciated that the effector protein is based on or derived from an enzyme, so the term ⁇ effector protein' certainly includes 'enzyme' in some embodiments. However, it will also be appreciated that the effector protein may, as required in some embodiments, have DNA or RNA binding, but not necessarily cutting or nicking, activity, including a dead-Cas effector protein function.
- Cellular targets include Hemopoietic Stem/Progenitor Cells (CD34+); Human T cells; and Eye (retinal cells) - for example photoreceptor precursor cells.
- Inventive methods can further comprise delivery of templates.
- Delivery of templates may be via the cotemporaneous or separate from delivery of any or all the CRISPR effector protein (Cas13b) or guide or crRNA and via the same delivery mechanism or different.
- CRISPR effector protein Cas13b
- a CRISPR effector (Cas 13n) protein may form a component of an inducible system.
- the inducible nature of the system would allow for spatiotemporal control of gene editing or gene expression using a form of energy.
- the form of energy may include but is not limited to electromagnetic radiation, sound energy, chemical energy and thermal energy.
- inducible system include tetracycline inducible promoters (Tet-On or Tet-Off), small molecule two-hybrid transcription activations systems (FKBP, ABA, etc), or light inducible systems (Phytochrome, LOV domains, or cryptochrome).
- the CRISPR effector protein may be a part of a Light Inducible Transcriptional Effector (LITE) to direct changes in transcriptional activity in a sequence-specific manner.
- the components of a light may include a CRISPR effector protein, a light-responsive cytochrome heterodimer (e.g. from Arabidopsis thaliana), and a transcriptional activation/repression domain.
- LITE Light Inducible Transcriptional Effector
- RNA in a cell Once all copies of RNA in a cell have been edited, continued a Cas13b effector protein expression or activity in that cell is no longer necessary.
- a Self-Inactivating system that relies on the use of RNA as to the Cas13b or crRNA as the guide target sequence can shut down the system by preventing expression of Cas13b or complex formation.
- kits containing any one or more of the elements disclosed in the above methods and compositions comprising a vector system as taught herein or one or more of the components of the CRISPR/Cas13b system or complex as taught herein, such as crRNAs and/or Cas13b effector protein or Cas13b effector protein encoding mRNA, and instructions for using the kit.
- Elements may be provide individually or in combinations, and may be provided in any suitable container, such as a vial, a bottle, or a tube.
- the kit described but not claimed herein includes instructions in one or more languages, for example in more than one language. The instructions may be specific to the applications and methods described herein.
- the kit described but not claimed herein comprises one or more reagents for use in a process utilizing one or more of the elements described herein.
- Reagents may be provided in any suitable container.
- a kit may provide one or more reaction or storage buffers.
- Reagents may be provided in a form that is usable in a particular assay, or in a form that requires addition of one or more other components before use (e.g., in concentrate or lyophilized form).
- a buffer can be any buffer, including but not limited to a sodium carbonate buffer, a sodium bicarbonate buffer, a borate buffer, a Tris buffer, a MOPS buffer, a HEPES buffer, and combinations thereof.
- the buffer may be alkaline.
- the buffer may have a pH from about 7 to about 10.
- the kit described but not claimed herein may comprise one or more oligonucleotides corresponding to a guide sequence for insertion into a vector so as to operably link the guide or crRNA sequence and a regulatory element.
- the kit may comprise a homologous recombination template polynucleotide.
- the kit may comprise one or more of the vectors and/or one or more of the polynucleotides described herein.
- the kit may advantageously allows to provide all elements of the systems of the invention.
- the invention has a broad spectrum of applications in, e.g., gene therapy, drug screening, disease diagnosis, and prognosis.
- polynucleotide refers to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof.
- Polynucleotides may have any three dimensional structure, and may perform any function, known or unknown.
- polynucleotides coding or non-coding regions of a gene or gene fragment, loci (locus) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, short interfering RNA (siRNA), short-hairpin RNA (shRNA), micro-RNA (miRNA), ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers.
- loci locus defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, short interfering RNA (siRNA), short-hairpin RNA (shRNA), micro-RNA (miRNA), ribozymes, cDNA, recombinant polynucleotides, branched poly
- a polynucleotide may comprise one or more modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer.
- the sequence of nucleotides may be interrupted by non-nucleotide components.
- a polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component.
- wild type is a term of the art understood by skilled persons and means the typical form of an organism, strain, gene or characteristic as it occurs in nature as distinguished from mutant or variant forms.
- a "wild type” can be a base line.
- variant should be taken to mean the exhibition of qualities that have a pattern that deviates from what occurs in nature.
- non-naturally occurring or “engineered” are used interchangeably and indicate the involvement of the hand of man.
- nucleic acid molecules or polypeptides mean that the nucleic acid molecule or the polypeptide is at least substantially free from at least one other component with which they are naturally associated in nature and as found in nature.
- “Complementarity” refers to the ability of a nucleic acid to form hydrogen bond(s) with another nucleic acid sequence by either traditional Watson-Crick base pairing or other non-traditional types.
- a percent complementarity indicates the percentage of residues in a nucleic acid molecule which can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, 10 out of 10 being 50%, 60%, 70%, 80%, 90%, and 100% complementary).
- Perfectly complementary means that all the contiguous residues of a nucleic acid sequence will hydrogen bond with the same number of contiguous residues in a second nucleic acid sequence.
- substantially complementary refers to a degree of complementarity that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% over a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, or more nucleotides, or refers to two nucleic acids that hybridize under stringent conditions.
- stringent conditions for hybridization refer to conditions under which a nucleic acid having complementarity to a target sequence predominantly hybridizes with the target sequence, and substantially does not hybridize to non-target sequences. Stringent conditions are generally sequence-dependent, and vary depending on a number of factors. In general, the longer the sequence, the higher the temperature at which the sequence specifically hybridizes to its target sequence. Non-limiting examples of stringent conditions are described in detail in Tijssen (1993), Laboratory Techniques In Biochemistry And Molecular Biology-Hybridization With Nucleic Acid Probes Part I, Second Chapter “Overview of principles of hybridization and the strategy of nucleic acid probe assay", Elsevier, N.Y .
- complementary or partially complementary sequences are also envisaged. These are preferably capable of hybridizing to the reference sequence under highly stringent conditions.
- relatively low-stringency hybridization conditions are selected: about 20 to 25° C lower than the thermal melting point (T m ).
- T m is the temperature at which 50% of specific target sequence hybridizes to a perfectly complementary probe in solution at a defined ionic strength and pH.
- highly stringent washing conditions are selected to be about 5 to 15° C lower than the T m .
- moderately-stringent washing conditions are selected to be about 15 to 30° C lower than the T m .
- Highly permissive (very low stringency) washing conditions may be as low as 50° C below the T m , allowing a high level of mis-matching between hybridized sequences.
- Other physical and chemical parameters in the hybridization and wash stages can also be altered to affect the outcome of a detectable hybridization signal from a specific level of homology between target and probe sequences.
- Preferred highly stringent conditions comprise incubation in 50% formamide, 5 ⁇ SSC, and 1% SDS at 42° C, or incubation in 5 ⁇ SSC and 1% SDS at 65° C, with wash in 0.2 ⁇ SSC and 0.1% SDS at 65° C.
- “Hybridization” refers to a reaction in which one or more polynucleotides react to form a complex that is stabilized via hydrogen bonding between the bases of the nucleotide residues. The hydrogen bonding may occur by Watson Crick base pairing, Hoogstein binding, or in any other sequence specific manner.
- the complex may comprise two strands forming a duplex structure, three or more strands forming a multi stranded complex, a single self-hybridizing strand, or any combination of these.
- a hybridization reaction may constitute a step in a more extensive process, such as the initiation of PCR, or the cleavage of a polynucleotide by an enzyme.
- a sequence capable of hybridizing with a given sequence is referred to as the "complement" of the given sequence.
- the term "genomic locus” or “locus” is the specific location of a gene or DNA sequence on a chromosome.
- a “gene” refers to stretches of DNA or RNA that encode a polypeptide or an RNA chain that has functional role to play in an organism and hence is the molecular unit of heredity in living organisms.
- genes include regions which regulate the production of the gene product, whether or not such regulatory sequences are adjacent to coding and/or transcribed sequences.
- a gene includes, but is not necessarily limited to, promoter sequences, terminators, translational regulatory sequences such as ribosome binding sites and internal ribosome entry sites, enhancers, silencers, insulators, boundary elements, replication origins, matrix attachment sites and locus control regions.
- expression of a genomic locus or “gene expression” is the process by which information from a gene is used in the synthesis of a functional gene product.
- the products of gene expression are often proteins, but in non-protein coding genes such as rRNA genes or tRNA genes, the product is functional RNA.
- the process of gene expression is used by all known life - eukaryotes (including multicellular organisms), prokaryotes (bacteria and archaea) and viruses to generate functional products to survive.
- expression of a gene or nucleic acid encompasses not only cellular gene expression, but also the transcription and translation of nucleic acid(s) in cloning systems and in any other context.
- expression also refers to the process by which a polynucleotide is transcribed from a DNA template (such as into and mRNA or other RNA transcript) and/or the process by which a transcribed mRNA is subsequently translated into peptides, polypeptides, or proteins. Transcripts and encoded polypeptides may be collectively referred to as "gene product.” If the polynucleotide is derived from genomic DNA, expression may include splicing of the mRNA in a eukaryotic cell.
- polypeptide polypeptide
- peptide and “protein” are used interchangeably herein to refer to polymers of amino acids of any length.
- the polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids.
- the terms also encompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component.
- amino acid includes natural and/or unnatural or synthetic amino acids, including glycine and both the D or L optical isomers, and amino acid analogs and peptidomimetics.
- domain or “protein domain” refers to a part of a protein sequence that may exist and function independently of the rest of the protein chain.
- sequence identity is related to sequence homology.
- Homology comparisons may be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs may calculate percent (%) homology between two or more sequences and may also calculate the sequence identity shared by two or more amino acid or nucleic acid sequences.
- wild type is a term of the art understood by skilled persons and means the typical form of an organism, strain, gene or characteristic as it occurs in nature as distinguished from mutant or variant forms.
- a "wild type” can be a base line.
- nucleic acid molecules or polypeptides mean that the nucleic acid molecule or the polypeptide is at least substantially free from at least one other component with which they are naturally associated in nature and as found in nature. In all aspects and embodiments, whether they include these terms or not, it will be understood that, preferably, the may be optional and thus preferably included or not preferably not included.
- non-naturally occurring and “engineered” may be used interchangeably and so can therefore be used alone or in combination and one or other may replace mention of both together.
- engineered is preferred in place of “non-naturally occurring” or “non-naturally occurring and/or engineered.”
- Sequence homologies may be generated by any of a number of computer programs known in the art, for example BLAST or FASTA, etc.
- a suitable computer program for carrying out such an alignment is the GCG Wisconsin Bestfit package (University of Wisconsin, U.S.A; Devereux et al., 1984, Nucleic Acids Research 12:387 ).
- Examples of other software than may perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel et al., 1999 ibid - Chapter 18), FASTA ( Atschul et al., 1990, J. Mol. Biol., 403-410 ) and the GENEWORKS suite of comparison tools.
- BLAST and FASTA are available for offline and online searching (see Ausubel et al., 1999 ibid, pages 7-58 to 7-60). However it is preferred to use the GCG Bestfit program. Percentage (%) sequence homology may be calculated over contiguous sequences, i.e., one sequence is aligned with the other sequence and each amino acid or nucleotide in one sequence is directly compared with the corresponding amino acid or nucleotide in the other sequence, one residue at a time. This is called an "ungapped" alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues.
- the default gap penalty for amino acid sequences is -12 for a gap and -4 for each extension. Calculation of maximum % homology therefore first requires the production of an optimal alignment, taking into consideration gap penalties.
- a suitable computer program for carrying out such an alignment is the GCG Wisconsin Bestfit package ( Devereux et al., 1984 Nuc. Acids Research 12 p387 ). Examples of other software than may perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel et al., 1999 Short Protocols in Molecular Biology, 4th Ed. - Chapter 18 ), FASTA ( Altschul et al., 1990 J. Mol. Biol. 403-410 ) and the GENEWORKS suite of comparison tools.
- BLAST and FASTA are available for offline and online searching (see Ausubel et al., 1999, Short Protocols in Molecular Biology, pages 7-58 to 7-60 ). However, for some applications, it is preferred to use the GCG Bestfit program.
- a new tool, called BLAST 2 Sequences is also available for comparing protein and nucleotide sequences (see FEMS Microbiol Lett. 1999 174(2): 247-50 ; FEMS Microbiol Lett. 1999 177(1): 187-8 and the website of the National Center for Biotechnology information at the website of the National Institutes for Health). Although the final % homology may be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pair comparison.
- a scaled similarity score matrix is generally used that assigns scores to each pair-wise comparison based on chemical similarity or evolutionary distance.
- An example of such a matrix commonly used is the BLOSUM62 matrix - the default matrix for the BLAST suite of programs.
- GCG Wisconsin programs generally use either the public default values or a custom symbol comparison table, if supplied (see user manual for further details). For some applications, it is preferred to use the public default values for the GCG package, or in the case of other software, the default matrix, such as BLOSUM62.
- percentage homologies may be calculated using the multiple alignment feature in DNASIS TM (Hitachi Software), based on an algorithm, analogous to CLUSTAL ( Higgins DG & Sharp PM (1988), Gene 73(1), 237-244 ).
- % homology preferably % sequence identity.
- the software typically does this as part of the sequence comparison and generates a numerical result.
- the sequences may also have deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent substance.
- Deliberate amino acid substitutions may be made on the basis of similarity in amino acid properties (such as polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues) and it is therefore useful to group amino acids together in functional groups.
- Amino acids may be grouped together based on the properties of their side chains alone. However, it is more useful to include mutation data as well.
- the sets of amino acids thus derived are likely to be conserved for structural reasons. These sets may be described in the form of a Venn diagram ( Livingstone C.D. and Barton G.J. (1993) "Protein sequence alignments: a strategy for the hierarchical analysis of residue conservation" Comput. Appl. Biosci.
- subject means a vertebrate, preferably a mammal, more preferably a human.
- Mammals include, but are not limited to, murines, simians, humans, farm animals, sport animals, and pets. Tissues, cells and their progeny of a biological entity obtained in vivo or cultured in vitro are also encompassed.
- therapeutic agent refers to a molecule or compound that confers some beneficial effect upon administration to a subject.
- the beneficial effect includes enablement of diagnostic determinations; amelioration of a disease, symptom, disorder, or pathological condition; reducing or preventing the onset of a disease, symptom, disorder or condition; and generally counteracting a disease, symptom, disorder or pathological condition.
- treatment or “treating,” or “palliating” or “ameliorating” are used interchangeably. These terms refer to an approach for obtaining beneficial or desired results including but not limited to a therapeutic benefit and/or a prophylactic benefit.
- compositions may be administered to a subject at risk of developing a particular disease, condition, or symptom, or to a subject reporting one or more of the physiological symptoms of a disease, even though the disease, condition, or symptom may not have yet been manifested.
- effective amount or “therapeutically effective amount” refers to the amount of an agent that is sufficient to effect beneficial or desired results.
- the therapeutically effective amount may vary depending upon one or more of: the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art.
- the term also applies to a dose that will provide an image for detection by any one of the imaging methods described herein.
- the specific dose may vary depending on one or more of: the particular agent chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to be imaged, and the physical delivery system in which it is carried.
- Vectors can be designed for expression of CRISPR transcripts (e.g. nucleic acid transcripts, proteins, or enzymes) in prokaryotic or eukaryotic cells.
- CRISPR transcripts can be expressed in bacterial cells such as Escherichia coli, insect cells (using baculovirus expression vectors), yeast cells, or mammalian cells.
- telomeres Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990 ).
- the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.
- Embodiments of the invention include sequences (both polynucleotide or polypeptide) which may comprise homologous substitution (substitution and replacement are both used herein to mean the interchange of an existing amino acid residue or nucleotide, with an alternative residue or nucleotide) that may occur i.e., like-for-like substitution in the case of amino acids such as basic for basic, acidic for acidic, polar for polar, etc.
- Non-homologous substitution may also occur i.e., from one class of residue to another or alternatively involving the inclusion of unnatural amino acids such as ornithine (hereinafter referred to as Z), diaminobutyric acid ornithine (hereinafter referred to as B), norleucine ornithine (hereinafter referred to as O), pyriylalanine, thienylalanine, naphthylalanine and phenylglycine.
- Z ornithine
- B diaminobutyric acid ornithine
- O norleucine ornithine
- pyriylalanine pyriylalanine
- thienylalanine thienylalanine
- naphthylalanine phenylglycine
- Variant amino acid sequences may include suitable spacer groups that may be inserted between any two amino acid residues of the sequence including alkyl groups such as methyl, ethyl or propyl groups in addition to amino acid spacers such as glycine or ⁇ -alanine residues.
- alkyl groups such as methyl, ethyl or propyl groups
- amino acid spacers such as glycine or ⁇ -alanine residues.
- a further form of variation which involves the presence of one or more amino acid residues in peptoid form, may be well understood by those skilled in the art.
- the peptoid form is used to refer to variant amino acid residues wherein the ⁇ -carbon substituent group is on the residue's nitrogen atom rather than the ⁇ -carbon.
- PrePPI a structure based PPI prediction method, combines structural evidence with non-structural evidence using a Bayesian statistical framework.
- the method involves taking a pair a query proteins and using structural alignment to identify structural representatives that correspond to either their experimentally determined structures or homology models. Structural alignment is further used to identify both close and remote structural neighbors by considering global and local geometric relationships. Whenever two neighbors of the structural representatives form a complex reported in the Protein Data Bank, this defines a template for modelling the interaction between the two query proteins. Models of the complex are created by superimposing the representative structures on their corresponding structural neighbor in the template. This approach is further described in Dey et al., 2013 (Prot Sci; 22: 359-66 ).
- amplification means any method employing a primer and a polymerase capable of replicating a target sequence with reasonable fidelity.
- Amplification may be carried out by natural or recombinant DNA polymerases such as TaqGold TM , T7 DNA polymerase, Klenow fragment of E.coli DNA polymerase, and reverse transcriptase.
- a preferred amplification method is PCR.
- the invention involves vectors.
- a "vector" is a tool that allows or facilitates the transfer of an entity from one environment to another. It is a replicon, such as a plasmid, phage, or cosmid, into which another DNA segment may be inserted so as to bring about the replication of the inserted segment.
- a vector is capable of replication when associated with the proper control elements.
- the term "vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
- Vectors include, but are not limited to, nucleic acid molecules that are single-stranded, double-stranded, or partially double-stranded; nucleic acid molecules that comprise one or more free ends, no free ends (e.g., circular); nucleic acid molecules that comprise DNA, RNA, or both; and other varieties of polynucleotides known in the art.
- vector refers to a circular double stranded DNA loop into which additional DNA segments can be inserted, such as by standard molecular cloning techniques.
- viral vector wherein virally-derived DNA or RNA sequences are present in the vector for packaging into a virus (e.g., retroviruses, replication defective retroviruses, adenoviruses, replication defective adenoviruses, and adeno-associated viruses (AAVs)).
- viruses e.g., retroviruses, replication defective retroviruses, adenoviruses, replication defective adenoviruses, and adeno-associated viruses (AAVs).
- Viral vectors also include polynucleotides carried by a virus for transfection into a host cell.
- vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as "expression vectors.” Common expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.
- Recombinant expression vectors can comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory elements, which may be selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed.
- "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory element(s) in a manner that allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).
- aspects of the invention relate to bicistronic vectors for guide RNA and wild type, modified or mutated CRISPR effector proteins/enzymes (e.g. Cas13b effector proteins).
- Bicistronic expression vectors guide RNA and wild type, modified or mutated CRISPR effector proteins/enzymes (e.g. Cas13b effector proteins) are preferred.
- modified or mutated CRISPR effector proteins/enzymes is preferably driven by the CBh promoter.
- the RNA may preferably be driven by a Pol III promoter, such as a U6 promoter. Ideally the two are combined.
- a loop in the guide RNA or crRNA is provided.
- This may be a stem loop or a tetra loop.
- the loop is preferably GAAA, but it is not limited to this sequence or indeed to being only 4bp in length.
- preferred loop forming sequences for use in hairpin structures are four nucleotides in length, and most preferably have the sequence GAAA.
- longer or shorter loop sequences may be used, as may alternative sequences.
- the sequences preferably include a nucleotide triplet (for example, AAA), and an additional nucleotide (for example C or G). Examples of loop forming sequences include CAAA and AAAG.
- a suitable vector can be introduced to a cell or an embryo via one or more methods known in the art, including without limitation, microinjection, electroporation, sonoporation, biolistics, calcium phosphate-mediated transfection, cationic transfection, liposome transfection, dendrimer transfection, heat shock transfection, nucleofection transfection, magnetofection, lipofection, impalefection, optical transfection, proprietary agent-enhanced uptake of nucleic acids, and delivery via liposomes, immunoliposomes, virosomes, or artificial virions.
- the vector is introduced into an embryo by microinjection.
- the vector or vectors may be microinjected into the nucleus or the cytoplasm of the embryo.
- the vector or vectors may be introduced into a cell by nucleofection.
- CRISPR transcripts e.g., nucleic acid transcripts, proteins, or enzymes
- CRISPR transcripts can be expressed in bacterial cells such as Escherichia coli, insect cells (using baculovirus expression vectors), yeast cells, or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990 ).
- the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.
- Vectors may be introduced and propagated in a prokaryote or prokaryotic cell.
- a prokaryote is used to amplify copies of a vector to be introduced into a eukaryotic cell or as an intermediate vector in the production of a vector to be introduced into a eukaryotic cell (e.g., amplifying a plasmid as part of a viral vector packaging system).
- a prokaryote is used to amplify copies of a vector and express one or more nucleic acids, such as to provide a source of one or more proteins for delivery to a host cell or host organism.
- Fusion vectors add a number of amino acids to a protein encoded therein, such as to the amino terminus of the recombinant protein.
- Such fusion vectors may serve one or more purposes, such as: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification.
- a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein.
- Such enzymes, and their cognate recognition sequences include Factor Xa, thrombin and enterokinase.
- Example fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988.
- GST glutathione S-transferase
- suitable inducible non-fusion E. coli expression vectors include pTrc ( Amrann et al., (1988) Gene 69:301-315 ) and pET 11d ( Studier et al., GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89 ).
- a vector is a yeast expression vector.
- yeast expression vectors for expression in yeast Saccharomyces cerivisae include pYepSec1 ( Baldari, et al., 1987. EMBO J. 6: 229-234 ), pMFa ( Kuijan and Herskowitz, 1982. Cell 30: 933-943 ), pJRY88 ( Schultz et al., 1987. Gene 54: 113-123 ), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (InVitrogen Corp, San Diego, Calif.).
- a vector drives protein expression in insect cells using baculovirus expression vectors.
- Baculovirus vectors available for expression of proteins in cultured insect cells include the pAc series ( Smith, et al., 1983. Mol. Cell. Biol. 3: 2156-2165 ) and the pVL series ( Lucklow and Summers, 1989. Virology 170: 31-39 ).
- a vector is capable of driving expression of one or more sequences in mammalian cells using a mammalian expression vector.
- mammalian expression vectors include pCDM8 ( Seed, 1987. Nature 329: 840 ) and pMT2PC ( Kaufman, et al., 1987. EMBO J. 6: 187-195 ).
- the expression vector's control functions are typically provided by one or more regulatory elements.
- promoters are derived from polyoma, adenovirus 2, cytomegalovirus, simian virus 40, and others disclosed herein and known in the art.
- suitable expression systems for both prokaryotic and eukaryotic cells see, e.g., Chapters 16 and 17 of Sambrook, et al., MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989 .
- the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid).
- tissue-specific regulatory elements are known in the art.
- suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, et al., 1987. Genes Dev. 1: 268-277 ), lymphoid-specific promoters ( Calame and Eaton, 1988. Adv. Immunol. 43: 235-275 ), in particular promoters of T cell receptors ( Winoto and Baltimore, 1989. EMBO J.
- a regulatory element is operably linked to one or more elements of or encoding a CRISPR Cas13b system or complex so as to drive expression of the one or more elements of the CRISPR system.
- CRISPRs Clustered Regularly Interspaced Short Palindromic Repeats
- SPIDRs Sacer Interspersed Direct Repeats
- the CRISPR locus comprises a distinct class of interspersed short sequence repeats (SSRs) that were recognized in E . coli ( Ishino et al., J. Bacteriol., 169:5429-5433 [1987] ; and Nakata et al., J.
- the CRISPR loci typically differ from other SSRs by the structure of the repeats, which have been termed short regularly spaced repeats (SRSRs) ( Janssen et al., OMICS J. Integ. Biol., 6:23-33 [2002] ; and Mojica et al., Mol. Microbiol., 36:244-246 [2000] ).
- SRSRs short regularly spaced repeats
- the repeats are short elements that occur in clusters that are regularly spaced by unique intervening sequences with a substantially constant length (Mojica et al., [2000], supra).
- CRISPR loci have been identified in more than 40 prokaryotes (See e.g., Jansen et al., Mol.
- RNA-targeting system refers collectively to transcripts and other elements involved in the expression of or directing the activity of RNA-targeting CRISPR-associated 13b (“Cas13b") genes (also referred to herein as an effector protein), including sequences encoding a RNA-targeting Cas (effector) protein and a guide RNA (or crRNA sequence), with reference to Table 1 as herein discussed.
- Cas13b RNA-targeting CRISPR-associated 13b
- a RNA-targeting system is characterized by elements that promote the formation of a RNA-targeting complex at the site of a target sequence.
- target sequence refers to a RNA sequence to which a guide sequence (or the guide or of the crRNA) is designed to have complementarity, where hybridization between a target sequence and a guide RNA promotes the formation of a RNA-targeting complex. Full complementarity is not necessarily required, provided there is sufficient complementarity to cause hybridization and promote formation of a RNA-targeting complex.
- a target sequence is located in the nucleus or cytoplasm of a cell. In some embodiments, the target sequence may be within an organelle of a eukaryotic cell.
- a sequence or template that may be used for recombination into the targeted locus comprising the target sequences is referred to as an "editing template” or “editing RNA” or “editing sequence”.
- an exogenous template RNA may be referred to as an editing template.
- the recombination is homologous recombination.
- a guide sequence is any polynucleotide sequence having sufficient complementarity with a target polynucleotide sequence to hybridize with the target sequence and direct sequence-specific binding of a nucleic acid-targeting complex to the target sequence.
- the degree of complementarity between a guide sequence and its corresponding target sequence when optimally aligned using a suitable alignment algorithm, is about or more than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or more.
- Optimal alignment may be determined with the use of any suitable algorithm for aligning sequences, non-limiting example of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler Transform (e.g.
- a guide sequence is about or more than about 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75, or more nucleotides in length. In some embodiments, a guide sequence is less than about 75, 50, 45, 40, 35, 30, 25, 20, 15, 12, or fewer nucleotides in length.
- a template polynucleotide may be of any suitable length, such as about or more than about 10, 15, 20, 25, 50, 75, 100, 150, 200, 500, 1000, or more nucleotides in length.
- the template polynucleotide is complementary to a portion of a polynucleotide comprising the target sequence.
- a template polynucleotide might overlap with one or more nucleotides of a target sequences (e.g.
- the nearest nucleotide of the template polynucleotide is within about 1, 5, 10, 15, 20, 25, 50, 75, 100, 200, 300, 400, 500, 1000, 5000, 10000, or more nucleotides from the target sequence.
- the RNA-targeting effector protein is part of a fusion protein comprising one or more heterologous protein domains (e.g., about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more domains in addition to the nucleic acid-targeting effector protein).
- the CRISPR Cas13b effector protein/enzyme is part of a fusion protein comprising one or more heterologous protein domains (e.g. about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more domains in addition to the CRISPR Cas13b enzyme).
- epitope tags include histidine (His) tags, V5 tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags.
- reporter genes include, but are not limited to, glutathione-S-transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT) beta-galactosidase, beta-glucuronidase, luciferase, green fluorescent protein (GFP), HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), and autofluorescent proteins including blue fluorescent protein (BFP).
- GST glutathione-S-transferase
- HRP horseradish peroxidase
- CAT chloramphenicol acetyltransferase
- beta-galactosidase beta-galactosidase
- beta-glucuronidase beta-galactosidase
- luciferase green fluorescent protein
- GFP green fluorescent protein
- HcRed HcRed
- DsRed cyan fluorescent protein
- a nucleic acid-targeting effector protein may be fused to a gene sequence encoding a protein or a fragment of a protein that bind DNA molecules or bind other cellular molecules, including but not limited to maltose binding protein (MBP), S-tag, Lex A DNA binding domain (DBD) fusions, GAL4 DNA binding domain fusions, and herpes simplex virus (HSV) BP16 protein fusions. Additional domains that may form part of a fusion protein comprising a nucleic acid-targeting effector protein are described in US20110059502 . In some embodiments, a tagged nucleic acid-targeting effector protein is used to identify the location of a target sequence.
- MBP maltose binding protein
- DBD Lex A DNA binding domain
- HSV herpes simplex virus
- a CRISPR Cas13b enzyme may form a component of an inducible system.
- the inducible nature of the system would allow for spatiotemporal control of gene editing or gene expression using a form of energy.
- the form of energy may include but is not limited to electromagnetic radiation, sound energy, chemical energy and thermal energy.
- inducible system include tetracycline inducible promoters (Tet-On or Tet-Off), small molecule two-hybrid transcription activations systems (FKBP, ABA, etc), or light inducible systems (Phytochrome, LOV domains, or cryptochrome).
- the CRISPR Cas13b enzyme may be a part of a Light Inducible Transcriptional Effector (LITE) to direct changes in transcriptional activity in a sequence-specific manner.
- the components of a light may include a CRISPR enzyme, a light-responsive cytochrome heterodimer (e.g. from Arabidopsis thaliana), and a transcriptional activation/repression domain.
- LITE Light Inducible Transcriptional Effector
- the invention provides methods comprising delivering one or more polynucleotides, such as or one or more vectors as described herein, one or more transcripts thereof, and/or one or proteins transcribed therefrom, to a host cell.
- the invention further provides cells produced by such methods, and organisms (such as animals, plants, or fungi) comprising or produced from such cells.
- a RNA-targeting effector protein in combination with (and optionally complexed with) a guide RNA or crRNA is delivered to a cell.
- Conventional viral and non-viral based gene transfer methods can be used to introduce nucleic acids in mammalian cells or target tissues.
- Non-viral vector delivery systems include DNA plasmids, RNA (e.g. a transcript of a vector described herein), naked nucleic acid, and nucleic acid complexed with a delivery vehicle, such as a liposome.
- Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell.
- Methods of non-viral delivery of nucleic acids include lipofection, nucleofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, polycation or lipid:nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA.
- Lipofection is described in e.g., U.S. Pat. Nos. 5,049,386 , 4,946,787 ; and 4,897,355 ) and lipofection reagents are sold commercially (e.g., Transfectam TM and Lipofectin TM ).
- Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides include those of Felgner, WO 91/17424 ; WO 91/16024 . Delivery can be to cells (e.g. in vitro or ex vivo administration) or target tissues (e.g. in vivo administration).
- a method of the invention may be used to create a plant, an animal or cell that may be used to model and/or study genetic or epigenetic conditions of interest, such as a through a model of mutations of interest or a disease model.
- disease refers to a disease, disorder, or indication in a subject.
- a method of the invention may be used to create an animal or cell that comprises a modification in one or more nucleic acid sequences associated with a disease, or a plant, animal or cell in which expression of one or more nucleic acid sequences associated with a disease are altered.
- Such a nucleic acid sequence may encode or be translated a disease associated protein sequence or may be a disease associated control sequence.
- a plant, subject, patient, organism or cell can be a non-human subject, patient, organism or cell.
- the invention provides a plant, animal or cell, produced by the present methods, or a progeny thereof.
- the progeny may be a clone of the produced plant or animal, or may result from sexual reproduction by crossing with other individuals of the same species to introgress further desirable traits into their offspring.
- the cell may be in vivo or ex vivo in the cases of multicellular organisms, particularly animals or plants. In the instance where the cell is in cultured, a cell line may be established if appropriate culturing conditions are met and preferably if the cell is suitably adapted for this purpose (for instance a stem cell).
- Bacterial cell lines produced by the invention are also envisaged.
- cell lines are also envisaged.
- the disease model can be used to study the effects of mutations, or more general altered, such as reduced, expression of genes or gene products on the animal or cell and development and/or progression of the disease using measures commonly used in the study of the disease.
- a disease model is useful for studying the effect of a pharmaceutically active compound on the disease.
- the disease model can be used to assess the efficacy of a potential gene therapy strategy. That is, a disease-associated RNA can be modified such that the disease development and/or progression is displayed or inhibited or reduced and then effects of a compound on the progression or inhibition or reduction are tested.
- association is used here in relation to the association of the functional domain to the Cas13b effector protein or the adaptor protein. It is used in respect of how one molecule ⁇ associates' with respect to another, for example between an adaptor protein and a functional domain, or between the Cas13b effector protein and a functional domain. In the case of such protein-protein interactions, this association may be viewed in terms of recognition in the way an antibody recognizes an epitope.
- one protein may be associated with another protein via a fusion of the two, for instance one subunit being fused to another subunit. Fusion typically occurs by addition of the amino acid sequence of one to that of the other, for instance via splicing together of the nucleotide sequences that encode each protein or subunit.
- the fusion protein may include a linker between the two subunits of interest (i.e. between the enzyme and the functional domain or between the adaptor protein and the functional domain).
- the Cas13b effector protein or adaptor protein is associated with a functional domain by binding thereto.
- the Cas13b effector protein or adaptor protein is associated with a functional domain because the two are fused together, optionally via an intermediate linker.
- the invention in some embodiments comprehends a method of modifying an cell or organism.
- the cell may be a prokaryotic cell or a eukaryotic cell.
- the cell may be a mammalian cell.
- the mammalian cell many be a non-human primate, bovine, porcine, rodent or mouse cell.
- the cell may be a non-mammalian eukaryotic cell such as poultry, fish or shrimp.
- the cell may also be a plant cell.
- the plant cell may be of a crop plant such as cassava, corn, sorghum, wheat, or rice.
- the plant cell may also be of an algae, tree or vegetable.
- the modification introduced to the cell by the present invention may be such that the cell and progeny of the cell are altered for improved production of biologic products such as an antibody, starch, alcohol or other desired cellular output.
- the modification introduced to the cell by the present invention may be such that the cell and progeny of the cell include an alteration that changes the biologic product produced.
- the system may comprise one or more different vectors.
- the effector protein is codon optimized for expression the desired cell type, preferentially a eukaryotic cell, preferably a mammalian cell or a human cell.
- Cas13b system(s) (e.g., single or multiplexed) can be used in conjunction with recent advances in crop genomics.
- Such CRISPR system(s) can be used to perform efficient and cost effective plant gene or genome or transcriptome interrogation or editing or manipulation-for instance, for rapid investigation and/or selection and/or interrogations and/or comparison and/or manipulations and/or transformation of plant genes or genomes; e.g., to create, identify, develop, optimize, or confer trait(s) or characteristic(s) to plant(s) or to transform a plant genome. There can accordingly be improved production of plants, new plants with new combinations of traits or characteristics or new plants with enhanced traits.
- Such CRISPR system(s) can be used with regard to plants in Site-Directed Integration (SDI) or Gene Editing (GE) or any Near Reverse Breeding (NRB) or Reverse Breeding (RB) techniques.
- animal cells may also apply, mutatis mutandis, to plant cells unless otherwise apparent; and, the enzymes herein having reduced off-target effects and systems employing such enzymes can be used in plant applciations, including those mentioned herein.
- the system of the invention can be applied in areas of former RNA cutting technologies, without undue experimentation, from this disclosure, including therapeutic, assay and other applications, because the present application provides the foundation for informed engineering of the system.
- the present invention provides for therapeutic treatment of a disease caused by overexpression of RNA, toxic RNA and/or mutated RNA (such as, for example, splicing defects or truncations).
- RNA toxic RNA
- mutated RNA such as, for example, splicing defects or truncations
- Expression of the toxic RNA may be associated with formation of nuclear inclusions and late-onset degenerative changes in brain, heart or skeletal muscle. In the best studied example, myotonic dystrophy, it appears that the main pathogenic effect of the toxic RNA is to sequester binding proteins and compromise the regulation of alternative splicing ( Hum. Mol. Genet.
- DM dystrophia myotonica
- the innate immune system detects viral infection primarily by recognizing viral nucleic acids inside an infected cell, referred to as DNA or RNA sensing.
- In vitro RNA sensing assays can be used to detect specific RNA substrates.
- the RNA targeting effector protein can for instance be used for RNA-based sensing in living cells. Examples of applications are diagnostics by sensing of, for examples, disease-specific RNAs.
- the RNA targeting effector protein (Table 1 Cas13b) of the invention can further be used for antiviral activity, in particular against RNA viruses.
- the effector protein (Table 1 Cas13b) can be targeted to the viral RNA using a suitable guide RNA selective for a selected viral RNA sequence.
- the effector protein may be an active nuclease that cleaves RNA, such as single stranded RNA.
- Therapeutic dosages of the enzyme system of the present invention to target RNA the above-referenced RNAs are contemplated to be about 0.1 to about 2 mg/kg the dosages may be administered sequentially with a monitored response, and repeated dosages if necessary, up to about 7 to 10 doses per patient.
- samples are collected from each patient during the treatment regimen to ascertain the effectiveness of treatment. For example, RNA samples may be isolated and quantified to determine if expression is reduced or ameliorated. Such a diagnostic is within the purview of one of skill in the art.
- the effector proteins (Table 1 Cas13b) and systems of the invention are useful for specific detection of RNAs in a cell or other sample.
- guide-dependent Cas13b nuclease activity may be accompanied by non-specific RNAse activity against collateral targets.
- a reporter substrate that can be detectably cleaved.
- a reporter molecule can comprise RNA, tagged with a fluorescent reporter molecule (fluor) on one end and a quencher on the other. In the absence of Cas13b RNase activity, the physical proximity of the quencher dampens fluorescence from the fluor to low levels.
- RNA-containing reporter molecule When Cas13b target specific cleavge is activated by the presence of an RNA target-of-interest and suitable guide RNA, the RNA-containing reporter molecule is non-specifically cleaved and the fluor and quencher are spatially separated. This causes the fluor to emit a detectable signal when excited by light of the appropriate wavelength.
- Cas13b effector, target-of-interest-specific guide RNA, and reporter molecule are added to a cellular sample. An increase in fluorescence indicates the presence of the RNA target-of-interes.
- a detection array is provided. Each location of the array is provided with Cas13b effector, reporter molecule, and a target-of-interest-specific guide RNA.
- the target-of-interest-specific guide RNAs at each location of the array can be the same, different, or a combination thereof. Different target-of-interest-specific guide RNAs might be provided, for example when it is desired to test for one or more targets in a single source sample. The same target-of-interest-specific guide RNA might be provided at each location, for example when it is desired to test multiple samples for the same target.
- Cas13b is provided or expressed in an in vitro system or in a cell, transiently or stably, and targeted or triggered to non-specifically cleave cellular nucleic acids.
- Cas13b is engineered to knock down ssDNA, for example viral ssDNA.
- Cas13b is engineered to knock down RNA. The system can be devised such that the knockdown is dependent on a target DNA present in the cell or in vitro system, or triggered by the addition of a target nucleic acid to the system or cell.
- the Cas13b system is engineered to non-specifically cleave RNA in a subset of cells distinguishable by the presence of an aberrant DNA sequence, for instance where cleavage of the aberrant DNA might be incomplete or ineffectual.
- a DNA translocation that is present in a cancer cell and drives cell transformation is targeted. Whereas a subpopulation of cells that undergoes chromosomal DNA and repair may survive, non-specific collateral ribonuclease activity advantageously leads to cell death of potential survivors.
- SHERLOCK highly sensitive and specific nucleic acid detection platform
- engineered Cas13b systems are optimized for RNA endonuclease activity and can be expressed in mammalian cells and targeted to effectively knock down reporter molecules or transcripts in cells.
- the collateral effect of engineered Cas13b with isothermal amplification provides a CRISPR-based diagnostic providing rapid DNA or RNA detection with high sensitivity and single-base mismatch specificity.
- the Cas13b-based molecular detection platform is used to detect specific strains of virus, distinguish pathogenic bacteria, genotype human DNA, and identify cell-free tumor DNA mutations.
- reaction reagents can be lyophilized for cold-chain independence and long-term storage, and readily reconstituted on paper for field applications.
- the ability to rapidly detect nucleic acids with high sensitivity and single-base specificity on a portable platform may aid in disease diagnosis and monitoring, epidemiology, and general laboratory tasks. Although methods exist for detecting nucleic acids, they have trade-offs among sensitivity, specificity, simplicity, cost, and speed.
- Cas13b can be reprogrammed with CRISPR RNAs (crRNAs) to provide a platform for specific DNA sensing. Upon recognition of its DNA target, activated Cas 13b engages in "collateral" cleavage of nearby non-targeted nucleic acids (i.e., RNA and/or ssDNA).
- This crRNA-programmed collateral cleavage activity allows Cas13b to detect the presence of a specific DNA in vivo by triggering programmed cell death or by nonspecific degradation of labeled RNA or ssDNA.
- an in vitro nucleic acid detection platform with high sensitivity based on nucleic acid amplification and Cas13b-mediated collateral cleavage of a commercial reporter RNA, allowing for real-time detection of the target.
- the Cas13b effector protein is from an organism identified in Table 1. In certain example embodiments, the Cas13b effector protein is from an organism selected from Bergeyella zoohelcum, Prevotella intermedia, Prevotella buccae, Porphyromonas gingivalis, Bacteroides pyogenes, Alistipes sp. ZOR0009, Prevotella sp. MA2016, Riemerella anatipestifer, Prevotella aurantiaca, Prevotella saccharolytica, Myroides odoratimimus CCUG 10230, Capnocytophaga canimorsus, Porphyromonas gulae, Prevotella sp.
- the one or more guide RNAs are designed to bind to one or more target RNA sequences that are diagnostic for a disease state.
- an RNA-based masking construct suppresses generation of a detectable positive signal, or the RNA-based masking construct suppresses generation of a detectable positive signal by masking the detectable positive signal, or generating a detectable negative signal instead, or the RNA-based masking construct comprises a silencing RNA that suppresses generation of a gene product encoded by a reporting construct, wherein the gene product generates the detectable positive signal when expressed.
- the RNA-based masking construct is a ribozyme that generates a negative detectable signal, and wherein the positive detectable signal is generated when the ribozyme is deactivated.
- the ribozyme converts a substrate to a first color and wherein the substrate converts to a second color when the ribozyme is deactivated.
- the RNA-based masking agent is an aptamer that sequesters an enzyme, wherein the enzyme generates a detectable signal upon release from the aptamer by acting upon a substrate, or the aptamer sequesters a pair of agents that when released from the aptamers combine to generate a detectable signal.
- the RNA-based masking construct comprises an RNA oligonucleotide to which are attached a detectable ligand oligonucleotide and a masking component.
- the detectable ligand is a fluorophore and the masking component is a quencher molecule.
- the invention provides a method for detecting target RNAs in samples, comprising: distributing a sample or set of samples into one or more individual discrete volumes, the individual discrete volumes comprising a CRISPR system comprising an effector protein, one or more guide RNAs, an RNA-based masking construct; incubating the sample or set of samples under conditions sufficient to allow binding of the one or more guide RNAs to one or more target molecules; activating the CRISPR effector protein via binding of the one or more guide RNAs to the one or more target molecules, wherein activating the CRISPR effector protein results in modification of the RNA-based masking construct such that a detectable positive signal is produced; and detecting the detectable positive signal, wherein detection of the detectable positive signal indicates a presence of one or more target molecules in the sample.
- the invention provides a method for detecting peptides in samples, comprising: distributing a sample or set of samples into a set of individual discrete volumes, the individual discrete volumes comprising peptide detection aptamers, a CRISPR system comprising an effector protein, one or more guide RNAs, an RNA-based masking construct, wherein the peptide detection aptamers comprising a masked RNA polymerase site and configured to bind one or more target molecules; incubating the sample or set of samples under conditions sufficient to allow binding of the peptide detection aptamers to the one or more target molecules, wherein binding of the aptamer to a corresponding target molecule exposes the RNA polymerase binding site resulting in RNA synthesis of a trigger RNA; activating the CRISPR effector protein via binding of the one or more guide RNAs to the trigger RNA, wherein activating the CRISPR effector protein results in modification of the RNA-based masking construct such that a detectable positive signal is
- the one or more guide RNAs are designed to bind to one or more target molecules that are diagnostic for a disease state.
- the disease state is an infection, an organ disease, a blood disease, an immune system disease, a cancer, a brain and nervous system disease, an endocrine disease, a pregnancy or childbirth-related disease, an inherited disease, or an environmentally-acquired disease, cancer, or a fungal infection, a bacterial infection, a parasite infection, or a viral infection.
- the RNA-based masking construct suppresses generation of a detectable positive signal
- the RNA-based masking construct suppresses generation of a detectable positive signal by masking the detectable positive signal, or generating a detectable negative signal instead
- the RNA-based masking construct comprises a silencing RNA that suppresses generation of a gene product encoded by a reporting construct, wherein the gene product generates the detectable positive signal when expressed, or the RNA-based masking construct is a ribozyme that generates the negative detectable signal, and wherein the positive detectable signal is generated when the ribozyme is inactivated.
- the ribozyme converts a substrate to a first state and wherein the substrate converts to a second state when the ribozyme is inactivated, or the RNA-based masking agent is an aptamer, or the aptamer sequesters an enzyme, wherein the enzyme generates a detectable signal upon release from the aptamer by acting upon a substrate, or the aptamer sequesters a pair of agents that when released from the aptamers combine to generate a detectable signal.
- the RNA-based masking construct comprises an RNA oligonucleotide with a detectable ligand on a first end of the RNA oligonucleotide and a masking component on a second end of the RNA oligonucleotide, or the detectable ligand is a fluorophore and the masking component is a quencher molecule.
- Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing Shengdar Q. Tsai, Nicolas Wyvekens, Cyd Khayter, Jennifer A. Foden, Vishal Thapar, Deepak Reyon, Mathew J. Goodwin, Martin J. Aryee, J. Keith Joung Nature Biotechnology 32(6): 569-77 (2014 ), relates to dimeric RNA-guided FokI Nucleases that recognize extended sequences and can edit endogenous genes with high efficiencies in human cells.
- Cas9 protein and sgRNA were mixed together at a suitable, e.g., 3:1 to 1:3 or 2:1 to 1:2 or 1:1 molar ratio, at a suitable temperature, e.g., 15-30C, e.g., 20-25C, e.g., room temperature, for a suitable time, e.g., 15-45, such as 30 minutes, advantageously in sterile, nuclease free buffer, e.g., 1X PBS.
- particle components such as or comprising: a surfactant, e.g., cationic lipid, e.g., 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP); phospholipid, e.g., dimyristoylphosphatidylcholine (DMPC); biodegradable polymer, such as an ethylene-glycol polymer or PEG, and a lipoprotein, such as a low-density lipoprotein, e.g., cholesterol were dissolved in an alcohol, advantageously a C 1-6 alkyl alcohol, such as methanol, ethanol, isopropanol, e.g., 100% ethanol.
- a surfactant e.g., cationic lipid, e.g., 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP); phospholipid, e.g., dimyristoylphosphatidylcholine (DMPC); biodegrad
- sgRNA may be pre-complexed with the Cas9 protein, before formulating the entire complex in a particle.
- Formulations may be made with a different molar ratio of different components known to promote delivery of nucleic acids into cells (e.g.
- DOTAP 1,2-dioleoyl-3-trimethylammonium-propane
- DMPC 1,2-ditetradecanoyl-sn-glycero-3-phosphocholine
- PEG polyethylene glycol
- cholesterol 1,2-dioleoyl-3-trimethylammonium-propane
- DMPC 1,2-ditetradecanoyl-sn-glycero-3-phosphocholine
- PEG polyethylene glycol
- cholesterol cholesterol
- aspects of the instant invention can involve particles; for example, particles using a process analogous to that of the Particle Delivery PCT, e.g., by admixing a mixture comprising crRNA and/or Cas13b as in the instant invention and components that form a particle, e.g., as in the Particle Delivery PCT, to form a particle and particles from such admixing (or, of course, other particles involving crRNA and/or Cas13b as in the instant invention).
- Cas13b proteins shown in Table 1 below are advantageously from codon optimization for expression in mammalian cells. Fusion constructs of each of the Cas13b orthologues with mCherry and optionally NLS or NES are made and cloned in a mammalian expression vector. The various Cas13b orthologues are transfected in HEK293 T cells and cellular localization is evaluated based on mCherry expression. Localizations of different Cas13b orthologues fused to a C-terminal and N-terminal NES, fused to a C-terminal and N-terminal NLS, or without NES or NLS fusion are determined. NES fusions efficiently result in cytoplasmic localization of the Cas13b protein.
- NLS fusions efficiently result in nuclear localization of the Cas13b protein. Variably, also nucleolar localization can be observed with NLS fusions.
- TABLE 1A Sinomicrob ium oceani WP_07 231947 6.1 Prevotella intermedia 12 Porphyrom onas gingivalis 19 A2033_102 05 [Bacteroide tes bacterium GWA2_31 _ _9] OFX18 020.1 SAMN054 21542_066 6 [Chryseoba cterium jejuense] SDI272 89.1 SAMN054 44360_113 66 [Chryseoba cterium carnipullor um] SHM52 812.1 SAMN054 21786_101 1119 [Chryseoba cterium ureilyticum ] SIS704 81.1 Reichenbac hiella agariperfor ans WP_07 312444 1.1 TABLE 1B Bergeyella zoo
- Prevotella sp. MA2016 7a Prevotella sp. MA2016 7b Riemerella anatipestife r 8
- Prevotella aurantiaca 9 Prevotella saccharolyt ica 10 HMPREF9 712_03108 [Myroides odoratimim us CCUG 10230] 11 Capnocyto phaga canimorsus 13 Porphyrom onas gulae 14 Prevotella sp. P5-125 15
- Flavobacter ium branchioph ilum 16 Myroides odoratimim us 17
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Detergent Compositions (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
Claims (16)
- Nicht-natürlich vorkommende oder künstlich hergestellte Zusammensetzung, umfassendi) ein Cas13b-Effektorprotein aus dem Bakterium Bacteroidetes GWA2_31_9 von Tabelle 1A, optional umfassend eine oder mehrere Mutationen und aufweisend eine Sequenzidentität von wenigstens 90% mit einem Cas13b-Effektorprotein aus dem Bakterium Bacteroidetes GWA2_31_9 von Tabelle 1A, undii) eine crRNA,wobei die crRNA a) eine Guide-Sequenz, die in der Lage ist eine Ziel-RNA-Sequenz zu hybridisieren, und b) eine Direct-Repeat(Direktwiederholungseinheit)-Sequenz umfasst,die in der Lage ist, einen CRISPR-Komplex zu bilden, der das Cas13b-Effektorprotein komplexiert mit der Guide-Sequenz, die in der Lage ist die Ziel-RNA-Sequenz zu hybridisieren, umfasst, und die optional ein akzessorisches Protein umfasst, das die Aktivität des Cas13b-Effektorproteins verstärkt, wobei das akzessorische Protein, das die Aktivität des Cas13b-Effektorproteins verstärkt, vorzugsweise ein csx28-Protein ist, oder die ein akzessorisches Protein umfasst, das die Aktivität des Cas13b-Effektorproteins unterdrückt, wobei das akzessorische Protein, das die Aktivität des Cas13b-Effektorproteins unterdrückt, vorzugsweise ein csx27-Protein ist.
- Nicht-natürlich vorkommende oder künstlich hergestellte Zusammensetzung nach Anspruch 1, wobei das Cas13b-Effektorprotein mit einer oder mehreren funktionellen Domänen assoziiert ist, wobei optional die funktionelle Domäne die Ziel-RNA-Sequenz spaltet oder wobei die funktionelle Domäne die Translation der Ziel-RNA-Sequenz modifiziert.
- Zusammensetzung nach Anspruch 1, wobei das Cas13b-Effektorprotein mit einer oder mehreren funktionellen Domänen assoziiert ist; und das Effektorprotein eine oder mehrere Mutationen innerhalb einer HEPN-Domäne enthält, wodurch der Komplex ein epigenetisches Modifikator- oder ein translationales Aktivations- oder Repressionssignal abgeben kann.
- Cas13b-Vektorsystem zum Bereitstellen der Zusammensetzung nach Anspruch 1, das einen oder mehrere Vektoren umfasst, umfassend:ein erstes regulatorisches Element, das mit einer Nukleotidsequenz funktionsfähig verknüpft ist, die ein Cas13b-Effektorprotein aus dem Bakterium Bacteroidetes GWA2_31_9 von Tabelle 1A codiert, das optional eine oder mehrere Mutationen umfasst und eine Sequenzidentität von wenigstens 90% mit einem Cas13b-Effektorprotein aus dem Bakterium Bacteroidetes GWA2_31_9 von Tabelle 1A aufweist und in der Lage ist, einen CRISPR-Komplex zu bilden, der das Cas13b-Effektorprotein komplexiert mit einer Guide-Sequenz umfasst, die in der Lage ist an eine Ziel-RNA-Sequenz zu hybridisieren, undein zweites regulatorisches Element, das mit einer Nukleotidsequenz funktionsfähig verknüpft ist, die die crRNA codiert, wobei optional die Nukleotidsequenz, die das Cas13b-Effektorprotein codiert, für die Expression in einer eukaryotischen Zelle codonoptimiert ist.
- Vektorsystem nach Anspruch 4, das ferner umfasst:
ein regulatorisches Element, das mit einer Nukleotidsequenz eines akzessorischen Proteins funktionsfähig verknüpft ist. - Vektorsystem nach Anspruch 4, wobei der eine oder die mehreren Vektoren Virusvektoren umfassen, wobei optional der eine oder die mehreren Vektoren einen oder mehrere retrovirale, lentivirale, adenovirale, adenoassoziierte oder Herpes-simplex-Virusvektoren umfassen.
- Zuführungssystem, das konfiguriert ist zum Zuführen eines Cas13b-Effektorproteins und einer oder mehrerer Nukleinsäurekomponenten einer nicht-natürlich vorkommenden oder künstlich hergestellten Zusammensetzung, umfassendi) Cas13b-Effektorprotein aus dem Bakterium Bacteroidetes GWA2_31_9 von Tabelle 1A, optional umfassend eine oder mehrere Mutationen und aufweisend eine Sequenzidentität von wenigstens 90% mit einem Cas13b-Effektorprotein aus dem Bakterium Bacteroidetes GWA2_31_9 von Tabelle 1A, undii) eine crRNA,wobei die crRNA a) eine Guide-Sequenz, die in der Lage ist an eine Ziel-RNA-Sequenz in einer Zelle zu hybridisieren, und b) eine Direct-Repeat-Sequenz umfasst,wobei das Cas13b-Effektorprotein die in der Lage isteines Komplexes mit der crRNA zu bilden, wobei die Guide-Sequenz in der Lage ist, die sequenzspezifische Bindung an die Ziel-RNA-Sequenz zu steuern,die in der Lage ist, einen CRISPR-Komplex zu bilden, der das Cas13b-Effektorprotein komplexiert mit der Guide-Sequenz, die in der Lage ist an die Ziel-RNA-Sequenz zu hybridisieren, umfasst.
- Zuführungssystem nach Anspruch 7, das einen oder mehrere Vektoren oder ein oder mehrere Polynukleotidmoleküle umfasst, wobei der eine oder die mehreren Vektoren oder das eine oder die mehreren Polynukleotidmoleküle, ein oder mehrere Polynukleotidmoleküle, die das Cas13b-Effektorprotein codieren, und eine oder mehrere Nukleinsäurekomponenten der nicht-natürlich vorkommenden oder künstlich hergestellten Zusammensetzung umfassen.
- Zuführungssystem nach Anspruch 7, das ein Zuführungssvehikel umfasst, das ein oder mehrere Liposom(en), Partikel(n), Exosom(en), Mikrovesikel, eine Genkanone oder ein oder mehrere Virusvektor(en) umfasst.
- Nicht-natürlich vorkommende oder künstlich hergestellte Zusammensetzung nach Anspruch 1 bis 3, Vektorsystem nach Anspruch 4 bis 6 oder Zuführungssystem nach Anspruch 7 bis 9 zur Verwendung in einem therapeutischen Behandlungsverfahren.
- In-vitro oder Ex-vivo-Verfahren zum Modifizieren der Expression eines interessierenden Zielgens, wobei das Verfahren das Inkontaktbringen einer Ziel-RNA mit einer oder mehreren nicht-natürlich vorkommenden oder künstlich hergestellten Zusammensetzungen umfasst, umfassendi) ein Cas13b-Effektorprotein aus dem Bakterium Bacteroidetes GWA2_31_9 von Tabelle 1A, optional umfassend eine oder mehrere Mutationen und aufweisend eine Sequenzidentität von wenigstens 90% mit einem Cas13b-Effektorprotein aus dem Bakterium Bacteroidetes GWA2_31_9 von Tabelle 1A, undii) eine crRNA,wobei die crRNA a) eine Guide-Sequenz, die in der Lage ist an eine Ziel-RNA-Sequenz in einer Zelle zu hybridisieren, und b) eine Direct-Repeat-Sequenz umfasst,wobei das Cas13b-Effektorprotein in der Lage ist eines Komplexes mit der crRNA zu bilden,wobei die Guide-Sequenz in der Lage ist, die sequenzspezifische Bindung an die Ziel-RNA-Sequenz in einer Zelle zu steuern,wodurch ein CRISPR-Komplex gebildet wird, der das Cas13b-Effektorprotein komplexiert mit der Guide-Sequenz, die in der Lage ist an die Ziel-RNA-Sequenz zu hybridisieren, umfasst,wodurch die Expression des interessierenden Ziellokus modifiziert wird, welches ferner optional das Inkontaktbringen der Ziel-RNA mit einem akzessorischen Protein umfasst, das die Aktivität des Cas13b-Effektorproteins verstärkt, wobei das akzessorische Protein, das die Aktivität des Cas13b-Effektorproteins verstärkt, vorzugsweise ein csx28-Protein ist, oder welches ferner das Inkontaktbringen der Ziel-RNA mit einem akzessorischen Protein umfasst, das die Aktivität des Cas13b-Effektorproteins unterdrückt, wobei das akzessorische Protein, das die Aktivität des Cas13b-Effektorproteins unterdrückt, vorzugsweise ein csx27-Protein ist,wobei es sich bei dem Verfahren nicht um ein Verfahren zum Modifizieren der genetischen Keimbahnidentität von Menschen handelt.
- Verfahren nach Anspruch 11, wobei das Modifizieren der Expression des Zielgens das Spalten der Ziel-RNA oder das Modifizieren von Spleißen, Transport, Lokalisierung, Translation oder Umsatz der Ziel-RNA umfasst.
- Isolierte Nukleinsäure, die ein Cas13b-Effektorprotein aus dem Bakterium Bacteroidetes GWA2_31_9 von Tabelle 1A codiert, die optional eine oder mehrere Mutationen umfasst und ein Cas13b-Effektorprotein codiert, das eine Sequenzidentität von wenigstens 90% mit einem Cas13b-Effektorprotein aus dem Bakterium Bacteroidetes GWA2_31_9 von Tabelle 1A aufweist und in der Lage ist, einen CRISPR-Komplex zu bilden, der das Cas13b-Effektorprotein komplexiert mit einer Guide-Sequenz, die in der Lage istan eine Ziel-RNA-Sequenz zu hybridisieren, umfasst, bei der es sich um eine DNA handelt und die ferner eine Sequenz, die eine crRNA codiert, umfasst.
- Isolierte eukaryotische Zelle, umfassend ein Cas13b-Effektorprotein aus dem Bakterium Bacteroidetes GWA2_31_9 von Tabelle 1A, das optional eine oder mehrere Mutationen umfasst und eine Sequenzidentität von wenigstens 90% mit einem Cas13b-Effektorprotein aus dem Bakterium Bacteroidetes GWA2_31_9 von Tabelle 1A aufweist und in der Lage ist, einen CRISPR-Komplex zu bilden, der das Cas13b-Effektorprotein komplexiert mit einer Guide-Sequenz, die in der Lage ist an eine Ziel-RNA-Sequenz zu hybridisieren, umfasst, oder eine Nukleinsäure, die das Cas13b-Effektorprotein codiert.
- Nicht-natürlich vorkommende oder künstlich hergestellte Zusammensetzung, umfassendi) eine mRNA, codierend ein Cas13b-Effektorprotein aus dem Bakterium Bacteroidetes GWA2_31_9 von Tabelle 1A und fähig zum Bilden eines CRISPR-Komplexes, der das Cas13b-Effektorprotein komplexiert mit einer Guide-Sequenz, die in der Lage ist an eine Ziel-RNA-Sequenz zu hybridisieren, umfasst, optional umfassend eine oder mehrere Mutationen und aufweisend eine Sequenzidentität von wenigstens 90% mit einem Cas13b-Effektorprotein aus dem Bakterium Bacteroidetes GWA2_31_9 von Tabelle 1A, undii) eine crRNA, wobei die crRNA a) eine Guide-Sequenz, die zum Hybridisieren an eine Ziel-RNA-Sequenz in der Lage ist, und b) eine Direct-Repeat-Sequenz umfasst.
- Nicht-natürlich vorkommende oder künstlich hergestellte Zusammensetzung nach einem der Ansprüche 1 bis 3, Vektorsystem nach einem der Ansprüche 4 bis 6, Zuführungssystem nach einem der Ansprüche 7 bis 9, Vefahren nach einem der Ansprüche 11 bis 12, oder nicht-natürlich vorkommende oder künstlich hergestellte Zusammensetzung nach Anspruch 15, wobei die Ziel-RNA ein Pathogen-abgeleitetes Ziel, vorzugsweise virale RNA, ist.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP23213666.3A EP4361261A3 (de) | 2017-03-15 | 2018-03-15 | Neuartige cas13b-orthologe crispr-enzyme und systeme |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762471710P | 2017-03-15 | 2017-03-15 | |
US201762566829P | 2017-10-02 | 2017-10-02 | |
PCT/US2018/022751 WO2018170333A1 (en) | 2017-03-15 | 2018-03-15 | Novel cas13b orthologues crispr enzymes and systems |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP23213666.3A Division EP4361261A3 (de) | 2017-03-15 | 2018-03-15 | Neuartige cas13b-orthologe crispr-enzyme und systeme |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3596207A1 EP3596207A1 (de) | 2020-01-22 |
EP3596207B1 true EP3596207B1 (de) | 2023-12-20 |
Family
ID=61874014
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP23213666.3A Pending EP4361261A3 (de) | 2017-03-15 | 2018-03-15 | Neuartige cas13b-orthologe crispr-enzyme und systeme |
EP18715416.6A Active EP3596207B1 (de) | 2017-03-15 | 2018-03-15 | Neuartige cas13b-orthologe-crispr-enzyme und systeme |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP23213666.3A Pending EP4361261A3 (de) | 2017-03-15 | 2018-03-15 | Neuartige cas13b-orthologe crispr-enzyme und systeme |
Country Status (8)
Country | Link |
---|---|
US (2) | US11739308B2 (de) |
EP (2) | EP4361261A3 (de) |
JP (2) | JP2020511141A (de) |
KR (2) | KR102185464B1 (de) |
CN (1) | CN110959039A (de) |
AU (3) | AU2018234825B2 (de) |
CA (1) | CA3056236A1 (de) |
WO (1) | WO2018170333A1 (de) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3024543A1 (en) * | 2015-10-22 | 2017-04-27 | The Broad Institute, Inc. | Type vi-b crispr enzymes and systems |
KR102185464B1 (ko) | 2017-03-15 | 2020-12-03 | 매사추세츠 인스티튜트 오브 테크놀로지 | 신규 cas13b 오르소로그 crispr 효소 및 시스템 |
US11174515B2 (en) | 2017-03-15 | 2021-11-16 | The Broad Institute, Inc. | CRISPR effector system based diagnostics |
US11104937B2 (en) | 2017-03-15 | 2021-08-31 | The Broad Institute, Inc. | CRISPR effector system based diagnostics |
WO2018183908A1 (en) | 2017-03-31 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
EP3610009A1 (de) * | 2017-04-12 | 2020-02-19 | The Broad Institute, Inc. | Neuartige typ-vi-crispr-orthologe und systeme |
WO2018204777A2 (en) | 2017-05-05 | 2018-11-08 | The Broad Institute, Inc. | Methods for identification and modification of lncrna associated with target genotypes and phenotypes |
US11897953B2 (en) | 2017-06-14 | 2024-02-13 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
KR20200031618A (ko) * | 2017-06-26 | 2020-03-24 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적화된 핵산 편집을 위한 crispr/cas-아데닌 데아미나아제 기반 조성물, 시스템 및 방법 |
KR102338449B1 (ko) * | 2017-09-21 | 2021-12-10 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적화된 핵산 편집을 위한 시스템, 방법, 및 조성물 |
AU2018346527A1 (en) * | 2017-10-04 | 2020-05-07 | Massachusetts Institute Of Technology | Systems, methods, and compositions for targeted nucleic acid editing |
WO2019084063A1 (en) * | 2017-10-23 | 2019-05-02 | The Broad Institute, Inc. | SYSTEMS, METHODS AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITION |
WO2019084062A1 (en) * | 2017-10-23 | 2019-05-02 | The Broad Institute, Inc. | SYSTEMS, METHODS AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITION |
US11332736B2 (en) | 2017-12-07 | 2022-05-17 | The Broad Institute, Inc. | Methods and compositions for multiplexing single cell and single nuclei sequencing |
AU2019213047A1 (en) * | 2018-01-29 | 2020-07-16 | Massachusetts Institute Of Technology | CRISPR effector system based diagnostics |
US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
CN112930395A (zh) | 2018-06-08 | 2021-06-08 | 洛卡纳生物股份有限公司 | 靶向rna的融合蛋白组合物和使用方法 |
AU2019281006A1 (en) * | 2018-06-08 | 2021-01-28 | Locanabio, Inc. | Compositions and methods for the modulation of adaptive immunity |
US12036240B2 (en) | 2018-06-14 | 2024-07-16 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
US20210269866A1 (en) | 2018-06-26 | 2021-09-02 | The Broad Institute, Inc. | Crispr effector system based amplification methods, systems, and diagnostics |
CA3102211A1 (en) | 2018-06-26 | 2020-01-02 | The Broad Institute, Inc. | Crispr double nickase based amplification compositions, systems, and methods |
EP3830301B1 (de) | 2018-08-01 | 2024-05-22 | Mammoth Biosciences, Inc. | Programmierbare nuklease-zusammensetzungen und verwendungsverfahren dafür |
KR102666695B1 (ko) * | 2018-10-12 | 2024-05-23 | 페킹 유니버시티 | Rna를 편집하기 위한 방법 및 조성물 |
CN109957568B (zh) * | 2018-10-16 | 2024-02-02 | 广州普世利华科技有限公司 | 用于靶向HBB RNA的gRNA及基于C2c2的HBB突变检测方法、检测试剂盒 |
WO2020124050A1 (en) | 2018-12-13 | 2020-06-18 | The Broad Institute, Inc. | Tiled assays using crispr-cas based detection |
AU2019419494A1 (en) * | 2018-12-31 | 2021-07-15 | Research Institute At Nationwide Children's Hospital | DUX4 RNA silencing using RNA targeting CRISPR-Cas13b |
EP3931313A2 (de) | 2019-01-04 | 2022-01-05 | Mammoth Biosciences, Inc. | Verbesserungen an programmierbarer nuklease und zusammensetzungen und verfahren zur nukleinsäureamplifikation und -detektion |
CN113518623A (zh) | 2019-01-22 | 2021-10-19 | 科罗生物公司 | Rna编辑的寡核苷酸及其用途 |
US20220154258A1 (en) | 2019-03-14 | 2022-05-19 | The Broad Institute, Inc. | Crispr effector system based multiplex diagnostics |
WO2020191102A1 (en) | 2019-03-18 | 2020-09-24 | The Broad Institute, Inc. | Type vii crispr proteins and systems |
US20220403356A1 (en) * | 2019-07-12 | 2022-12-22 | Duke University | 3' utr crispr-dcas 13 engineering system and methods of using same |
WO2021046155A1 (en) | 2019-09-03 | 2021-03-11 | Voyager Therapeutics, Inc. | Vectorized editing of nucleic acids to correct overt mutations |
US20220333208A1 (en) | 2019-09-03 | 2022-10-20 | The Broad Institute, Inc. | Crispr effector system based multiplex cancer diagnostics |
CN115175996A (zh) * | 2019-09-20 | 2022-10-11 | 博德研究所 | 新颖vi型crispr酶和系统 |
US11844800B2 (en) | 2019-10-30 | 2023-12-19 | Massachusetts Institute Of Technology | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia |
CN116590257B (zh) * | 2020-02-28 | 2024-04-30 | 辉大(上海)生物科技有限公司 | VI-E型和VI-F型CRISPR-Cas系统及其用途 |
CN112430586B (zh) * | 2020-11-16 | 2021-09-07 | 珠海舒桐医疗科技有限公司 | 一种VI-B型CRISPR/Cas13基因编辑系统及其应用 |
WO2022182863A1 (en) * | 2021-02-24 | 2022-09-01 | University Of Massachusetts | Inducible single aav system and uses thereof |
BR112023024985A2 (pt) | 2021-06-01 | 2024-02-20 | Arbor Biotechnologies Inc | Sistemas de edição de genes compreendendo uma crispr nuclease e usos dos mesmos |
WO2022253351A1 (zh) * | 2021-06-04 | 2022-12-08 | 中国科学院脑科学与智能技术卓越创新中心 | 新型Cas13蛋白及其筛选方法和应用 |
CN113832180B (zh) * | 2021-08-03 | 2024-06-28 | 华中农业大学 | CRISPR/Cas13b介导的棉花RNA转录调控方法 |
WO2023069628A2 (en) * | 2021-10-21 | 2023-04-27 | Nanothera Biosciences, Inc. | Compositions and methods for silencing kras |
WO2023081902A1 (en) * | 2021-11-05 | 2023-05-11 | University Of Florida Research Foundation, Inc. | Systems and methods for target polynucleotide detection with crispr/cas12a using activators |
WO2023220566A1 (en) * | 2022-05-09 | 2023-11-16 | The Regents Of The University Of California | Crispr-cas effector polypeptides and methods of use thereof |
GB202214015D0 (en) * | 2022-09-26 | 2022-11-09 | Univ Oxford Innovation Ltd | RNA editing vector |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017070605A1 (en) * | 2015-10-22 | 2017-04-27 | The Broad Institute Inc. | Type vi-b crispr enzymes and systems |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
DE122007000007I2 (de) | 1986-04-09 | 2010-12-30 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
WO1991017424A1 (en) | 1990-05-03 | 1991-11-14 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
GB9114259D0 (en) | 1991-07-02 | 1991-08-21 | Ici Plc | Plant derived enzyme and dna sequences |
AU670316B2 (en) | 1992-07-27 | 1996-07-11 | Pioneer Hi-Bred International, Inc. | An improved method of (agrobacterium)-mediated transformation of cultured soybean cells |
US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
US5789156A (en) | 1993-06-14 | 1998-08-04 | Basf Ag | Tetracycline-regulated transcriptional inhibitors |
US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
WO1996039154A1 (en) | 1995-06-06 | 1996-12-12 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US5985662A (en) | 1995-07-13 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense inhibition of hepatitis B virus replication |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5846946A (en) | 1996-06-14 | 1998-12-08 | Pasteur Merieux Serums Et Vaccins | Compositions and methods for administering Borrelia DNA |
GB9907461D0 (en) | 1999-03-31 | 1999-05-26 | King S College London | Neurite regeneration |
GB9720465D0 (en) | 1997-09-25 | 1997-11-26 | Oxford Biomedica Ltd | Dual-virus vectors |
IL135776A0 (en) | 1997-10-24 | 2001-05-20 | Life Technologies Inc | Recombinational cloning using nucleic acids having recombination sites |
US6750059B1 (en) | 1998-07-16 | 2004-06-15 | Whatman, Inc. | Archiving of vectors |
GB0024550D0 (de) | 2000-10-06 | 2000-11-22 | Oxford Biomedica Ltd | |
WO2003045304A2 (en) | 2001-09-26 | 2003-06-05 | Mayo Foundation For Medical Education And Research | Mutable vaccines |
GB0125216D0 (en) | 2001-10-19 | 2001-12-12 | Univ Strathclyde | Dendrimers for use in targeted delivery |
AU2002353231B2 (en) | 2001-12-21 | 2008-10-16 | Oxford Biomedica (Uk) Limited | Method for producing a transgenic organism using a lentiviral expression vector such as EIAV |
DE60334618D1 (de) | 2002-06-28 | 2010-12-02 | Protiva Biotherapeutics Inc | Verfahren und vorrichtung zur herstellung von liposomen |
AU2003256857A1 (en) | 2002-08-08 | 2004-02-25 | Dharmacon, Inc. | Short interfering rnas having a hairpin structure containing a non-nucleotide loop |
GB0220467D0 (en) | 2002-09-03 | 2002-10-09 | Oxford Biomedica Ltd | Composition |
EP1558724A4 (de) | 2002-11-01 | 2006-08-02 | New England Biolabs Inc | Organellen-targeting von rna und verwendung davon bei der unterbrechung des genflusses in der umwelt |
US20050064595A1 (en) | 2003-07-16 | 2005-03-24 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering RNA |
AU2004272646B2 (en) | 2003-09-15 | 2011-11-24 | Arbutus Biopharma Corporation | Polyethyleneglycol-modified lipid compounds and uses thereof |
GB0325379D0 (en) | 2003-10-30 | 2003-12-03 | Oxford Biomedica Ltd | Vectors |
AU2005251403B2 (en) | 2004-06-07 | 2011-09-01 | Arbutus Biopharma Corporation | Cationic lipids and methods of use |
ATE536418T1 (de) | 2004-06-07 | 2011-12-15 | Protiva Biotherapeutics Inc | Lipidverkapselte interferenz-rna |
CA2573702C (en) | 2004-07-16 | 2013-10-15 | The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services | Vaccine constructs and combination of vaccines designed to improve the breadth of the immune response to diverse strains and clades of hiv |
GB0422877D0 (en) | 2004-10-14 | 2004-11-17 | Univ Glasgow | Bioactive polymers |
US7838658B2 (en) | 2005-10-20 | 2010-11-23 | Ian Maclachlan | siRNA silencing of filovirus gene expression |
ES2377660T3 (es) | 2005-10-28 | 2012-03-29 | Mitsubishi Tanabe Pharma Corporation | Nuevo péptido que penetra en las células |
EP2395012B8 (de) | 2005-11-02 | 2018-06-06 | Arbutus Biopharma Corporation | Modifizierte siRNA-Moleküle und Verwendungen davon |
GB0526211D0 (en) | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Viral vectors |
US7915399B2 (en) | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
JP2008078613A (ja) | 2006-08-24 | 2008-04-03 | Rohm Co Ltd | 窒化物半導体の製造方法及び窒化物半導体素子 |
WO2008042156A1 (en) | 2006-09-28 | 2008-04-10 | Northwestern University | Maximizing oligonucleotide loading on gold nanoparticle |
WO2008064289A2 (en) | 2006-11-21 | 2008-05-29 | The Samuel Roberts Noble Foundation, Inc. | Biofuel production methods and compositions |
WO2008149176A1 (en) | 2007-06-06 | 2008-12-11 | Cellectis | Meganuclease variants cleaving a dna target sequence from the mouse rosa26 locus and uses thereof |
CA2711179A1 (en) | 2007-12-31 | 2009-07-16 | Nanocor Therapeutics, Inc. | Rna interference for the treatment of heart failure |
US8058069B2 (en) | 2008-04-15 | 2011-11-15 | Protiva Biotherapeutics, Inc. | Lipid formulations for nucleic acid delivery |
EP2283029A1 (de) | 2008-06-04 | 2011-02-16 | Medical Research Council | Peptide |
EP2323630B1 (de) | 2008-06-30 | 2014-11-19 | Silenseed Ltd | Verfahren, zusammensetzungen und systeme zur lokalen abgabe von arzneimitteln |
EP2309980A1 (de) | 2008-07-08 | 2011-04-20 | S.I.F.I. Societa' Industria Farmaceutica Italiana | Ophthalmische zusammensetzungen zur behandlung von erkrankungen des hinteren augensegments |
US8969353B2 (en) | 2008-11-07 | 2015-03-03 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
GB2465749B (en) | 2008-11-25 | 2013-05-08 | Algentech Sas | Plant cell transformation method |
WO2010096488A1 (en) | 2009-02-17 | 2010-08-26 | The Regents Of The University Of California | Method of reducing acetylation in plants to improve biofuel production |
US8236943B2 (en) | 2009-07-01 | 2012-08-07 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein B |
ES2613498T3 (es) | 2009-07-01 | 2017-05-24 | Protiva Biotherapeutics Inc. | Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos |
EP2454371B1 (de) | 2009-07-13 | 2021-01-20 | Somagenics, Inc. | Chemische modifikation kleiner haarnadel-rnas zur genexpressionshemmung |
US8889394B2 (en) | 2009-09-07 | 2014-11-18 | Empire Technology Development Llc | Multiple domain proteins |
US20120003201A1 (en) | 2010-04-21 | 2012-01-05 | Nicholas Susanne B | Vault agents for chronic kidney disease |
KR101880536B1 (ko) | 2010-04-26 | 2018-07-23 | 상가모 테라퓨틱스, 인코포레이티드 | 아연 핑거 뉴클레아제를 사용하는 로사 좌위의 게놈 편집 |
US8372951B2 (en) | 2010-05-14 | 2013-02-12 | National Tsing Hua University | Cell penetrating peptides for intracellular delivery |
JP5965392B2 (ja) | 2010-05-28 | 2016-08-03 | オックスフォード バイオメディカ (ユーケー) リミテッド | 脳へのレンチウイルスベクターの送達 |
EP2609135A4 (de) | 2010-08-26 | 2015-05-20 | Massachusetts Inst Technology | Poly(beta-amino-alkohole), ihre herstellung und verwendungen davon |
PL2691443T3 (pl) | 2011-03-28 | 2021-08-30 | Massachusetts Institute Of Technology | Sprzężone lipomery i ich zastosowania |
CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US20120295960A1 (en) | 2011-05-20 | 2012-11-22 | Oxford Biomedica (Uk) Ltd. | Treatment regimen for parkinson's disease |
DE12858350T1 (de) | 2011-12-16 | 2021-10-07 | Modernatx, Inc. | Modifizierte mrna zusammensetzungen |
US20130185823A1 (en) | 2012-01-16 | 2013-07-18 | Academia Sinica | Mesoporous silica nanoparticle-mediated delivery of dna into arabidopsis root |
DK3494997T3 (da) | 2012-07-25 | 2019-12-02 | Broad Inst Inc | Inducerbare dna-bindende proteiner og værktøjer til genomperturbation samt anvendelser deraf |
US8614194B1 (en) | 2012-07-25 | 2013-12-24 | Kaohsiung Medical University | Anionic cell penetrating peptide and its use for intracellular delivery |
WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
MX2015007550A (es) | 2012-12-12 | 2017-02-02 | Broad Inst Inc | Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas. |
EP2931899A1 (de) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Funktionale genomik unter verwendung von crispr-cas systemen, zusammensetzungen, verfahren, knockout-bibliotheken und anwendungen davon |
US20140186843A1 (en) | 2012-12-12 | 2014-07-03 | Massachusetts Institute Of Technology | Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
DK2931898T3 (en) | 2012-12-12 | 2016-06-20 | Massachusetts Inst Technology | CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS |
EP2931892B1 (de) | 2012-12-12 | 2018-09-12 | The Broad Institute, Inc. | Verfahren, modelle, systeme und vorrichtungen zur identifikation von zielsequenzen für cas-enzyme oder crispr-cas-systeme für zielsequenzen und förderresultate davon |
AU2013359262C1 (en) | 2012-12-12 | 2021-05-13 | Massachusetts Institute Of Technology | CRISPR-Cas component systems, methods and compositions for sequence manipulation |
AU2013359212B2 (en) | 2012-12-12 | 2017-01-19 | Massachusetts Institute Of Technology | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
CN105121648B (zh) | 2012-12-12 | 2021-05-07 | 布罗德研究所有限公司 | 用于序列操纵的系统、方法和优化的指导组合物的工程化 |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
US11332719B2 (en) | 2013-03-15 | 2022-05-17 | The Broad Institute, Inc. | Recombinant virus and preparations thereof |
WO2014204727A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof |
DK3011031T3 (da) | 2013-06-17 | 2020-12-21 | Broad Inst Inc | Fremføring og anvendelse af crispr-cas-systemerne, vektorer og sammensætninger til levermålretning og -terapi |
WO2014204723A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Oncogenic models based on delivery and use of the crispr-cas systems, vectors and compositions |
WO2014204725A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation |
BR112015031611A2 (pt) | 2013-06-17 | 2017-12-12 | Massachusetts Inst Technology | aplicação, manipulação e otimização de sistemas, métodos e composições para direcionamento e modelação de doenças e distúrbios de células pós-mitóticas |
DK3011029T3 (da) | 2013-06-17 | 2020-03-16 | Broad Inst Inc | Administration, modificering og optimering af tandem-guidesystemer, fremgangsmåder og sammensætninger til sekvensmanipulering |
AU2014281031B2 (en) | 2013-06-17 | 2020-05-21 | Massachusetts Institute Of Technology | Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for targeting disorders and diseases using viral components |
WO2015065964A1 (en) | 2013-10-28 | 2015-05-07 | The Broad Institute Inc. | Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof |
JP2017503485A (ja) | 2013-12-12 | 2017-02-02 | ザ・ブロード・インスティテュート・インコーポレイテッド | 遺伝子産物の発現、構造情報、及び誘導性モジュラーcas酵素を変更するためのcrispr−cas系並びに方法 |
EP3079725B1 (de) * | 2013-12-12 | 2019-10-16 | The Broad Institute, Inc. | Abgabe, verwendung und therapeutische anwendungen der crispr-cas-systeme und zusammensetzungen zur genomeditierung |
EP3080257A1 (de) * | 2013-12-12 | 2016-10-19 | The Broad Institute Inc. | Zusammensetzungen und verfahren zur verwendung von crispr-cas-systemen bei nukleotid-repeat-erkrankungen |
MX2016007327A (es) | 2013-12-12 | 2017-03-06 | Broad Inst Inc | Suministro, uso y aplicaciones terapeuticas de sistemas y composiciones crispr-cas para dirigirlos a trastornos y enfermedades usando componentes para suministro de particulas. |
WO2016028682A1 (en) | 2014-08-17 | 2016-02-25 | The Broad Institute Inc. | Genome editing using cas9 nickases |
WO2016049163A2 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder |
WO2016049024A2 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo |
WO2016049258A2 (en) | 2014-09-25 | 2016-03-31 | The Broad Institute Inc. | Functional screening with optimized functional crispr-cas systems |
WO2016094880A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs) |
CN107709555A (zh) | 2015-05-15 | 2018-02-16 | 达尔马科恩有限公司 | 用于Cas9介导的基因编辑的合成的单向导RNA |
US9790490B2 (en) * | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
CA3028158A1 (en) * | 2016-06-17 | 2017-12-21 | The Broad Institute, Inc. | Type vi crispr orthologs and systems |
WO2018107103A1 (en) | 2016-12-09 | 2018-06-14 | The Broad Institute, Inc. | Crispr-systems for modifying a trait of interest in a plant |
KR102185464B1 (ko) | 2017-03-15 | 2020-12-03 | 매사추세츠 인스티튜트 오브 테크놀로지 | 신규 cas13b 오르소로그 crispr 효소 및 시스템 |
-
2018
- 2018-03-15 KR KR1020197030158A patent/KR102185464B1/ko active IP Right Grant
- 2018-03-15 KR KR1020207034051A patent/KR102454284B1/ko active IP Right Grant
- 2018-03-15 CA CA3056236A patent/CA3056236A1/en active Pending
- 2018-03-15 AU AU2018234825A patent/AU2018234825B2/en active Active
- 2018-03-15 US US16/493,464 patent/US11739308B2/en active Active
- 2018-03-15 WO PCT/US2018/022751 patent/WO2018170333A1/en unknown
- 2018-03-15 EP EP23213666.3A patent/EP4361261A3/de active Pending
- 2018-03-15 EP EP18715416.6A patent/EP3596207B1/de active Active
- 2018-03-15 CN CN201880033145.8A patent/CN110959039A/zh active Pending
- 2018-03-15 JP JP2019551295A patent/JP2020511141A/ja active Pending
-
2021
- 2021-03-17 AU AU2021201683A patent/AU2021201683B2/en active Active
-
2023
- 2023-03-22 JP JP2023045024A patent/JP2023088984A/ja active Pending
- 2023-07-10 US US18/349,707 patent/US20240018494A1/en active Pending
- 2023-11-23 AU AU2023270311A patent/AU2023270311A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017070605A1 (en) * | 2015-10-22 | 2017-04-27 | The Broad Institute Inc. | Type vi-b crispr enzymes and systems |
Non-Patent Citations (2)
Title |
---|
AARON A SMARGON ET AL: "Supplemental Information Cas13b Is a Type VI-B CRISPR-Associated RNA-Guided RNase Differentially Regulated by Accessory Proteins Csx27 and Csx28", MOLECULAR CELL, 5 January 2017 (2017-01-05), XP055731019, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/pii/S1097276516308668?via%3Dihub> [retrieved on 20200916] * |
SMARGON AARON A ET AL: "Cas13b Is a Type VI-B CRISPR-Associated RNA-Guided RNase Differentially Regulated by Accessory Proteins Csx27 and Csx28", MOLECULAR CELL, ELSEVIER, AMSTERDAM, NL, vol. 65, no. 4, 5 January 2017 (2017-01-05), pages 618, XP029924355, ISSN: 1097-2765, DOI: 10.1016/J.MOLCEL.2016.12.023 * |
Also Published As
Publication number | Publication date |
---|---|
EP3596207A1 (de) | 2020-01-22 |
AU2018234825B2 (en) | 2020-12-17 |
AU2021201683A1 (en) | 2021-04-08 |
KR20200135581A (ko) | 2020-12-02 |
JP2023088984A (ja) | 2023-06-27 |
US11739308B2 (en) | 2023-08-29 |
CA3056236A1 (en) | 2018-09-20 |
KR20190129088A (ko) | 2019-11-19 |
US20240018494A1 (en) | 2024-01-18 |
CN110959039A (zh) | 2020-04-03 |
WO2018170333A1 (en) | 2018-09-20 |
EP4361261A2 (de) | 2024-05-01 |
AU2018234825A1 (en) | 2019-10-31 |
KR102185464B1 (ko) | 2020-12-03 |
JP2020511141A (ja) | 2020-04-16 |
KR102454284B1 (ko) | 2022-10-12 |
EP4361261A3 (de) | 2024-07-10 |
AU2023270311A1 (en) | 2024-02-15 |
US20200131488A1 (en) | 2020-04-30 |
AU2021201683B2 (en) | 2023-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021201683B2 (en) | Novel CAS13B orthologues CRISPR enzymes and systems | |
US20240110165A1 (en) | Novel type vi crispr orthologs and systems | |
AU2021203747B2 (en) | Novel Type VI CRISPR orthologs and systems | |
US20200231975A1 (en) | Novel type vi crispr orthologs and systems | |
US20220364071A1 (en) | Novel crispr enzymes and systems | |
EP3645728A1 (de) | Neuartige typ-vi-crispr-orthologe und systeme | |
CA3024543A1 (en) | Type vi-b crispr enzymes and systems | |
US20200308560A1 (en) | Novel type vi crispr orthologs and systems | |
CN110799645B (zh) | 新型vi型crispr直系同源物和系统 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20191014 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20200922 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230527 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20230714 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602018062870 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240321 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231220 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20231220 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231220 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231220 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240321 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231220 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231220 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240320 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240327 Year of fee payment: 7 Ref country code: GB Payment date: 20240327 Year of fee payment: 7 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1642471 Country of ref document: AT Kind code of ref document: T Effective date: 20231220 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231220 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231220 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231220 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240320 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231220 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231220 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231220 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20240325 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240420 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231220 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231220 |